Effect of proteinase-activated receptor 2 activating peptide, 2-furoyl-LIGRLO-amide, on murine mesenteric endothelial cell Ca²⁺-events by Hennessey, John C.
  
Effect of proteinase-activated receptor 2 activating peptide, 2-furoyl-LIGRLO-amide, on 
murine mesenteric endothelial cell Ca
2+
-events. 
 
By 
© John C. Hennessey 
A thesis submitted to the School of Graduate Studies 
in partial fulfillment of the 
requirements for the degree 
Master of Science (Medicine) 
Cardiovascular and Renal Sciences 
Division of BioMedical Sciences 
Faculty of Medicine 
Memorial University 
May 2015 
 
 
 
 
 
 
 
 
 
 
 
 
St. John’s                                                                                              Newfoundland and Labrador
i 
 
Abstract 
 Proteinase-activated receptor 2 (PAR2)-mediated elevations of cytosolic Ca
2+
, induced by 
PAR2 agonist 2-furoyl-LIGRLO-amide (2fly), have been demonstrated in cell culture 
experiments. The properties of individual PAR2-mediated Ca
2+
-events in endothelial cells (EC) 
have yet to be described, and the role that these Ca
2+
-events play in the preservation of PAR2-
mediated vascular reactivity in endothelial dysfunction is not understood. Male C57BL/6J 
(PAR2-WT) and PAR2 knockout (PAR2-KO) mice were implanted with sub-cutaneous micro-
osmotic pumps containing either saline (control) or angiotensin II (endothelial dysfunction). 
Doses of angiotensin II were 1.5 mg/kg/day, control pumps were filled with 100 µl of saline. 
Imaged under spinning disk confocal microscopy, Fluo-4 loaded Ang II-treated ECs exhibited 
21% and 23% attenuation in the density of ACh-evoked muscarinic (M3)-mediated, Ca
2+
-events 
in PAR2-WT and PAR2-KO, respectively. 2fly-mediated Ca
2+
-events were unaffected by Ang II 
treatment. The density of Ca
2+
-release sites were reduced by IP3R inhibition using xestospongin-
C and TRPV channel inhibition using ruthenium red. This study identified two populations of 
non-propagating Ca
2+
-events in murine mesenteric ECs: small peripheral and large-repeating 
transients. The study concluded that PAR2 Ca
2+
-signaling is preserved in the presence of 
endothelial dysfunction. Immunocytochemistry experiments of fixed and permeabilized ECs, on 
a line-scan confocal microscope, revealed that the distribution of eNOS was significantly 
attenuated with Ang II treatment. This reduction of eNOS in Ang II-treated ECs may contribute 
to the attenuation of resistance vessel relaxation in endothelial dysfunction.  
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Chapter 1: Introduction 
1.1 Research problem, hypotheses and objectives 
1.1.1 Research problem 
 Proteinase-activated receptor 2 (PAR2) mediated vasodilation has been demonstrated 
across many species, even in the presence of endothelial dysfunction where other mechanisms of 
vascular relaxation are impaired (McGuire et al., 2008). In experimental models of endothelial 
dysfunction the potent and selective PAR2 activating peptide (PAR2-AP) 2-furoyl-LIGRLO-
amide (2fly) induces sustained relaxation of arteries in Ang II-treated mice where other agonists 
bradykinin and acetylcholine (ACh) for example, show attenuated vasodilation (Chia et al., 
2011; McGuire et al., 2008). 2fly has become the most commonly used synthetic agonist for 
PAR2 with 10 to 300 times the in vitro potency for vascular relaxation and hyperpolarization as 
compared to legacy PAR2-AP, SLIGRL-NH2 (McGuire et al., 2004b). Chia et al., (2011) 
utilized myograph isometric tension experiments to demonstrate that ACh-induced relaxations of 
mesenteric arteries in angiotensin-II (Ang II) infused C57BL/6J par2 wild-type (PAR2-WT) 
mice and B6.Cg-F2rl1
tm1mslb
/J par2 knockout mice (PAR2-KO) were attenuated by 12% and 
14% respectively compared to saline-treated controls. Despite endothelial dysfunction reducing 
the muscarinic type 3 (M3)-mediated relaxations, PAR2-mediated relaxations were sustained in 
PAR2-WT. It is worthwhile to note that ACh is not selective for M3 receptors but stimulate all 
classes of cholinergic receptors. The vascular endothelium only expresses the M3 subtype of 
cholinergic receptors. The literature suggests that mechanisms other than nitric oxide (NO) and 
prostacyclin (PGI2) may account for preserved resistance vessel PAR2 vasodilation in 
endothelial dysfunction (Chia et al., 2011; Ramachandran et al., 2012b). 
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 In resistance vasculature, endothelium-derived hyperpolarizing factors (EDHF) are 
believed to mediate the majority of vasodilator response (Garland et al., 2011; Taylor et al., 
1988). Unique Ca
2+
-events in endothelium may be the signal transduction initiators for EDHF 
(Ledoux et al., 2008; Tran et al., 2012). Ca
2+
-events stimulate calcium-activated potassium 
channels which initiate vascular hyperpolarization (Dora et al., 2008; Ledoux et al., 2008). Aside 
from triggering Ca
2+
-transients, PAR2 activation is also associated with the sensitization of 
transient-receptor potential vanilloid (TRPV) channel subtype 1 and 4 (Chen et al., 2011) which 
further enhances Ca
2+
-influx into the endothelium (Poole et al., 2013). The Ca
2+
-events initiated 
by ACh and carbachol (CCh) in vascular endothelium in situ have been studied in murine 
(Ledoux et al., 2008; Marie et al., 2002; Ohata et al., 2003), rat (Dora et al., 2008; Mumtaz et al., 
2011; Oishi et al., 2001; Tang et al., 2007; Yip et al., 1996), hamster (Tran et al., 2012; 
Uhrenholt et al., 2007), porcine (Budel et al., 2001) and cultured endothelial cells (EC) (Mutoh et 
al., 2008). The PAR2 activation cascade and the resultant rise in endothelial cytosolic [Ca
2+
]i is 
similar to M3-mediated signal transduction (Browning, 2010; Macfarlane et al., 2001; 
Ramachandran et al., 2011).  
There has been no detailed work on the Ca
2+
-events associated with PAR2 activation in 
ECs. It is possible that preserved Ca
2+
-signaling is the mechanism of persistent PAR2-mediated 
vascular relaxation in endothelial dysfunction. The majority of work on endothelial Ca
2+
-events 
has been conducted in cultured cells or in situ. These studies raise the issue of dealing with the 
abnormal physiology of cultured cells (Dawson et al., 2012), or the interference from other cell 
types. Studying PAR2-mediated Ca
2+
-signaling in freshly isolated ECs allows for the elementary 
components (dynamics and kinetics) of transients to be identified. 
1.1.2 Hypothesis and objectives 
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 The overall objective is to characterize the PAR2-mediated Ca
2+
-signaling activity in 
isolated mesenteric endothelial cells from a murine model of endothelial cell dysfunction. To 
address the objective within the ECs I intend to examine 2fly-induced Ca
2+
-events, the effects of 
Ca
2+
-channel inhibitors on Ca
2+
-signaling and expression of Ca
2+
-signaling related proteins. 
 Hypothesis 1 is that Ca
2+
-events evoked by PAR2-AP 2-furoyl-LIGRLO-amide will not 
diminish in a mouse model of endothelial dysfunction where Ca
2+
-events induced by M3-agonist 
ACh will be attenuated. To test hypothesis 1 2fly and ACh concentration response curves (CRC) 
measuring Ca
2+
-events were obtained in freshly isolated murine mesenteric EC. Ca
2+
-events 
were obtained through Nipkow spinning disk confocal microscopy. The model of endothelial 
dysfunction was created by surgically implanting sub-cutaneous (s.c.) micro-osmotic pumps into 
mice with a 14 day release of Ang II (1.5 mg/kg/day) modified from previous work (Chia et al., 
2011; McGuire et al., 2008). The experimental model was compared to mice with the 
implantation of saline pumps over the same time course.  Objective 1: To determine baseline 
Ca
2+
-events, freshly isolated murine mesenteric ECs were examined under a Nipkow spinning 
disk confocal microscope with FITC (488 nm) laser excitation modified from techniques used 
extensively in the past (Haq et al., 2013; Ledoux et al., 2008haq; Tran et al., 2012). Objective 2: 
To characterize the effects of PAR2 and M3 activation on the EC Ca
2+
-events, 2fly (0.1 nM to 3 
µM) and ACh (1 nM to 30 µM) concentration response curves (CRC) were constructed.  
 Hypothesis 2 is that inositol triphosphate receptors (IP3R) and TRPV channels 
contribute to the calcium activity seen in our animal models. I expect that inhibiting IP3R and 
TRPV channels will reduce intracellular Ca
2+
-events in both experimental (endothelial 
dysfunction) and control (saline) animals. To test hypothesis 2 the same Ca
2+ 
imaging techniques 
were employed as in hypothesis 1. Objective 1: Characterize the IP3R inhibition (xestospongin 
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C (XeC), 2 µM) in isolated ECs while PAR2 is activated (2fly; 30 nM).  Objective 2: 
Characterize the effects of TRPV inhibition (ruthenium red (RR), 75 µM) in isolated ECs while 
PAR2 is activated (30 nM 2fly). We compared 2fly-induced Ca
2+
-events to those elicited by 
ACh. 
 Hypothesis 3 is that the expression of PAR2 and intermediate conductance potassium 
channel (IKCa) will be increased in Ang II treated PAR2-WT compared to controls, and that 
eNOS distribution will be reduced in Ang II treated animals. PAR2 and IKCa are essential 
mediators of the preserved PAR2 NO/PGI2-independent resistance vessel relaxations (Chia et al., 
2011). It is expected that these proteins will be up regulated in endothelial dysfunction as a 
compensatory mechanism. A possible explanation for the loss of relaxation activity in vessels 
with endothelial dysfunction is the reduction in activity or expression of eNOS. To test 
hypothesis 3 immunocytochemistry experiments will be carried out and individual cells imaged 
by a CCD camera on a line-scan confocal microscope. Objective 1: Determine the expression of 
PAR2 and IKCa, freshly isolated ECs were incubated with protein specific 1° antibody (Ab) and 
FITC 2° Ab and imaged via line-scan confocal microscopy, modified from previous studies 
(Dora et al., 2008; Stuyvers et al., 2005). The expression of eNOS, IP3R and SKca were 
evaluated, to shed light on the extent of endothelial dysfunction. Finally all cells will be co-
probed with 1° Ab for platelet endothelial cell adhesion molecule (PECAM-1) and Texas Red 2° 
Ab to positively identify cells in the preparation as ECs.  
 This study is expected to inform on the potential role of Ca
2+
- signaling in the 
preservation of PAR2 activity during endothelial dysfunction. In particular, I anticipate an 
explanation at the Ca
2+
-signal transduction level for the attenuation in M3-mediated vascular 
relaxation observed in other studies on Ang II treated mice.  
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1.2 Literature Review 
1.2.1 Hypertension, angiotensin II and endothelial dysfunction 
 Heart disease, atherosclerosis, myocardial infarction, stroke and ischemia related diseases 
accounted for 29% of deaths in Canada in 2009 (Statistics Canada, 2009). Hypertension is still 
on the rise, while the trend in cardiovascular related deaths has been declining (Statistics Canada, 
2013). From 2005 the number of adults living with high blood pressure (greater than 140 mm Hg 
systolic / 90 mm Hg diastolic pressure measured in a physician’s office) increased by 2.6% to 
18% total in 2011 (Statistics Canada, 2013).  
 Endothelial dysfunction is a vascular pathology that can be defined by impaired 
vasodilation, increased inflammation and a greater tendency for thrombosis (Endemann et al., 
2004). Generally speaking, endothelial dysfunction causes increased blood pressure when 
endothelium-derived contracting factors (EDCF) are increased disproportionately to 
endothelium-derived relaxing factors (EDRF) such as nitric oxide (NO) or prostacyclin (PGI2) 
(Ayajiki et al., 2000). Possible etiologies and resultant symptoms of endothelial dysfunction are 
broad. Heritable conditions, hypertension, toxic substances and other cardiovascular risk factors 
activate endothelial cells (Deanfield et al., 2007). Prolonged exposure to cardiovascular risk 
factors can exhaust endothelial cells’ anti-inflammatory and vasodilatory machinery (Deanfield 
et al., 2007; Higashi et al., 2012). Some of the endothelial proteins affected by cardiovascular 
risk factors include NADPH oxidase, xanthine oxidase and cyclooxygenases which may produce 
reactive oxygen species (Hamilton et al., 2002; Silva et al., 2012). A proposed mechanism for 
eNOS includes a functional shift during the prolonged risk factor period. Studies suggest that the 
enzyme changes to a reactive oxygen species-mediated silencing (Deanfield et al., 2007; Rhee, 
2006). These reactive molecules may further perturb eNOS by uncoupling the enzyme (Yang et 
6 
 
al., 2009) and decreasing tetrahydrobiopterin bioavailability (Bevers et al., 2006). Some of the 
biological mediators which precipitate endothelial dysfunction are messengers of the renin 
angiotensin aldosterone system (Aroor et al., 2013; Patel et al., 2012). 
 Ang II infusion is used in laboratory animals to create models of endothelial dysfunction 
(Avendano et al., 2013; Wang et al., 2013). Ang II is converted from angiotensin I by 
angiotensin converting enzyme (Carey, 2013).  Angiotensin I is converted from angiotensinogen 
through the enzyme renin, produced in juxtaglomerular cells (Herichova et al., 2013). Ang II acts 
to promote aldosterone release from the adrenal cortex (Ansurudeen et al., 2010) and to constrict 
the glomerular efferent arterioles enhancing glomerular filtration (Schiessl et al., 2013). These 
physiological responses are a mechanism to conserve extracellular fluid and blood volume or to 
prevent sodium losses (Spitzer, 1982). Ang II is a potent systemic vasoconstrictor when 
continually administered through infusion (Parisi et al., 1985). Ang II binds the Gq/11-protein 
coupled AT1 receptor on vascular smooth muscle cells (Lassegue et al., 1995). This binding 
activates phospholipase C which cleaves phosphatidylinositol-4,5-bisphosphate (PIP2) into IP3 
and diacylglycerol (DAG). The increase of cytosolic [IP3]i  ultimately raises smooth muscle 
[Ca
2+
]i, causing constriction (Chen et al., 2013). Saturation studies of AT1 on rodent thoracic 
aortic rings demonstrate that Ang II causes concentration-dependent spikes in smooth muscle 
[Ca
2+
]i (Arun et al., 2005). The chronic effects of Ang II on vascular smooth muscle, including 
consistently elevated cytosolic calcium, leads to vascular remodeling and dysfunction (Gao et al., 
2013; Wakui et al., 2013). 
 Endothelial cells possess Ang II receptors AT1 and AT2, where exposure to Ang II 
increases cytosolic [Ca
2+
]i and stimulates NO production (Pueyo et al., 1998; Rajagopalan et al., 
1996). Cultured rodent microcoronary artery endothelial cells exposed to Ang II exhibit Ca
2+
-
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sparks with a measured sustained rise in cytosolic [Ca
2+
]i (Nistri et al., 2012).  Subcutaneous 
infusion of Ang II has been used to generate an effective model of endothelial dysfunction. Ang 
II infusion was used in Nox4 knockout mice by Schröder and colleagues. Ang II infusion in the 
absence of NO production caused vascular bed inflammation, media hypertrophy and endothelial 
dysfunction determined by increased oxidative stress (Schroder et al., 2012). Ang II infusion has 
been used in rodents to elevate NADPH-mediated vascular superoxide production (Mollnau et 
al., 2002). Analysis of the rodent vessels revealed Ang II treatment induced eNOS uncoupling 
and enhanced oxidative stress within the endothelium (Mollnau et al., 2002). Previous studies 
show attenuated relaxation of murine mesenteric arteries to ACh following subcutaneous Ang II 
infusion (Chia et al., 2011; Marchesi et al., 2013). Here we utilize the same approach using a 
murine model of Ang II-induced endothelial dysfunction in mesenteric arteries. 
1.2.2 Proteinase-activated receptors (PARs) and their activation 
 Proteinase-activated receptors (PARs) are a family of four G-protein coupled 7-
transmembrane domain receptors (GPCRs) (Ramachandran et al., 2012b). PAR subfamily 
nomenclature comes from the order of discovery, first PAR1 also known as thrombin receptor 
(Hollenberg, 2003). PAR2 was identified through molecular cloning and functional expression 
experiments that identified trypsin, but not thrombin, as an enzyme activator (Nystedt et al., 
1995; Nystedt et al., 1994). PARs can be found in the tissues and isolated cells of many species 
(Adams et al., 2011; Thorsen et al., 2008). All PARs are found on EC plasma membranes 
(D'Andrea et al., 1998; Hamilton et al., 2001). PAR2 is found in generic fibroblasts (D'Andrea et 
al., 1998), PAR1, PAR3 and PAR4 are found on platelets (Kahn et al., 1998; Vu et al., 1991) and 
PAR1 in smooth muscle cells (D'Andrea et al., 1998; Hamilton et al., 2001). PARs share a 
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unique mechanism of activation by serine proteinases. Cleavage involves a cryptic tethered 
ligand binding to the second extracellular loops on the PARs (Ramachandran et al., 2012b).  
The cryptic tethered ligands contain a coded residue motif (Table 1) that is revealed upon 
selective cleavage by trypsin-like serine proteases (Macfarlane et al., 2001). The binding of the 
tethered ligand to the PAR extracellular loops induces a conformational change that activates G-
protein coupled pathways (Ramachandran et al., 2012b). Trypsin-like serine proteases that 
activate PARs demonstrate substrate specificity for the cleavage sites that produce the tethered 
ligands. For example, thrombin activates PAR1, PAR3 and PAR4 (Macfarlane et al., 2001) 
whereas trypsin activates PAR2 at low, and PAR4 at high, concentrations (Carr et al., 2000). 
PARs can also be activated by PAR-APs, small peptides that bind directly to an extracellular 
loop (ECL) of the PAR (Ramachandran et al., 2012b). In the case of PAR1 and PAR2, this loop 
is ECL-2 (Ramachandran et al., 2012b). PAR activation by PAR-APs is unique because it does 
not require exposure of the tethered ligand to induce the conformational change (Hollenberg et 
al., 1997). PAR-APs have become very useful tools for PAR research over the past two decades, 
due to their higher potency and specificity than proteases (Lee et al., 2012a). 
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Receptor Designation  Tethered Ligand Sequence 
(IUPHAR)   
PAR1 Human: SFLLRN... 
 
Mouse: SFFLRN… 
PAR2 Human: SLIGKV… 
 
Mouse: SLIGRL... 
PAR3 Human: TFRGAP… 
 
Mouse: SFNGGP... 
PAR4 Human: GYPGQV... 
 
Mouse: GYPGKF... 
IUPHAR = International Union of Pharmacology 
(Hollenberg et al., 2002) 
Table 1. Amino terminus tethered ligand residue 
sequence of human and murine PARs following cleavage 
by trypsin-like serine proteases. Modified from (Hansen et 
al., 2008) 
 
1.2.3 PAR2 activation by trypsin-like serine proteases 
 The proposed mediators of PAR2 activation in vivo are trypsin-like serine proteases 
(Ramachandran et al., 2012b). For PAR2, these enzymes include: pancreatic trypsin (Nystedt et 
al., 1995), extrapancreatic trypsin IV (Cottrell et al., 2004), mast cell tryptase (Brass et al., 1997), 
membrane-tethered serine-protease 1 (Takeuchi et al., 2000) and kallikreins (Ramachandran et 
al., 2012a). Each of these proteases has been demonstrated to activate PAR2 by endolytic 
cleavage of the extracellular amino terminus arm, revealing the tethered ligand motif in vitro. 
Rodent and murine PAR2 have nearly identical homology, receptor confirmation and the same 
tethered ligand motif “SLIGRL…” (Hansen et al., 2008). Several residues offer themselves as 
candidates for trypsin-like proteolysis along the amino terminus of rodent PAR2: R
36
, R
41
, K
51
 
and K
72 
(Al-Ani et al., 2003). In vitro bioassays utilizing mutant rats have uncovered that only 
R
36
 is preferentially cleaved exposing the NH2-S
37LIGRL… motif (Al-Ani et al., 2003). After 
cleavage of R
36
/S
37
, increasing [trypsin]o does not lead to further cleavage of the amino terminus. 
This suggests that after cleavage of this preferential locus the remaining three potential sites for 
cleavage are inaccessible to the enzyme (Al-Ani et al., 2003). Indeed the significance of R
36
 is 
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highlighted upon mutation to alanine, where no PAR2 effects could be measured in vitro upon 
the addition of trypsin (Al-Ani et al., 2003). This persistent and irreversible activation of PAR2 
leads to: desensitization of the tissue to PAR2 activators (Defea et al., 2000; Ricks et al., 2009), 
endocytosis of the receptor (Dery et al., 1999) and reduces its vesicular trafficking 
(Ramachandran et al., 2012b; Roosterman et al., 2003).  
1.2.4 PAR2 activation at ECL2: tethered ligand motif, PAR2-APs and small molecules 
 The first PAR-APs were mimetic of the tethered ligand motifs for the receptors: TFLLR-
NH2 for PAR1 (Hollenberg et al., 1997), SLIGRL for PAR2 (Hollenberg et al., 1996), TFRGAP 
for PAR3 (Kawao et al., 2003) and AYPGKF-NH2 for PAR4 (Bretschneider et al., 2003). 2fly 
has 10- to 300-times the in vitro potency of SLIGRL-NH2, depending on the in-vitro assay 
(McGuire et al., 2004b). 2-furoyl substitutes for the S in SLIGRL, provides a functional hydroxyl 
group and demonstrates some protection from aminopeptidases (Kawabata et al., 2004a). 
Interestingly the terminal ornithine leads to an increased potency (McGuire et al., 2004b). 
 The first reports of small non-peptide molecules that activated PAR2 came in 2008 by 
Gardell and colleagues. This cohort synthesized molecules that have anionic bonds with peptide 
characteristics and contain aromatic phenyl derivatives. The first small molecule activators had 
potencies comparable to 2fly, this was determined by assaying phosphatidylinositol hydrolysis in 
cell culture (Gardell et al., 2008). The non-peptidic molecules induced the same rat paw edema 
inflammatory response seen in other PAR2-AP studies (Gardell et al., 2008; Tae et al., 2003). 
Another PAR2 agonist, GB110, was shown to have potency comparable to 2fly demonstrated by 
Ca
2+
-response assays in HT29 carcinoma cells (Barry et al., 2010).  
PAR2-APs are still capable of activating PAR2 that has been cleaved by enzymes, such 
as elastase (Hansen et al., 2008). Elastase cleaves PAR2 by cleaving the carboxyl side of the 
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tethered ligand motif (Hansen et al., 2008). During vascular dysfunction such as blood thrombus 
development, neutrophil elastase leaks into the blood plasma where it is free to interact with the 
surface of the endothelium (Wachtfogel et al., 1983). Elastase activation of PAR2 (i.e. 
disarming) stimulates mitogen-activated protein kinase (MAPK) pathways which modulate gene 
transcription (Ramachandran et al., 2011).  
1.2.5 PAR2 inhibitors and the cessation of PAR2 signaling 
 In vivo PAR2 silencing is thought to be mediated by phosphorylation and receptor 
internalization. The natural termination of PAR2 signaling follows its activation and the 
phosphorylation of several serine and threonine residues on the internal carboxyl terminus 
(Bohm et al., 1996; Ricks et al., 2009). The phosphorylation, mediated by G-protein coupled 
receptor kinases, is a crucial step in recruiting β-arrestin 1 and 2 which are essential to 
desensitize the receptor (Dery et al., 1999; Ricks et al., 2009; Seatter et al., 2004). This 
phosphorylated C-terminus and β-arrestin complex then docks to an AP2 adapter protein that 
mediates clathrin-coated pit formation around PAR2 (Wolfe et al., 2007). The C-terminus of the 
receptor, adapter and scaffolding protein complex is subsequently ubiquitinated and targeted for 
internalization and trafficking to RAB5A-positive early endosomes (Hasdemir et al., 2009).  
 PAR2 silencing is achieved experimentally through the use of synthetic inhibitors. The 
first PAR2 antagonist discovered to inhibit both the tethered ligand and PAR2-AP activation was 
GB83 (Barry et al., 2010). GB83 is a complex pyrroloquinazoline derivative that causes 
surmountable competitive inhibition against SLIGRL-NH2 induced [Ca
2+
]i elevation in HT29 
carcinoma cells (Barry et al., 2010). Peptide-mimetic competitive inhibitors of PAR2 were 
synthesized by Kanke et al., (2009); K-12940 and K-14585 (Kanke et al., 2009). These inhibitors 
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eliminated SLIGKV-induced [Ca
2+
]i elevations in PAR2-transfected human keratinocytes and 
displaced radiolabelled [
3
H]-2-furoyl-LIGRL-NH2 from PAR2 (Kanke et al., 2009).  
 Antibodies against PAR2 that are specific for the amino terminus residues, have been 
used for immunostaining receptor expression and inhibiting proteolytic activation 
(Ramachandran et al., 2012b). The rabbit anti-PAR2 polyclonal antibody (Ab) B5 recognizes K
51
 
and K
72
 of the amino terminus (Al-Ani et al., 2003). Anti-PAR2 Ab SAM-11 recognizes 
S
37
LIGKVDGTSHVTG
50
 of the amino terminus in human PAR2, with murine and rodent cross 
reactivity (Kelso et al., 2006). Murine studies have demonstrated that intra-articular 
carrageenan/kaolin mediated joint inflammation is attenuated by B5 and SAM-11 in vivo (Kelso 
et al., 2006; Ramachandran et al., 2012b). Additionally, cell penetrating pepducins have been 
designed for inhibiting PAR1, 2 and 4 (Ramachandran et al., 2012b). For example, PAR2-
binding lipopeptide pepducin P2pal-18S inhibited mast cell tryptase-induced paw inflammation 
in mice in vivo (Sevigny et al., 2011). The PAR2 activation and inhibitory mechanisms are 
shown in Figure 1. It is also important to discuss another tool for receptor investigation, the 
PAR2-deficient (PAR2-KO) mouse. 
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1.2.6 The PAR2-KO mouse 
 Transgenic PAR2-KO mice are used to research the in vivo effects of par2 gene deletion 
and to investigate the specificity of the in vitro effects of PAR2 agonists. The use of whole 
animal par2 deletion is not without criticism. For example, compensatory resistance vessel 
relaxation pathways may be up regulated in PAR2-KO. Since the first development of a PAR2-
KO mouse strain by Damiano et al., (1999) some differences in the physiology of the transgenic 
model have been discovered. Data acquired by radiotelemetery showed that systolic blood 
pressure in PAR2-KO were ~5 mm Hg higher than PAR2-WT (McGuire et al., 2008). Models of 
inflammation appear to be decreased in PAR2-KO, which is expected considering that PAR2 
activation is associated with enhanced inflammation in vivo.  
Figure 1. Mechanisms of PAR2 activation and inhibition. PAR2 activation via trypsin-like serine 
proteases, PAR2-APs and small molecules (green arrows). PAR2 inhibition by peptidic and non-
peptidic molecules, anti-PAR2 antibodies and pepducins (red lines). See references: (Barry et al., 
2010; Boitano et al., 2011; Ferrell et al., 2003; McGuire et al., 2004b; Ramachandran et al., 2012b; 
Sevigny et al., 2011). 
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 PAR2-KO, used in experiments reported in this thesis, are progeny from crosses of par2 
deficient mice generated by Jackson Laboratory (Bar Harbor, ME). This PAR2-KO model was 
first created by Lindner et al., (2000). Researchers screened a 129/SvJ mouse genomic library for 
the par2 gene, located on chromosome 13, and generated a pNTK targeting vector with a 
neomycin phosphotransferase expression cassette. The recombinant pNTK vectors replaced the 
par2 gene and were electroporated into embryonic 129/SvJ stem cells. Selection then took place 
for male PAR2 heterozygous (PAR2-HET) chimeras. Male PAR2-HETs were mated with female 
wild-type C57BL/6J mice. B6.Cg-F2rl1
tm1mslb
/J PAR2 knockout mice were generated by 
breeding the male and female PAR2-HETs. 
1.2.7 PAR2 and animal models of human disease 
 The motivation for developing specific PAR-APs and antagonists lies in exploring the 
role of PARs in disease states (Ramachandran et al., 2012b). PAR2 may act in a beneficial or 
deleterious manner depending on the disease model (McGuire, 2004). In models of colitis 
(Lohman et al., 2012), arthritis (Kelso et al., 2006) and asthma (Gu et al., 2009) PAR2 activation 
has been associated with increased macrophage infiltration while PAR2-KOs showed an 
improved disposition (Lee et al., 2012b). Yet chronic in vivo activation of PAR2 lowers systolic 
blood pressures in mice (Hughes et al., 2013) but PAR2-KOs have modestly increased systolic 
blood pressures (McGuire et al., 2008). Chronic infusion of PAR2-AP 2fly also caused vascular 
dysfunction in mice, which may have limited its blood pressure lowering activity (Hughes et al., 
2013). This PAR2-AP induced dysfunction caused attenuated NO-mediated relaxation in murine 
aortas (Hughes et al., 2013). PAR2 activation may benefit organ perfusion; resistance vessels 
relax to PAR2 agonists in the presence of endothelial dysfunction despite impairment of other 
vasodilation mechanisms (Chia et al., 2011; Smeda et al., 2010). Naturally the specific pathology 
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would dictate whether inhibition or activation of PAR2 would be of greatest therapeutic benefit 
(McGuire, 2004).With a foundation of PAR2 molecular biology and physiology, the endothelial 
signaling pathways of the receptor will now be presented. 
1.2.8 NO/ PGI2-mediated vascular smooth muscle relaxation 
 In 1980 classical experiments by Furchgott and Zawadzki demonstrated that isolated 
rabbit aortas precontracted with α1 adrenergic receptor agonist could relax to ACh (Furchgott et 
al., 1980). A series of experiments by Furchgott and Zawadzki determined that the source of this 
relaxation was the endothelium; in endothelium denuded aortas ACh induced contraction 
(Furchgott et al., 1980). This contraction is not surprising, now that we know VSM cells 
(VSMC) have M3 receptors (Karashima et al., 1981). Ignarro et al. (1987) examined perfused 
bovine intrapulmonary artery and vein for the relaxation properties of EDRF and compared these 
to NO. In the same year another consortium led by Ferid Murad recognized soluble guanylyl 
cyclase (sGC) and 3’, 5’-cyclic guanosine monophosphate (cGMP) as secondary messengers in 
endothelium-dependent NO-mediated VSM relaxation (Murad et al., 1987). The collective 
efforts of Furchgott, Ignarro and Murad to characterize the NO-mediated vascular relaxation led 
to their co-award of The Nobel Prize in Physiology or Medicine in 1998 (The Nobel Foundation, 
1998).  
 ACh binds M3, a 7-transmembrane GPCR located on the plasma membrane of vascular 
ECs (Berstein et al., 1992; Dauphin et al., 1990). When M3 is activated it initiates a signaling 
pathway like that shown in Figure 2. PAR2 activation follows a similar messaging cascade as 
that laid out below. This signal transduction pathway and its effects on VSMC [Ca
2+
]i , as they 
pertain to PAR2 activation, are highlighted in Figure 3.  
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Figure 2. 7-transmembrane G-protein coupled receptor messaging cascade. This GPCR signaling 
pathway occurs in vascular endothelium and leads to the efflux of Ca2+ ions from the endoplasmic 
reticulum into the cytosol. 
A = ligand, i.e. acetylcholine; GPCR = 7-transmembrane G-protein (αβγ) coupled receptor, i.e. M3; 
DAG = diacylglycerol; PIP2 = phosphatidylinositol-4,5-bisphosphate; PLC = phospholipase C; 
PKC = protein kinase C; IP3(R) = inositol triphosphate (receptor).  
 
Figure 3. PAR2 Endothelial-dependent NO and Kca-mediated vascular smooth muscle relaxation. 
Activation of PAR2 by proteinases leads to NO production and Kca activation in vascular endothelium. The NO 
diffuses across the sarcolemma to activate soluble guanylyl cyclase. Kca produces hyperpolarizing membrane 
potential. The result is a decrease in Ca2+ bioavailability in the vascular smooth muscle tissue.  
PAR2 = proteinase-activated receptor 2; eNOS = endothelial nitric oxide synthase; sGC = soluble guanylyl 
cyclase; NO = nitric oxide; GTP = Guanosine-5'-triphosphate; cGMP =3’, 5’-cyclic guanosine monophosphate; 
S/I Kca = small/intermediate calcium-activated potassium channels.  
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 NO-mediated vasodilation has been extensively documented following PAR2 activation. 
We have shown that PAR2 activation by 2fly relaxes aortas in PAR2-WT and PAR2 
heterozygotes (Hennessey et al., 2013). Isometric tension experiments with NOS inhibitor, Nω-
nitro-L-arginine-methyl ester hydrochloride (L-NAME), obliterate PAR2-mediated relaxations in 
PAR2-WT and PAR2 heterozygous murine aortas (Hennessey et al., 2013). In addition many 
conduit arteries other than the aorta rely to varying degrees on NO or PGI2. Vascular relaxation 
mechanisms are different in vessels of smaller diameter which are responsible for perfusion of 
the tissues (Shimokawa et al., 1996) .  
In resistance vessels there is decreasing reliance on NO and PGI2 for relaxation.  In 
murine mesenteric arteries, trypsin and SLIGRL-NH2 induced vasodilation is only slightly 
inhibited by L-NAME (McGuire et al., 2002). Rodent mesenteric artery diameter is inversely 
proportional to reliance on NO for vasodilation (Shimokawa et al., 1996). In murine mesenteric 
arteries incubated with L-NAME, indomethacin and sGC inhibitor 1H-[1, 2, 4] oxadiazolo [4, 3-
α] quinoxalin-1-one (ODQ), there are still robust relaxations to 2fly (Chia et al., 2011).  
1.2.9 NO/PGI2-independent vascular smooth muscle relaxation 
 The first observation of vascular hyperpolarization and relaxation occurring in tandem 
was in guinea pig anterior mesenteric arteries after muscarinic receptor activation by CCh 
(Bolton et al., 1984). Without modern inhibitors, researchers of the time used methylene blue to 
inhibit sGC and hemoglobin to scavenge NO. Through the use of these compounds, and 
indomethacin to inhibit COX, investigators distinguished EDHF as a separate entity from NO 
and PGI2 (Chen et al., 1988). An excellent review by Waldron and Garland in 1994 speculated 
that vascular hyperpolarization closed voltage-dependent calcium channels (VDCC) and 
attenuated smooth muscle contractility. The authors also considered that resistance arteries rely 
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more heavily on extracellular Ca
2+
 during contraction than intracellular stores, setting the stage 
for EDHF research in resistance vessels.  
The NO and PGI2 relaxation pathways are independent from endothelium-derived 
hyperpolarization (EDH). Still, NO has been suggested as an essential mediator in the EDHF 
response (Takaki et al., 2008). Acute inhibition of rodent eNOS in vivo with L-NAME attenuated 
intermediate (IKCa) and small (SKCa) conductance Ca
2+
-activated potassium channel-sensitive 
EDHF-mediated vasodilatation (EDV) (Desai et al., 2006). Hyperpolarization of VSM correlates 
with the opening of large conductance (BKCa) Ca
2+
-activated potassium channels (Chen et al., 
2012). VSM BKCa activation increases NO release from endothelium in rat superior mesenteric 
artery, which may be responsible for some of the EDHF response (Climent et al., 2012). NO 
causes endothelium and vascular smooth muscle hyperpolarization in a variety of tissue, species 
and gender specific manners (Csanyi et al., 2006; Feletou et al., 2006; Feletou et al., 2012). The 
PGI2 pathway is not considered to be directly involved in EDHF-mediated EDV, though it 
causes hyperpolarization in select studies (Giles et al., 2012; Triggle et al., 2012). Molecular 
candidates for EDHF include: hydrogen sulfide (H2S) (Yang et al., 2008), hydrogen peroxide 
(H2O2) (Gao et al., 2007), arachidonic acid metabolites (Brunt et al., 2012), and c-type natriuretic 
peptide (Khambata et al., 2011). It is accepted that potassium channels are essential in all forms 
of EDH and the potassium ion itself is proposed as an EDHF. 
1.2.10 K
+
 channels and the K
+
 ion as EDHF 
 Garland and colleagues disputed the contribution of KATP to the hyperpolarizing 
phenomenon, the EDHF-response was unaffected by glibenclamide in rat mesenteric artery and 
rabbit basilar artery (Adeagbo et al., 1993; Garland et al., 1992; Plane et al., 1993). Dendrotoxin 
studies on rat mesenteric arterial bed proved that EDHF-mediated hyperpolarization would shut 
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KV, ruling out this channel as a contributor (Adeagbo et al., 1993).  KATP-sensitive EDH is only 
observed where classical apamin/ChTX-sensitive EDHF responses are limited (Ohashi et al., 
2005; Skovgaard et al., 2011).The importance of BKCa in EDHF has been challenged by studies 
proving the inability of IbTX to inhibit hyperpolarization (Gluais et al., 2005; White et al., 1997; 
Yamauchi et al., 2012). Chen et al., (2012) have shown that SKCa inhibitors apamin, d-
tubocurarine (dose-dependent) (Teshima et al., 2003) and scyllatoxin (Ayajiki et al., 2000) 
attenuate ACh-mediated relaxations of murine mesenteric arteries. Yet these relaxations and 
hyperpolarizations are also sensitive to IbTX (Chen et al., 2012). Determining which K
+
-
channels are most tightly coupled to hyperpolarization and relaxation is not so straightforward. 
In vivo all subtypes of S/I/BKCa may be active during EDH, though not all mediate the EDHF 
response. BKCa-sensitive relaxations with classical S/IKCa-inhibitor sensitive EDHF have been 
observed in: rodent femoral (Leung et al., 2006), rodent ocular ciliary (Dong et al., 2010) and 
bovine coronary arteries (Yi et al., 2007).   
 Studies have described attenuation or outright ablation of EDHF-mediated effects by 
SKCa inhibitor apamin (Craig et al., 2012; Edwards et al., 1998) and IKCa blockers 1-[(2-
chlorophenyl) diphenylmethyl]-1H-pyrazole (TRAM-34) or ChTX but not BKCa blocker IbTX 
(Craig et al., 2012; Stankevicius et al., 2011). Stankevicius and colleagues (2011) examined 
NS309-mediated (S/IKCa activator) relaxation in rat small mesenteric arteries. They found that 
apamin slightly attenuated relaxation and hyperpolarization, while TRAM-34 had similar effects 
(Stankevicius et al., 2011). The authors found that the combination of both apamin and TRAM-
34 abolished EDHF-mediated relaxation while IbTX had little effect. Table 2 provides a synopsis 
of recent work on K
+
-channels, as they have been implicated in EDHF-mediated responses.  
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 The “K+-cloud” is a phenomenon described in the literature and suggested to be a 
contributor to EDHF. K
+
-clouds are associated with a local rise in internal elastic lamina [K
+
]o 
which is not high enough to induce VSM depolarization, yet sufficient enough to potentiate 
hyperpolarization and relaxation of the vasculature (Edwards et al., 2004). The precise origin and 
functional role of this transient and moderate rise in extracellular [K
+
]o is a matter of contention. 
ECs release of K
+
 ions from SKCa and IKCa that hyperpolarizes VSMCs by activating Kir and 
Na
+
/K
+
-ATPases (Edwards et al., 2004; Weston et al., 2008). These increases in [K
+
]o are 
typically in the range of 6-16 mM (Edwards et al., 1988; Knot et al., 1996) and are sensitive to 
Ba
2+
 + ouabain (Edwards et al., 1998). I can surmise the modern school of thought by stating: K
+ 
-channels are the quintessential generators of EDH and that several factors (EDHFs) can lead to 
the activation of some combination of these K
+
-channels. EDH originates in the endothelium by 
opening SKCa and IKCa and the current traverses across myoendothelial gap junctions (MEGJs) 
onto VSM sarcolemma (Kerr et al., 2012; Mather et al., 2005). A more detailed discussion on 
MEGJs and the propagation of vascular hyperpolarizing current will be presented later. We now 
consider the role PAR2 has played in the dynamic field of EDHF. 
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Model
Reference
 
Proposed  
EDHF 
Sensitive to  inhibition 
of   
K
+
-channel 
K
+
-channel inhibitor used -  
channel inhibited 
Murine corpus cavernosum  
smooth muscle strips (Joshi et al., 2012) 
HNO BKCa IbTX - BKCa 
Murine small mesenteric 
 arteries (Chen et al., 2012) 
NO BKCa IbTX - BKCa 
Rat third-order mesenteric 
 arteries (Favaloro et al., 2009) 
NO Kv 4-aminopyridine - Kv 
Rat coronary arteries (Cheang et al., 2010) H2S Kv 4-aminopyridine - Kv 
Murine small mesenteric 
 arteries (Mustafa et al., 2011) 
H2S 
KATP, (some SKCa  
and IKCa) 
Glibenclamide - KATP;  
apamin - SKCa; ChTX - B/IKCa 
Rabbit carotid arteries (Ohashi et al., 2005) ONOO- KATP Glibenclamide - KATP 
Rat superior mesenteric  
arteries (Gao et al., 2003) 
H2O2 Kv, IKCa, BKCa 
TEA - Kv;  ChTX - B/IKCa; 
 IbTX - BKCa 
Human coronary  
arterioles (Liu et al., 2011) 
H2O2 BKCa IbTX - BKCa 
Human forearm skin 
 arterioles (Brunt et al., 2012) 
CYP2C9-derrived EETs Kv TEA - Kv 
Isolated porcine coronary  
endothelial and vascular smooth  
muscle cells (Weston et al., 2005) 
14,15 and 11,12-EET 
SKCa and IKCa  
(some BKCa) 
Apamin - SKCa; TRAM-39 - IKCa; 
 IbTX - BKCa 
Rat aortas (Lopez-Miranda et al., 2010) Anandamide BKCa IbTX - BKCa 
Rat small mesenteric  
arteries (White et al., 1997) 
Anandamide Kv TEA - Kv 
Rabbit aortas (Li et al., 2010) CNP KATP, Kir 
Glibenclamide - KATP;  
60 mM [KCl] - Kir 
Rat pulmonary arteries (Vang et al., 2010) CNP BKCa IbTX - BKCa 
Rat renal arteries (Zhang et al., 2010) 
Anemoside-A3  
transduction product 
SKCa, IKCa, Kv 
Apamin - SKCa; ChTX - B/IKCa;  
TEA - Kv 
Rat femoral arteries (Leung et al., 2006) 
Acetylcholine  
transduction product  
(H2O2 and/or K
+) 
SKCa, IKCa (some BKCa  
and Na+/K+-ATPase) 
Apamin - SKCa; ChTX - B/IKCa;  
IbTX - BKCa; ouabain - Na
+/K+-
ATPase 
Rat small mesenteric 
 arteries (Stankevicius et al., 2011) 
K+ SKCa and IKCa Apamin - SKCa; TRAM-34 - IKCa 
Rat small mesenteric  
arteries (Weston et al., 2002) 
K+-derived from  
“K+ cloud” 
BKCa and  
Na+/K+-ATPase 
IbTX - BKCa;   
ouabain - Na+/K+-ATPase 
Table 2. Overview of select K
+
-channels involved in EDHF-mediated vasodilation. SKCa - small 
conductance calcium-activated potassium channel; IKCa - intermediate conductance calcium-activated 
potassium channel; BKCa - large conductance calcium-activated potassium channel; ChTX - 
charybdotoxin; IbTX - iberiotoxin; TEA - tetraethylammonium; EET - epoxyeicosatrienoic acid; CNP 
- C-type natriuretic peptide.  
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1.2.11 PAR2 and EDHF 
The presentation of EDHF is heterogeneous across tissues and experimental models. This 
can be illustrated with different experiments on PAR2 in resistance vasculature. KCa-sensitive, 
EDHF-like, PAR2-mediated relaxation was found in murine mesenteric arteries (McGuire et al., 
2002). These tissues relaxed to SLIGRL-NH2 after the NO/PGI2 pathways were inhibited by L-
NAME, indomethacin and ODQ. Relaxation of these arteries was completely inhibited by adding 
apamin and ChTX (McGuire et al., 2002). Independently, apamin or ChTX shifted the CRCs of 
SLIGRL-NH2-mediated relaxations to the right (McGuire et al., 2002). When substituting ChTX 
for IbTX, the relaxations were similar to apamin. This suggests that SKCa and IKCa, but not BKCa, 
play the major role in this PAR2 mechanism (McGuire et al., 2002). McGuire et al., (2004) 
directly observed VSM hyperpolarization upon activation of PAR2 with SLIGRL-NH2. 
NO/PGI2-relaxation pathways and sGC were not required to mediate the hyperpolarization 
(McGuire et al., 2004a). Na
+
/K
+
-ATPase and Kir were, albeit to a much lesser extent, also 
implicated in the vascular hyperpolarization response (McGuire et al., 2004a). This was the first 
time that hyperpolarization and isometric tension data were collected concurrently upon 
activation of PAR2. This group went on to demonstrate that 2fly induced the EDHF response in 
murine small caliber blood vessels (McGuire et al., 2004b).  
 Simultaneous in situ [Ca
2+
]i and isometric tension data were collected from 
PAR2-mediated relaxations in porcine coronary arteries (Nakayama et al., 2001). Using the NOS 
inhibitor nitroarginne and COX inhibitor indomethacin, researchers demonstrated that PAR2-
mediated NO/PGI2-independent relaxation occurred in tandem with decreases in VSM [Ca
2+
]i 
(Nakayama et al., 2001). The use of apamin and ChTX completely inhibited trypsin-mediated 
relaxations and decreases in VSMC [Ca
2+
]i in coronary arteries (Nakayama et al., 2001). An in 
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vivo study by Kawabata et al., (2004) demonstrated that gastric mucosal blood flow was 
increased in rodents upon PAR2-activation by trypsin or SLIGRL-NH2. The authors determined 
that PAR2-mediated increases in gastric mucosal blood flow in anesthetized rats were sensitive 
to apamin and ChTX but resistant to L-NAME and indomethacin (Kawabata et al., 2004b).  
A SLIGRL-induced, NO/PGI2-independent and IKCa-dependent PAR2-mediated 
relaxation was observed in rodent middle cerebral arteries (MCA) (McNeish et al., 2005). 
Modest (15 mM) increases in extracellular [K
+
]o was found to hyperpolarize and relax MCA. 
This K
+
-cloud emulation was inhibited by ouabain and Ba
2+
, suggesting a role for VSM K
+
 
influx through Na
+
/K
+
-ATPase and K
+
-channels (McNeish et al., 2005). A likely candidate for 
the PAR2-mediated EDHF is potassium because inhibition of K
+
-channels attenuates the 
SLIGRL-induced hyperpolarization and relaxation effects. These data suggest that IKCa causes 
PAR2-mediated EDH (McNeish et al., 2005). Smeda et al., (2010) observed PAR2-mediated 
relaxation in rodent MCA. Stroke-prone spontaneously hypertensive rats (SHR) were observed 
to have vascular injury, edema and inflammation which led to endothelial dysfunction and the 
loss of bradykinin-mediated relaxations (Smeda et al., 2010). Despite this, 2fly-induced PAR2-
mediated relaxation was preserved. Significant NO/PGI2-indepdnent relaxation was noted in 
SHR MCA. PAR2-mediated relaxations were sensitive to IKCa blockade by TRAM-34 and SKCa 
inhibition by apamin (Smeda et al., 2010). By eliminating the contribution of NO, COX, CYP 
metabolites, other K
+
-channels and Na
+
/K
+
-ATPase, the authors conclude that endothelial 
hyperpolarizing current generated by IKCa and SKCa propagates through MEGJs to lower VSM 
[Ca
2+
]i causing vasodilation (Smeda et al., 2010).  
Chia et al., (2011) observed similar trends in murine mesenteric arteries from mice 
infused with Ang II. Our group has determined that in murine models of hypertension and 
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endothelial dysfunction (Ang II infusion), ACh-induced relaxations are attenuated while 2fly-
induced vasodilation is preserved (Chia et al., 2011). Utilizing TRAM-34, Chia et al., (2011) 
demonstrated IKCa reliance during NO/PGI2-indepdnent PAR2-mediated relaxation. The 
heterogeneous EDHF mechanisms all rely on KCa, but how are the channels activated? It is more 
than a rise in intracellular [Ca
2+
]i, but a complex and discrete network of Ca
2+
-signaling events.  
1.2.12 Vascular endothelium Ca
2+
-events 
 The majority of work on vascular EC Ca
2+
-transients is performed on cell culture and in 
situ arterial preparations. Few studies are available with data on freshly isolated vascular ECs. 
Advantages of examining isolated cells include removing cell-cell communication that could 
alter individual Ca
2+
-transient dynamics and removing background-noise which can limit the 
sensitivity for local Ca
2+
-transients (Cheng et al., 2008). It is difficult to distinguish cell-cell 
Ca
2+
-communication across gap junctions from bona-fide local Ca
2+
-transients and initiation 
sites for cell wide Ca
2+
-waves (CWW). When comparing the available literature it is evident that 
Ca
2+
-events in situ are more consistent and realistic than in cultured EC. The majority of studies 
utilize fluorescent indicator dyes, like the Fluo-4 AM dye used in this thesis. A drawback to the 
use of fluorescent indicators includes difficulty in standardizing baseline measurements 
(Takahashi et al., 1999). Fluorescent molecules have incomplete affinities for [Ca
2+
]i. 
Mathematical modeling allows for the changes in fluorescence to be correlated  to actual ion 
concentrations (Takahashi et al., 1999).  Hüser and Blatter (1997) examined cultured calf 
pulmonary artery endothelial cells (CPAE) for their local Ca
2+
 response to adenosine-5’-
triphosphate (ATP). CPAE incubated with fluo-3 (cytosolic Ca
2+
-indicating dye) showed small 
discrete Ca
2+
-transients and initiation points for Ca
2+
-induced Ca
2+
-release (CICR) generating 
CWW in peripheral pseudo-phillapodia (Huser et al., 1997). These events labeled “Ca2+-waves” 
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took 24 s to spread across the entire cultured EC, far longer than anything seen in situ (Cheng et 
al., 2008; Huser et al., 1997). It is well documented that cultured cells have different 
cytoskeletal, Ca
2+
 signal transduction and surface receptor properties from freshly isolated and in 
situ preparations (Dawson et al., 2012; Gauthier et al., 2002).  
Ca
2+
-puffs are transients that can propagate across the vascular endothelial layer (Cheng 
et al., 2008; Mumtaz et al., 2011; Tran et al., 2012). In situ these types of events are thought to 
activate SKCa and cause CICR because IP3R are located continuously throughout the ER of the 
endothelium and are concentrated near the plasma membrane and nucleus (Grayson et al., 2004; 
Ledoux et al., 2008). Ca
2+
-events originating in the ER that activate KCa are IP3R dependent, 
considering that XeC and 2-aminoethoxydiphenyl borate (2-APB), a non-selective IP3R 
inhibitor, abolish the Ca
2+
-events (Bintig et al., 2012; Kameritsch et al., 2012). Ca
2+
-puffs may 
be initiated by smaller Ca
2+
-events in very close proximity to the plasma membrane (Cheng et 
al., 2008; Isshiki et al., 2004; Mumtaz et al., 2011). Subplasmalemmal Ca
2+
-wavelets have been 
recorded at < 0.2 µm from the plasma membrane in cultured endothelial cells (Isshiki et al., 
2004). TRPV1 and TRPV4 are non-selective extracellular cation channels which allow 
extracellular Ca
2+
 into ECs upon excitation (Kassmann et al., 2013). This excitation is induced 
by shear stress in vivo and elicited by ACh (in EC) and PAR2 (demonstrated only in non-EC) in 
vitro (Amadesi et al., 2006; Chen et al., 2011; Kassmann et al., 2013; Zhang et al., 2009). The 
implication is that Ca
2+
-puffs may be more than ER Ca
2+
-store release, but an extracellular Ca
2+
-
dependent influx mediated by TRPV (Sonkusare et al., 2012; Sullivan et al., 2012). Large 
TRPV4-mediated Ca
2+
-events are caused by cooperative recruitment of other TRPV4 channels 
during the excitation period, and are known as “Ca2+-sparklets” (Sonkusare et al., 2012). These 
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Ca
2+
-sparklets were ~ 11 µm
2
 in diameter and had a low but sustained amplitude (study 
standardized F/Fo ≈ 0.19-0.29) relative to Ca
2+
-puffs (Sonkusare et al., 2012).  
 Low intraluminal pressure activates TRPV4 receptors in murine cremaster and 
mesenteric artery endothelium (Bagher et al., 2012). Resistance artery preparations were 
mounted on pressure myographs and loaded with Ca
2+
-indicator 488 BAPTA-1 AM. The influx 
of Ca
2+
 from the extracellular space into the ECs was measured on spinning-disk confocal 
microscopy (Bagher et al., 2012). TRPV4 antagonist RN1734 was utilized to separate TRPV4 
Ca
2+
-events from other channel transients. It was concluded that the TRPV4-mediated 
mechanism of vasodilation at low intraluminal pressures is a counterbalance to peripheral 
vasculature autoregulation during hypotension (Bagher et al., 2012). Of further interest is that 
TRAM-34, but not apamin, has similar effects as RN1734 on pressure induced vasodilation. This 
additional KCa data suggests that EC signaling microdomains play a role in the counterbalance of 
autoregulation (Bagher et al., 2012). Our study utilized ruthenium red (RR) to inhibit TRP 
channels. It is important to note that this compound has other effects on cellular Ca
2+
 transport 
including inhibition of mitochondrial Ca
2+
-shuttling (Yoon et al., 2014). Researchers described 
Ca
2+
-event frequency and amplitude correlations to ACh in freshly isolated EC tubes from the 
intima of murine mesenteric arteries (Socha et al., 2012). ACh-induced observations included 
Ca
2+
-event frequency of 10/min (1 µM ACh); amplitude F/Fo ≈ 3.10 and frequency of 5/min (100 
nM ACh) (Socha et al., 2012). At higher agonist concentrations the ECs displayed an even 
distribution of Ca
2+
-waves and Ca
2+
-transients while at lower ACh concentrations the events 
were transient in nature. These data suggest an IP3R threshold mechanism for EC-EC Ca
2+
-
communication (Socha et al., 2012). The calcium events described so far are different from those 
localized around the EC IEL projections.  
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Ledoux et al., (2008) report unique Ca
2+
-events in the endothelial IEL projections from 
3
rd
 order murine mesenteric arteries. This group utilized fast-capture, 30 frames per second (fps), 
Nipkow spinning disk confocal microscopy and found Ca
2+
-events occurring in IEL projections. 
Large, oscillatory ACh-induced Ca
2+
-releases were observed and named “Ca2+-pulsars” (Ledoux 
et al., 2008). The quantitative characteristics of in situ Ca
2+
-pulsars are: larger in size than puffs 
(14-16 µm
2
), have rapid decay (t1/2≈ 140-170 ms) and are larger in amplitude (F/Fo > 1.70) with 
a measureable frequency (Dora et al., 2008; Ledoux et al., 2008). In XeC treated tissues, Ca
2+
-
pulsar frequency was reduced to half and vascular depolarization of ~ 8 mV was recorded. In 
ChTX treated tissues there was no effect on Ca
2+
-pulsars but 8 mV depolarization still occurred 
(Ledoux et al., 2008). These data show the same potentiating effects occur with inhibition of 
Ca
2+
-pulsars as with IKCa-inhibition. The findings are supported with observations made by Dora 
et al., (2008), who examined Ca
2+
-pulsars in the IEL projections of rat mesenteric artery. A 
summary of the vascular Ca
2+
-event characteristics are shown in Table 3.  
One possibility is that the Ca
2+
-puffs and Ca
2+
-pulsars activate endothelial KCa, which 
generate a K
+
-cloud within the IEL whilst hyperpolarizing the vasculature. Studies suggest that 
IP3, Ca
2+
 and other small molecules can travel between EC and VSM along MEGJs. These 
MEGJ are also the proposed route for the transfer of hyperpolarization from the endothelial to 
the smooth muscle layer (Triggle et al., 2012). It is clear that little is known about PAR2 Ca
2+
 
signaling. A brief summary of the available literature is presented. 
28 
 
Ca
2+
-event 
                   
Model
Reference
 
  
[Ca
2+
]o 
(mM) 
 Agonist 
Max amplitude 
(F/Fo) or                                            
max local [Ca
2+
]i 
(nM) 
Area (µm
2
) 
or                            
linear 
spread 
(µm) 
Velocity 
(µm/s) 
t1/2 
(ms) 
Frequency 
(Hz) 
Puffs / endothelial 
sparks 
in situ mouse mesenteric 
endothelial tubes(Socha et al., 2012) 
2.0 [acetylcholine] =      1 µM F/Fo ≈ 3.11 ± 0.20 N/A N/A N/A N/A 
cultured calf-pulmonary                       
artery cells EC (CPAE)(Huser et 
al., 1997) 
2.0 [ATP] = 250 nM 
F/Fo ≈ 1.6 to 2.0             
(~ 23 nM) 
~ 30 µm N/A < 100 N/A 
cultured calf-pulmonary                        
artery EC (CPAE)(Aromolaran et al., 
2007) 
2.0 
[2-deoxy-D-glucose] =10 
mM 
F/Fo ≈ 1.43 ~ 12 µm N/A < 700 N/A 
cultured rat microcoronary                   
EC(Nistri et al., 2012) 
2.0 [angiotensin II] =  1 µM F/Fo ≈ 2.5 N/A N/A N/A N/A 
Pulsars 
in situ mouse third order 
mesenteric artery EC(Ledoux et al., 
2008) 
2.0 [acetylcholine]  = 10 µM F/Fo ≈ 1.77 ~ 16 µm
2 N/A ~ 146 0.06 to 0.10 
in situ mouse third order 
mesenteric artery EC(Nausch et al., 
2012)  
2.0 
Electric field stimulation 
of sympathetic neurons 
F/Fo ≈ 1.37 ~ 14 µm
2 N/A ~ 153 ~ 0.07 
Subplasmalemmal 
cultured bovine aortic EC    
(BAEC)(Isshiki et al., 2004) 
1.2 
Ca2+-free medium 
switched to [Ca2+] = 1.2 
mM medium 
[Ca2+] ≈  45 to       350 
nM 
≤ 0.2 µm 56 ± 26 N/A N/A 
Propagating wave 
in situ rat tail artery EC(Mumtaz et 
al., 2011) 
2.0 [carbachol] = 1 µM F/Fo ≈ 3.0 ~ 50 µm 14  to 44 N/A 0.08 to 0.33* 
in situ hamster feed artery 
EC(Uhrenholt et al., 2007) 
2.0 
[acetylcholine] = 
unknown 
F/Fo ≈ 2.5 > 750 µm 111 N/A N/A 
cultured calf-pulmonary artery 
EC (CPAE) (Huser et al., 1997) 
2.0 [ATP] = 250 nM [Ca2+] ≈ 50 to 100 nM ~ 60 µm 7 to 61 < 1000 ~ 0.02* 
in situ rat ureter artery 
EC(Burdyga et al., 2003) 
2.5 Baseline F/Fo ≈ 4.0 40 to 80 µm 18 to 30 ~ 500 0.15 to 0.4* 
VSMC Sparks 
freshly isolated porcine 
cerebral arteriole VSMC(Liang et 
al., 2012) 
2.0 
[Na2S] = 10 µM (S
2- 
donor for H2S) 
F/Fo ≈ 1.4 (187 ± 12 
nM) 
> 20 µm N/A N/A ~ 4.0* 
freshly isolated rat cerebral 
artery VSMC(Perez et al., 1999) 
1.6 Baseline      F/Fo ≈ 2.0 13.6 µm2 N/A 55.9 N/A 
Table 3. Sample of Ca
2+
-events found in isolated and in situ vascular endothelial cells. Vascular smooth muscle cell (VSMC) sparks are 
presented for comparison. Amplitude data have been standardized by individual research groups and cannot be compared unless direct 
translation to [Ca2+]i has been made, shown where applicable. N/A indicated that the corresponding study did not report these data. * 
indicates where non-repeating events have Ca2+-oscillations superimposed on them. The only events reported to have their own inherent 
frequency are Ca2+-pulsars. 
  
1.2.13 PAR2 and EC [Ca
2+
]i 
 It has been well documented that PAR2 activation results in elevation of cytosolic [Ca
2+
]i 
(Ramachandran et al., 2012b). Most studies only examined PAR2-mediated rises in global 
[Ca
2+
]i and have not commented on the discrete Ca
2+
-transients themselves. Ca
2+
-fluctuations 
have been used as an indicator of the magnitude and sensitivity of PAR2 modulation (Al-Ani et 
al., 1999b; Kanke et al., 2009). Al-Ani et al., 1999 showed that PAR2 activation with trypsin, 
SLIGRL-NH2 or SFLLR-NH2 elevates [Ca
2+
]i  in fluo-3 loaded KNRK cells. McGuire et al., 
2004 demonstrated 2fly concentration-dependent increase of [Ca
2+
]i in KNRK and HEK293 
cells. Similar PAR2-mediated [Ca
2+
]i fluctuations are reported in human umbilical vein 
endothelial cells (HUVEC) (Cleator et al., 2006), human epidermal keratinocytes (Kanke et al., 
2009) and human colon adenocarcinoma grade II (HT29) cells (Barry et al., 2010).  
 PAR2-mediated [Ca
2+
]i fluctuations were observed in rodent cerebral and testicular 
arterioles in situ via spinning-disk confocal microscopy (Misaki et al., 2006). Both trypsin (1000 
U/ml) and SLIGLV-NH2 (100 µM) elicited a time dependent rise in endothelial [Ca
2+
]i (F/Fo ≈ 
2.5 at 800 sec) from Ca
2+
-indicator indo-1 AM loaded arterioles (Misaki et al., 2006). Trypsin 
and SLIGLV-NH2 reversibly decreased VSM [Ca
2+
]i and total arteriole [Ca
2+
]i (Misaki et al., 
2006). Unfortunately, Misaki et al., (2006) did not describe spatial or temporal characteristics of 
PAR2-mediated increases in EC [Ca
2+
]i. This leaves a gap in PAR2 Ca
2+
-event literature. If 
PAR2 Ca
2+
-events are similar to ACh-induced Ca
2+
-pulsars described by Ledoux et al (2008), 
this would explain a portion of the PAR2 hyperpolarization signal transduction cascade. 
Likewise, discovering a relationship between PAR2-mediated Ca
2+
-transient characteristics and 
TRPV may offer an explanation for preserved vasodilation at the signal transduction level.  
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1.2.14 Vascular endothelium signaling microdomains 
Signaling microdomains have been discovered on the plasma membrane of the 
endothelial IEL projections. Microdomains are stabilized by caveolin scaffolding on lipid rafts 
and cooperatively propagate hyperpolarizing current from the endothelial to VSM layer 
(Edwards et al., 2007; Sandow et al., 2009; Triggle et al., 2012). In non-depolarized rodent 
mesenteric artery EDV was sensitive to apamin but not TRAM-34 (Crane et al., 2003). Yet at 
depolarizing potentials only the combination of apamin and TRAM-34 would inhibit EDHF-
mediated EDV (Crane et al., 2003). Researchers hypothesize that different membrane potential 
effects on KCa-dependence mean that SKCa and IKCa occupy different membrane locations on the 
EC (Crane et al., 2003). SKCa is localized to caveolin-rich lipid rafts in close association with 
TRP subtypes V1, V4 and C1 and near endothelial homocellular gap junctions (Absi et al., 2007; 
Dora et al., 2008; Dora, 2010; Mendoza et al., 2010; Saliez et al., 2008; Sandow et al., 2009). 
Studies demonstrate that TRPV4 is localized to ECs of murine mesenteric arteries. Control 
arteries increased endothelial [Ca
2+
]i when subjected to shear stress, while TRPV4 knockout 
mice showed no such response (Mendoza et al., 2010). In mesenteric artery endothelium TRPV4 
are co-localized with caveolin-1 (Saliez et al., 2008). MEGJ connexin proteins (Cx) 37, 40 and 
43 are co-localized with caveolin-1 in regions without TRPV4 (Saliez et al., 2008).  
IKCa is in close association with MEGJs and Na
+
/K
+
-ATPase, occupying a second distinct 
microdomain near endothelial IEL projections. This domain is speculated to be near IP3R on the 
endothelial ER extensions (Ledoux et al., 2008). Intact pressurized rodent mesenteric arteries 
were probed for SKCa, IKCa, Na
+
/K
+
-ATPase and MEGJs (Dora et al., 2008). IKCa and Na
+
/K
+
-
ATPase were preferentially expressed at the site of IEL projections on endothelium. Dora et al., 
(2008) observed MEGJs on the endothelial IEL projections in the same region as IKCa and 
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Na
+
/K
+
-ATPase. MEGJs transport small molecules such as: IP3, ATP, K
+
, Na
+
 and to a lesser 
extent Ca
2+
 and Mg
2+
, but not large peptides or proteins (Behringer et al., 2012; Mather et al., 
2005). MEGJ transport is proposed to be bi-directional and based on the concentration gradient 
(Sandow et al., 2004; Straub et al., 2011). 
 Microsignalling domain proteins SKCa, IKCa and TRPV are involved in PAR2-mediated 
vascular hyperpolarization. It is not known if PAR2 is associated with the same caveolin-rich 
domains. However PAR2 interacts with caveolin during receptor termination in clathrin-coated 
pits (Canto et al., 2012; Ramachandran et al., 2012b). Researchers have colocalized caveolae, 
PAR2 and TF-VIIa in cultured human breast carcinoma cells (Awasthi et al., 2007). Studies must 
be performed to determine if PAR2 is located on signaling microdomains and how PAR2-
containing microdomains may interact with other lipid rafts in vascular hyperpolarization.  
1.2.15 Summary 
 The in vitro effects of PAR2 activation on resistance artery preparations are well 
understood: PAR2 elicits relaxation and hyperpolarization, both  of which are preserved in the 
face of endothelial dysfunction. Yet little research has been conducted on the receptor signal 
transduction in freshly isolated ECs. Studying PAR2 Ca
2+
-events at the level of isolated ECs 
builds a foundation for in situ Ca
2+
-transients and whole artery myograph studies. The focus of 
the study is to determine what purpose is served by PAR2 Ca
2+
-transients in the setting of 
endothelial dysfunction. Using high-temporal resolution spinning disk confocal microscopy and 
the PAR2-KO model this study is the first to identify basic elements of Ca
2+
-transients in EC 
PAR2 signaling. The study observed peripheral and central-repeating Ca
2+
-transients in murine 
mesenteric ECs. I report that EC PAR2-mediated Ca
2+
-signaling is preserved in Ang II-induced 
hypertension where M3-mediated Ca
2+
-events are attenuated. The 2fly experiments have been 
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controlled by comparison to ACh-induced Ca
2+
-events. In addition, I investigated the role of 
IP3R and TRP channels in 2fly and ACh-activated ECs. Both IP3R and TRP channels play 
different but significant roles in PAR2 and ACh-mediated EC Ca
2+
-dynamics. To explore the 
contribution of proteins associated with EDH I examined the expression of PAR2, eNOS, IP3R, 
SKCa and IKCa in fixed EC preparations. This study found the distribution of eNOS was 
attenuated in response to Ang II infusion, and concludes that the reduction may be responsible 
for the reduced vasodilation seen in endothelial dysfunction. 
 Dora, Garland, Ledoux, Segal, Taylor and others shaped the landscape of resistance 
vessel EDHF research. This work aims to contribute to the body of literature by contributing data 
from a family of GPCRs yet to be explored in detail at the Ca
2+
-transient level. If the source of 
the preserved endothelial PAR2 functionality during disease can be pinpointed it could serve as a 
therapeutic target in hypertension, stroke and diabetes. It remains to be determined if various 
Ca
2+
-transients lead to different mechanical activity in blood vessels. This work should provide a 
more complete picture from molecular signaling to mechanical reactivity following PAR2 
activation.  
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Chapter 2: Materials and Methods 
2.1 Mice 
 Littermate PAR-WT and PAR2-KO mice were bred from parental PAR2-WT, PAR2-KO 
and PAR2-HET crosses. All animals were genotyped to confirm identities prior to experiments. 
Male mice (11 to 13 weeks of age; 22 to 33 g) were used in all experiments. Mice were housed 
in a pathogen-free barrier facility from birth until experiments. Barrier temperature, humidity and 
light cycles were monitored by Animal Care Services in the Health Sciences Centre. All 
handling and experimental procedures involving animals were approved by the Institutional 
Animal Care Committee of Memorial University in accordance with guidelines of the Canadian 
Council of Animal Care. 
2.2 Breeding Protocol 
C57BL/6J (PAR-WT) and B6.Cg-F2rl1
tm1Mslb
/J (PAR-KO) mice were initially purchased 
from Jackson Laboratory (Bar Harbor, ME). Multiple crosses of PAR-WT and PAR-KO mice 
were performed to yield F2 C57BL/6J /B6.Cg-F2rl1
tm1Mslb
/J (PAR2-HET) mice with different F1 
lineages. F2 PAR2-HET were crossed to yield F3 PAR2-WT and PAR2-KO animals. 
Additionally F2 PAR2-WT and F2 PAR2-KO were crossed to generate F3 PAR2-WT and PAR2-
KO animals. Mice were weaned at 21 days, tagged, separated by sex and a 2 mm tail clip was 
obtained for genotyping. To reduce variability between groups littermate F3 and F4 generations 
were used in experiments. 
2.3 Materials 
 For the live-cell confocal protocol Fluo-4 AM was purchased from Invitrogen 
(Burlington, ON). Ruthenium red (sc-202328) and xestospongin C (sc-201505) were purchased 
from Santa Cruz Biotechnology (Dallas, TX). 2fly was purchased from Peptides International 
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(Louisville, KT). For the immunocytochemistry (ICC) protocol: bovine serum albumin (BSA) 
was purchased from EMD MilliPore (Billerica, MA). Primary antibodies: polyclonal eNOS anti-
rabbit (ab66127), polyclonal KCNN3 (SKCa) anti-rabbit (ab83737), polyclonal KCNN4 (IKCa) 
anti-rabbit (ab83740) were purchased from Abcam, Inc. (Toronto, ON). Polyclonal IP3R anti-
rabbit, pan isoform in mouse, (407140) was purchased from Calbiochem (Etobicoke, ON). 
Polyclonal PECAM-1 anti-goat (sc-1506) was purchased from Santa Cruz Biotechnology 
(Dallas, TX). The polyclonal PAR2 primary antibody, B5 anti-rabbit, was provided by Dr. 
Morely D. Hollenberg (Calgary, AB). Fluorescein (FITC)-conjugated AffinPure Goat Anti-
Rabbit IgG secondary antibody (111-095-003) and Texas Red® dye-conjugated AffinPure 
Bovine Anti-Goat IgG secondary antibody (805-075-180) were purchased from Jackson 
ImmunoResearch Laboratories, Inc. (West Grove, PA). For the genotyping protocol, 
oligonucleotide primers were purchased from Eurofins MWG Operon (Huntsville, AL) while 
Taq polymerase, MgCl2, DNAse-free water and 10 x PCR buffer were purchased from Bio Basic 
Inc. (Markham, ON). SYBR® Safe for deoxyribonucleic (DNA) gel staining and 1kb plus DNA 
ladder were purchased from Invitrogen (Burlington, ON). All other chemicals and reagents were 
purchased from Sigma-Aldrich (Oakville, ON). 
2.4 Genotyping 
 Mice were genotyped from a modification of the supplier’s protocol (Jackson Laboratory, 
Bar Harbor, ME). DNA extraction was accomplished by heating 2 mm tail clips in 50mM NaOH 
at 95 ˚C for 1 hour, adding Tris-HCl buffer (pH 7.5) and centrifuging at 10,000 x g for 2 min 
before extracting supernatant containing the DNA. DNA samples were kept in storage at -20 ˚C 
until used. PCR was carried out utilizing three oligonucleotide primers to target characteristic 
genes in PAR2-WT and PAR2-KO (Appendix A). The reaction mixture with primers amplified a 
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portion of exon 2 in the par2 gene present in PAR2-WT and a fragment of the neomycin gene 
present in PAR2-KO. PAR2-HETs were identified as containing amplified par2 exon 2 and 
neomycin gene fragments. Gel electrophoresis and DNA staining techniques were employed to 
identify the amplified DNA bands. Gels cast were 1.5% agarose w/v dissolved in tris borate 
ethylenediaminetetraacetic acid (TBE) buffer containing 10 µL SYBR® Safe DNA chelating 
dye.1kb plus DNA ladder, resolving to 100 bp increments, was run parallel to the PCR products 
to discern the sizes of fragments. Gels ran for 1.5 hours at 90 V to separate the DNA bands from 
at a distance ≥ 4 cm from the wells. Migrated PCR products were imaged with Alpha Imager® 
EP (Cell Biosciences, Santa Clara, CA) using trans-illumination with ultraviolet light. 
2.5 Model of endothelial dysfunction: subcutaneous angiotensin II infusion 
Endothelial dysfunction was induced by chronic administration of low doses of 
angiotensin II. Ang II was administered by subcutaneous infusion using micro-osmotic pumps 
(Chia et al., 2011) (Alzet, Cupertino, CA). Micro-osmotic pumps (model #: 1002, pump rate of 
0.25 µl/h) were filled with saline (controls) or Ang II (Chia et al., 2011), then equilibrated for 12 
h at 37 ºC as per manufacturer’s recommendation (Alzet, Cupertino, CA). Male PAR2-WT and 
PAR2-KO were anesthetized with 2% isoflurane (2 L O2/min). Pumps were implanted 
subcutaneously through a dorsal incision on the neck, into a pocket filled with saline along the 
flank, as described previously (McGuire et al., 2008). Surgeries to implant micro-osmotic pumps 
lasted 5-10 min and were followed by administration of 0.02 ml of i.m. duplocillin 
(benzylpenicillin procaine and benzylpenicillin benzathine suspension). After 5 min post-surgical 
recovery the mice were returned to the holding room in the animal care facility. Doses of Ang II 
(1.5 mg/kg/day), delivered over 14 days, were based on previous vascular reactivity studies with 
the Ang II model (Chia et al., 2011).  
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2.6 Endothelial and vascular smooth muscle cell isolation 
 Mice were euthanized by an overdose inhalation of isoflurane followed by cardiac 
puncture with a syringe for blood sampling (1.0 ml), containing 0.1 ml of heparin (10 units). 
Mesentery tissue was extracted and placed in 4 ºC endothelial cell (EC) isolation buffer with the 
following composition (mM): NaCl, 55; glutamate, 80; KCl, 6; MgCl2, 2; CaCl2 1; 4-(2-
hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES), 10; glucose, 10; pH 7.4. The 
mesenteric arteries were then stripped of fat and connective tissue and finely cut into small 
pieces. A modified cellular isolation procedure was then implemented, based on isolation of 
vascular smooth muscle cells for electrophysiology studies (Gauthier et al., 2002). The finely cut 
mesenteric arteries were placed in 4 ºC vascular smooth cell (VSMC) isolation buffer, a Ca
2+
-
free solution, with the following composition (mM):  NaCl, 55; glutamate, 80; KCl, 5; MgCl2, 2; 
ethylene glycol tetraacetic acid (EGTA), 0.1 mM; HEPES, 10; glucose, 10; pH 7.4. 
Dithiothreitol (DDT), 0.5 µg/µL; and protease papain, 0.5 µg/µL; were added to the VSMC 
isolation buffer and tissue mix. The tissue containing solution was then incubated for 30 min at 
37 ºC with agitation. Then CaCl2 (0.2 mM) and proteases collagenase IV 1.0 µg/µL, and neutral 
protease 1.0 µg/µL were added to the 1.0 mL final volume VSMC isolation buffer and tissue 
mix. The preparation was incubated for 25 min at 37 ºC with agitation. After incubation the 
preparation was washed twice with modified EC isolation buffer at 4 ºC. The following washing 
procedure was used, the preparation was centrifuged at 120 x g (Eppendorf micro-centrifuge 
5415c at 1200 rpm) for 5 min and 800 µL supernatant was removed leaving only cell pellet and 
200 µL of VSMC isolation buffer. The buffer was replaced with an equal volume (800 µL) of 2 
mM [Ca
2+
] EC isolation buffer and triturated with a 1000 µL pipette tip (cut at 45 º angle) to 
disperse and suspend the cells. The preparation was kept on ice at 4 ºC and contained a mix of 
isolated ECs and VSMCs. 
37 
 
2.7 Ca
2+
-event imaging 
Cell preparation 
 Aliquots (100 µL) of cells were transferred to separate tubes (1.5 mL) containing EC 
isolation buffer (900 µL) with 2 mM [Ca
2+
]o, plus Fluo-4 AM Ca
2+
-indicator dye (10 µg/mL), 
then incubated at room temperature for 10 min at 37 ºC (pH 7.4). Following Fluo-4 AM 
incubation the preparation was transferred to a 35 mm uncoated glass FluoroDish® (Catalogue #: 
FD35-100, World Precision Instruments, Inc., Sarasota, FL) and cells were allowed to settle for 7 
minutes. The FluoroDish® preparation was transferred to a confocal microscope set up and the 
cells were washed with EC isolation buffer, 2 mM [Ca
2+
]o at 37 ºC and pH 7.4, for 10 min (1 
ml/min). Cell Fluo-4 AM loading and incubation procedure was similar to other described 
protocols (Burdyga et al., 2003; Mumtaz et al., 2011; Socha et al., 2012; Stuyvers et al., 2005). 
Microscope setup for Ca
2+
-image sampling procedures 
 The Fluo-4 loaded cells were positioned in an experimental chamber on the stage of a 
motorized inverted microscope, Olympus IX81 (Olympus, Center Valley, PA). The microscope 
was equipped with 10x ocular, 10x, 40x and 60x objective lenses. The microscope also had a 
1.6x magnifying extension in use for all experiments, total magnification 960x (60x objective 
lens). The microscope was attached to a Nipkow spinning disc unit (Yokogawa CSU-X1, Tokyo, 
Japan). Images were captured on a Fast 1394 Rolera-MGI Plus CCD camera (Q Imaging, Surrey, 
BC).  Illumination for the Fluo-4 dye was provided by a FRAP-3D MAG Biosystems
TM
 laser 
unit equipped with argon diode laser, 488 nm excitation (Microimaging Applications Group 
Worldwide, USA). 512 x 512 pixel images were captured using MAG Biosystems
TM
 CSU 
software version 7.7.0.0 (Molecular Devices, Inc., Sunnyvale, CA). This setup is similar to that 
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used in previous work on cardiac purkinje fibers (Haq et al., 2013; Stuyvers et al., 2005). EC 
isolation buffer perfusion was driven by a Rabbit® Peristaltic pump (Rainin Instrument 
Company, Inc., France). In RR and XeC inhibitor experiments perfusion was provided by an 
11Plus microperfusion apparatus (Harvard Apparatus, Holliston, MA). 
Sampling procedure for PAR2 and M3-mediated Ca
2+
-events 
 After washing, cells were perfused (1 ml/min) with EC isolation buffer, 2 mM [Ca
2+
]o at 
37 ºC and pH 7.4, containing a range of 2fly concentrations (0.1 nM to 3 µM) or ACh (1 nM to 
30 µM). Agonist concentrations corresponding to ED50 values were selected based on isometric 
tension assays of murine mesenteric arteries (Chia et al., 2011). Baseline was not reevaluated 
following agonist addition. After 1 min equilibration with agonist-containing buffer, individual 
cells were resolved at 960x magnification with 488 nm excitation using a 60x objective lens 
under oil-immersion. The calibration of raw images (512 x 512 pixels) was set to 6.825 
pixels/µm. Ca
2+
-events were measured through changes in Fluo-4 fluorescence intensity and 
were resolved in 2D at 30 fps on the mid planar region of the ECs. Acquisition of Ca
2+
-events 
lasted for 7 min after agonist addition (10 s per cell). Baseline Ca
2+
-events (free of agonist) was 
recorded in cells from each animal and served as the reference. A total of 20 animals were 
dedicated to this study alone; 5 each of saline and Ang II infused PAR2-WT and PAR2-KO. 10 
cells were imaged for each concentration of 2fly, ACh, and baseline from 5 PAR2-WT and 5 
PAR2-KO infused with saline or Ang II. Data with median CRC values of agonists [2fly] = 30 
nM and [ACh] = 300 nM were collected from a sample of cells from each animal. Baseline 
activity was also recorded for a sample of cells from each animal. Ca
2+
-events were acquired 
over a 10 s period from each cell with MAG Biosystems
TM
 CSU software version 7.7.0.0 
(Molecular Devices, Inc., Sunnyvale, CA). See Appendix B for a schematic of the protocol.  
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Sampling procedure for IP3R and TRP inhibition effects on Ca
2+
-events 
 After washing, cells were perfused (1 ml total volume per FluoroDish®) with EC 
isolation buffer, [Ca
2+
]o = 2 mM at 37 ºC (pH 7.4) containing either XeC, 2 µM and/or RR, 75 
µM. Concentrations of XeC, IC50 ≈ 358 nM for IP3R channels (Bishara et al., 2002; Gafni et al., 
1997; Naser et al., 2013) and RR, IC50 ≈ 5 nM for TRPV channels (Jornot et al., 1999; Mendoza 
et al., 2010; Phan et al., 2009) were selected based on our trials and other work shown to inhibit 
Ca
2+
-events . Following a 10 min incubation period with XeC and/or RR, either 30 nM 2fly or 
300 nM ACh were added to assess the role of IP3R and TRP channels in the PAR2 and M3-
mediated Ca
2+
-responses. 30 nM 2fly and 300 nM ACh were selected because these agonist 
concentrations correspond to the approximate mid-point (EC50) of the Ca
2+
-event CRCs. Ca
2+
-
events were resolved in ECs as per the non-inhibitor study. 16 animals were dedicated to this 
study alone; 4 each of saline and Ang II infused PAR2-WT and PAR2-KO.10 cells were imaged 
for each combination of XeC, RR, 2fly, ACh and baseline from 4 PAR2-WT and 4 PAR2-KO 
infused with saline or Ang II. Ca
2+
-events were acquired over a 10 s period from each cell with 
MAG Biosystems
TM
 CSU software version 7.7.0.0 (Molecular Devices, Inc., Sunnyvale, CA). 
Refer to Appendix C for a schematic of this experimental protocol.  
2.8 Protein expression study 
Cell preparation 
Following isolation the cell preparations were centrifuged at 120 x g (Eppendorf micro-
centrifuge 5415c at 1200 rpm) for 5 min. The supernatant was decanted leaving behind 200 µL 
of EC isolation buffer and the cell pellet. The cell pellet was then incubated for 5 min with a 600 
µL solution of 1.26% formaldehyde in phosphate buffered saline (PBS) at 4 ºC. 50:1 
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PBS:formaldehyde solution, where formaldehyde was 37 wt. % in water and PBS composition 
was as follows (mM): NaCl, 137; KCl, 2.7; Na2HPO4, 10; KH2PO4, 2.0; pH 7.4 at 4 ºC. After 
fixing, the preparation was centrifuged at 120 x g (Eppendorf micro-centrifuge 5415c at 1200 
rpm) for 5 min and 600 µL of supernatant was decanted leaving the cell pellet. For cell 
membrane permeabilization and non-specific blocking of protein the preparation was incubated 5 
min with 600 µL of 0.1% saponin and 3% BSA solution in PBS at 4 ºC. After permeabilization 
and blocking the preparation was centrifuged at 120 x g (Eppendorf micro-centrifuge 5415c at 
1200 rpm) for 5 min and 800 µL of supernatant was decanted leaving behind the cell pellet. Cells 
were triturated with 800 µL of fresh PBS at 4 ºC and aliquots were distributed according to the 
number of primary antibodies tested. Primary antibody stocks were diluted as follows: 
polyclonal eNOS anti-rabbit, 5 µg/mL; polyclonal IP3R anti-rabbit, 1:1000; polyclonal SKCa, 
KCNN3 anti-rabbit, 1:2000; polyclonal IKCa, KCNN4 anti-rabbit, 1:2000; polyclonal PECAM-1 
anti-goat, 1:500; polyclonal PAR2 primary antibody B5 anti-rabbit, 1:1000. Each preparation 
was dual-labeled with PECAM-1 that was stained with Texas Red®-containing secondary 
antibody, and one of the other above mentioned primary antibodies that was stained by 
Fluorescein isothiocyanate (FITC)-containing secondary antibody. All primary antibodies were 
fully cross reactive with mouse proteins. For each animal a negative staining control preparation 
was run, containing no primary antibody with FITC and Texas Red® secondary antibodies. Each 
preparation contained fixed, permeabilized and isolated ECs and VSMCs. Dilutions of primary 
antibodies were determined based on manufacturers’ recommendation and preliminary testing by 
JCH in our laboratory. Cell preparations were left to incubate with primary antibodies overnight 
at 4 ºC. After 12-16 hrs preparations were centrifuged at 120 x g (Eppendorf micro-centrifuge 
5415c at 1200 rpm) for 5 min and the supernatant removed, leaving behind pellets. 800 µL of 
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fresh PBS at 4 ºC was added and the cell preparations were incubated at 4 ºC for 1 hour 30 
minutes with secondary antibodies:  FITC-conjugated AffinPure Goat Anti-Rabbit IgG, 1:1000; 
Texas Red® dye-conjugated AffinPure Bovine Anti-Goat IgG, 1:500. Dilutions of secondary 
antibodies were determined based on manufacturers’ recommendation and preliminary testing by 
JCH in our laboratory. Following secondary antibody incubation preparations were centrifuged 
at 120 x g (Eppendorf micro-centrifuge 5415c at 1200 rpm) for 5 min and the supernatant was 
decanted leaving behind the cell pellet. 500 µL of fresh PBS at 4 ºC was added and the cell 
preparations were finally moved to 8-well Lab-Tek II chamber covered glass slides (Thermo 
Fisher Scientific, Inc., Rochester, NY).  Cell fixation protocol for ICC was modified from those 
used on cardiac myocytes and purkinje fibers (Stuyvers et al., 2005). 
Microscope set up for immunocytochemistry in situ 
 The fluorescence of secondary antibodies was imaged using an inverted line-scan 
confocal microscope, Olympus Fluoview® FV1000 FV10-ASW (Olympus, Center Valley, PA). 
The microscope was equipped with 10x ocular, 10x, and 60x objective lenses. The microscope 
was attached to an Olympus Fluoview® control unit, main system line scanner for image 
resolution (Olympus, Center Valley, PA). Images were captured on a Spot RT CCD Cool 
Camera (Spot Imaging Solutions, Sterling Heights, MI). Illumination for FITC and Texas Red® 
dyes was provided by a MELESS Griot argon (488 nm excitation) and HeNe (520 nm excitation) 
diode laser unit (CIVI laser optics and MELESS Griot, Albuquerque, NM), powered by a FV10-
MCPSU laser diode power supply system (Olympus, Center Valley, PA). 1024 x 1024 images, 
with 1.6x digital zoom, were captured on Olympus Fluoview® application software, version 5 
(Olympus, Center Valley, PA). Total magnification of images collected was 960x. The 
calibration of raw images (1024 x 1024 pixels) was set at 121.951 pixels/µm. 
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Sampling procedure for secondary antibody fluorescence 
 Fluorescent signals from EC and VSMC were illuminated by dual 488 and 520 nm 
excitation. 2D images were line-scanned at a rate of 4 µs/pixel. Z-stacks through fixed and 
settled cells were acquired at 0.25 µm step thickness. Images were also attained for EC and 
VSMCs without primary antibodies but with FITC and Texas Red® to determine non-specific 
signals. 16 animals were dedicated to this study; 3 ECs from each well were acquired from 4 
PAR2-WT and 4 PAR2-KO that were infused with saline or Ang II. All images and z-stacks 
were captured on Olympus Fluoview® software, version 5 (Olympus, Center Valley, PA). 
2.9 Data processing 
(a) Intracellular Ca
2+
-events 
 All image processing was performed using the open source NIH software ImageJ version 
1.47 (Research Services Branch, National Institutes of Health, Bethesda, MD). The dynamics of 
intracellular Ca
2+
 was imaged by capturing a series of 300 frames (512 x 512 pixels, 30 frames 
per second). Serial frames were stored as stacks of images and later converted to AVI files on 
MAG Biosystems
TM
 CSU software. Converted image stacks were then examined by a semi-
automatic method to examine the spatial and temporal characteristics of Ca
2+
-events. First the 
number of Ca
2+
-release sites and the number of Ca
2+
-events per site were counted frame by 
frame visually during a 10 s acquisition sequence. The “Z Profiler” plugin for ImageJ (Kevin 
(Gali) Baler and Wayne Rasband, National Institutes of Health, Bethesda, MD) was utilized to 
scan the entire image stack for confirmation of Ca
2+
-release site number and Ca
2+
-events per site. 
F/Fo ratio image stacks were created for each Ca
2+
-event by dividing pixel by pixel (“Ratio Plus” 
ImageJ plugin) all images (F) in the stack by a frame (Fo) selected immediately before a transient 
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rise in fluorescence. F/Fo images reflected the actual rise in fluorescence that was directly 
proportional to the [Ca
2+
]i variations. Image stacks were then smoothed (single pass) using the 
ImageJ “Gaussian Smoothing” function. Spatial properties of Ca2+-events were analyzed using 
the “Dynamic Profiler” line scans. Finally, the temporal characteristics of Ca2+-events in 
smoothed ratio images were captured using the “Z Profiler” ImageJ plugin. All spatial and 
temporal quantitative characteristics were exported using ImageJ to Microsoft Excel®, 2010 
(Microsoft, Redmond, WA). The repetitive nature of individual central Ca
2+
-release sites was 
determined by maintaining a small (< 0.5 µm) fixed Z-profiler region over the release site of 
interest. The 300 frame video was then cycled and all central Ca
2+
-event initiations (determined 
by maximal fluorescence falling within the Z-profiler region) were counted. 
 Further intracellular Ca
2+
-events was processed as follows: 
(i) Non-propagating Ca
2+
-event determination 
All Ca
2+
-events, peripheral and central-repeating, were determined to be non-propagating 
by analyzing the fluorescence (F/Fo) of discrete events spatially. The transition of fluorescence 
between cytosol and extracellular space localized the EC plasma membrane in transverse scans 
to determine cell boundaries. Dynamic profiles of Ca
2+
-events across the cell, pixel-to-pixel, 
determined that from the point of origin of a Ca
2+
-event there was no sustained rise in 
fluorescence. This is characteristic of Ca
2+
-event diffusion and not CICR. This type of transverse 
line-scan to determine non-propagation is similar to that performed in the past with cardiac 
purkinje fibers (Stuyvers et al., 2005). 
(ii) Spatial data processing 
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Dynamic Profiler data from ImageJ was graphed for all Ca
2+
-events. Groups’ spatial 
profiles were averaged and the mean curves were compared. Maxima (maximum amplitude or 
greatest F/Fo) were measured directly from the spatial graph. GraphPad Prizm version 4.0 
interpolation function was utilized to determine Full-width at half-maximum amplitude 
(FWHM). Frequencies (Hz) of central-repeating Ca
2+
-transients were calculated by dividing the 
number of events from a single central locus into the time period (10 s) of the video. Frequencies 
of each individual central Ca
2+
-release site per cell were combined into a cell average, which was 
then combined into a group average (10 cells per group).  
(iii) Temporal data processing 
Z Profiler data from ImageJ was graphed for all Ca
2+
-events. Groups’ temporal profiles were 
averaged and the mean curves were compared. Total duration was determined by using 
GraphPad® Prizm version 4.0 interpolation function to intersect time (s) and fluorescence return 
to baseline (F/Fo ≈ 1). Interpolation determined the time to rise to maximum amplitude from 
baseline (trise = tMAXIMA – to) and time to decay to half maximum amplitude from event maxima 
(t1/2 = thalf-MAXIMA – tMAXIMA). 
(b) Protein expression in situ 
 All image processing was performed on ImageJ version 1.47 (Research Services Branch, 
National Institutes of Health, Bethesda, MD). As indicated above, the cells were sliced optically 
(z-stepping) by collecting vertical series of frames across the full thickness of the preparation. 
This operation was performed automatically (software controlled) by progressively changing the 
confocal plan (focus) by 0.25µm steps. First, the analysis of the immunodistribution begins with 
selection of the optical section that is close to the equator of EC . Red staining of EC membrane 
45 
 
protein PECAM-1 was used to position the plasma membrane. The cell equator was detected by 
tracking the greatest circumference of the cell across the z-stack images. Image stacks were 
smoothed (single pass) using the ImageJ “Gaussian Smoothing” function. Image J plugins were 
used to process dual channel (488 nm and 522 nm) images from the cell equator by a method 
similar to work by Edwin Moore and colleagues (Fletcher et al., 2010; Scriven et al., 2008; 
Scriven et al., 2005). Briefly, images were separated into 488 nm and 522 nm channels and 
converted from the grey scale intensity domain into the frequency domain using the “Fast 
Fourier Transform” function on ImageJ. The resulting power spectra were filtered by a baseline 
black mask to filter low-frequency noise from the image.  
 Power spectra were then de-convoluted using the inverse FFT function on Image J. 
“Dynamic Profiler” ImageJ plugin was then used to perform spatial line scans across images. 
The scan line was selected manually so that it covered the entire width of the cell at the center. 
Line scans were conducted at the same location at both wavelengths for all images. For KCNN3 
and KCNN4 ICC experiments, scans were carried out at the periphery of the cell. The expression 
of the potassium channels was discontinuous around the plasma membrane and the circular ‘free-
hand’ line-scan tool in Image J was utilized. This ‘free-hand’ tool allowed for the total 
fluorescence to be quantified on the EC equator periphery. Representative images were 
processed as above and converted from grey-scale (8-bit) to RGB (32 bit) pseudo-color scales. 
 Line scan data of each channel from processed ICC images were imported into GraphPad 
Prizm software version 4.0 (GraphPad, San Diego, CA). Fluorescent signal intensity grey value 
(scaled from 0 to 255) were expressed as % Maximum Fluorescence (255 grey value = 100%). 
The signal intensities distributed along the length axis of each cell was averaged across groups as 
% Cell Length. These processes were conducted to accommodate the expression changes across 
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differently sized cells. To determine protein distribution, peak signal FWHM and total area 
integrals were calculated. Area under the curve integration was calculated across the line scan 
from one end of the cell to the other (%Maximum Fluorescence x % Cell Length). KCNN3 and 
KCNN4 were heterogeneously expressed on the cell periphery in discrete populations. To fairly 
represent this discrete expression, peripheral scan integrals of total peripheral fluorescence were 
calculated for KCNN3 and KCNN4 (%Maximum Fluorescence x Cell circumference).  
2.10 Statistical Analyses 
 GraphPad Prizm software version 4.0 (GraphPad, San Diego, CA) was used to generate 
graphs and to conduct the statistical analyses of all data.  In results tables and graphs the 
statistical significant notations are: “a or *” p <0.05; “b or **” p < 0.01; “c or ***” p < 0.001. 
2fly and ACh concentration response curves (CRCs) 
10 cells per data point from a total of 5 different animals across both par2 strains and 
treatments (saline or Ang II-treated) were used to construct each CRC. The software fit drug 
CRCs for each agonist to a four-parameter equation by nonlinear regression equation to calculate 
the variables Emax, pD2, Bottom and Hill slope:  
Number of Ca
2+
-release sites/cell (or number of Ca
2+
-events/release site/s) = Bottom + 
(Emax - Bottom) / (1 + 10 ^ (log EC50 - log[Drug]) * Hill slope)  
 Where: Emax is maximum number of Ca
2+
-release sites/cell (or maximum number of 
Ca
2+
-events/release site/s); pD2 is negative log10 of curve EC50 value; Bottom is baseline level of 
Ca
2+
-events (minimum response region); Hill slope is curve steepness (rate of change in the 
number of Ca
2+
-events with increasing drug concentration); Drug is 2fly or ACh. CRC variables 
were compared by two-way ANOVA followed by Bonferroni post-hoc test. 
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Effect of XeC and RR on 2fly and ACh Ca
2+
-response 
10 cells per data point from a total of 4 different animals across both par2 strains and 
across treatments (saline or Ang II-treated) were used to evaluate each XeC and /or RR with 30 
nM 2fly or 300 nM ACh combination. Data were arranged in bar graphs where maximum 
response in number of Ca
2+
-release sites/cell or number of Ca
2+
-events/release site/s were 
compared by two-way ANOVA followed by Bonferroni post-hoc test. Where S.E.M. = 0 
unweighted two-way ANOVA was used. No variance was observed in some inhibitor 
preparations due to the low number of cells with Ca
2+
-events.  
Spatial and temporal characteristics of non-propagating Ca
2+
-events 
Ca
2+
-event characteristics variables (amplitude, trise, t1/2, FWHM and frequency) were 
compared by the following method: the means of two independent groups were compared by 
Student’s t-test for unpaired data where p < 0.05 was considered significant. Statistical 
comparisons of the means of more than two independent groups were performed by two-way 
ANOVA followed by Bonferroni post-hoc test. n = the number of cells from each group. 
Protein expression in situ 
 Secondary antibody parameters, relative maximum fluorescence (PAR2 and IP3R) and 
the integral of relative maximum fluorescence (eNOS, KCNN3 and KCNN4), were compared by 
two-way ANOVA (treatment x genotype) and compared by Bonfferoni post-hoc test. n = 6 cells 
from each group. 
Chapter 3: Results 
3.1 Genotyping of par2 strains 
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We determined the genotype of all mice using PCR (section 2.4) to identify carriers of 
the par2 gene. Agarose gel electrophoresis was conducted to separate amplified par2 and 
neomycin DNA fragments (Figure 4). par2 DNA bands were observed in all PAR2-WT and 
neomycin bands were found in all PAR2-KO mice used in this study. 
 
 
 
3.2 Morphology of endothelial cells 
 The mesenteric artery cellular isolation (section 2.6) contained a mix of endothelial and 
vascular smooth muscle cells. The typical dimensions of ECs from mesenteric arteries measured 
13 ± 0.1 µm wide by 16 ± 0.1 µm long. Endothelial cells were generally round-oval and flat in 
shape with a smooth surface following isolation. VSMCs were considerably larger than ECs, 
with dimensions 3-5 times the length of ECs. The gross morphology of ECs and VSMCs under 
white light did not vary across par2 strains or with Ang II treatment (Figure 5). 
Figure 4. par2 genotyping gel experiment. Representative PCR products from mouse tail samples were 
separated by agarose gel electrophoresis and stained by SYBR® Safe (section 2.4). Positive identification of 
par2 gene (385 base pairs) in lanes 2 and 4. Positive identification for neomycin gene (198 base pairs) in lanes 
3 and 5. Previously identified PAR2-WT (lane 4) and PAR2-KO (lane 5) were run as positive and negative 
controls, respectively. Lane 1 contains the 1 Kb Plus DNA Ladder used for band identification.  
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3.3 Effect of PAR2 activation on Ca
2+
-events of endothelial cells 
 To determine the effect of PAR2 activation on intracellular calcium activity, Fluo-4 
fluorescent dye experiments were performed using a spinning-disk confocal microscope setup.  
Fluo-4 intensity is proportionate to free cytosolic [Ca
2+
]i. Changes in Ca
2+
-events are inferred 
from relative elevations in Fluo-4 fluorescence. Endothelial dysfunction in PAR2-WT and 
PAR2-KO was produced by continuous subcutaneous infusion with Ang II for 14 days; saline 
was used in controls.  In separate mesenteric arterial ECs, Ca
2+
-Fluo 4 fluorescence data were 
recorded before and during exposure to different concentrations of PAR2 agonist 2fly (0.1 nM to 
3 µM) or ACh (1 nM to 30 µM). ECs were constantly perfused with agonist in buffer containing 
2 mM [Ca
2+
]o. At concentrations of [Ca
2+
]o between 1-10 mM, preliminary work indicated that 
the number of Ca
2+
-release sites or firing rates were relatively stable in our isolated ECs over a 
10 s imaging sequence.  
Figure 5. Gross morphology of representative endothelial and vascular smooth muscle cells 
isolated from mesenteric arteries in mice. Isolated endothelial cells from saline (a, c) and angiotensin 
II (b, d) treated PAR2-WT (a, b) and PAR2-KO (c, d) were imaged in transmitted light mode. A saline treated 
PAR2-WT vascular smooth muscle cell (e) is shown for comparison. Both endothelial and vascular smooth 
muscle cells were found in all preparations. Scale bars 10 µm, magnification 960 x. 
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 In PAR2-WT, we found that both 2fly and ACh increased the number of Ca
2+
-release 
sites per cell and the Ca
2+
-event firing rate in a concentration dependent manner (Figure 6). 2fly 
increased the number of Ca
2+
-release sites 12-fold and Ca
2+
-event firing rate 6-fold in PAR2-WT 
over PAR2-KO. In PAR2-WT, compared to 2fly, the number of Ca
2+
-firing sites and firing rate 
were 50% lower in presence of ACh (Figure 6). PAR2 agonist 2fly enlisted the same number of 
Ca
2+
-release sites per cell and had equivalent Ca
2+
-event firing rates in Ang II treated PAR2-WT 
and controls (Figure 6).  
 Yet the recruitment of the Ca
2+
-release sites by ACh was attenuated by 22% in Ang II 
PAR2-WT (p < 0.001, Emax, Figure 6b). Similarly for ACh, Ca
2+
-event firing rate was decreased 
by 24% in Ang II PAR2-WT compared to controls (p < 0.01, Emax, Figure 6d). These 
attenuations in Ca
2+
-events were not observed for 2fly CRCs. Notably, the same Ca
2+
-event 
firing rate was measured in the presence of 2fly and ACh in Ang II and control PAR2-WT (p > 
0.05, Emax, Figure 6c, 6d). The slope of the Ca
2+
-event firing rate curve was 1.5-times steeper for 
2fly than ACh (p < 0.01, Hill slope).  
 Data collected from PAR2-KO confirmed the specificity of 2fly for activating PAR2 
(Figure 6a, 6c) and showed that par2 genotype had no effect on Ca
2+
 activities elicited by ACh 
(Figure 6b, 6d). Curve-fit function variables for concentration response curves (CRCs) are 
located in supplement Tables S1 and S2.  
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Figure 6. Effect of chronic angiotensin II infusion on PAR2 and M3-mediated endothelial Ca
2+
-events. 
Freshly isolated mesenteric endothelial cells from saline and angiotensin II-infused male PAR2-WT and PAR2-KO 
were perfused with varying concentrations of either (a, c) 2-furoyl-LIGRLO-amide (2fly) or (b, d) acetylcholine 
(ACh). Top graphs (a, b) represent the increase in Ca2+-event sites by agonists, bottom graphs (c, d) represent change 
in Ca2+-event site firing rate. Symbols are means ± S.E.M., n = number of endothelial cells per point, 5 animals per 
curve. Lines represent 4 parameter logistic curves which calculate the variables: pD2, Emax and Hill slope. Variables 
were compared by 2 way ANOVA (treatment x genotype), followed by Bonferroni post-hoc testing. (b) cp < 0.001, 
Emax, Ang II PAR2-WT and PAR2-KO vs Controls. (d) 
bp < 0.01, Emax, Ang II PAR2-WT vs Controls. 
ap < 0.05, Emax, 
Ang II PAR2-KO vs Controls. bp < 0.01, Hill slope, PAR2-WT 2fly vs ACh. 
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3.4 Effects of inhibition of IP3R and TRPV channels on intracellular Ca
2+
-
activities 
 To determine the molecular nature of the Ca
2+
-release units, endothelial cells were 
pretreated with  an inhibitor of IP3R (xestospongin C, XeC, 2 µM) and/or transient receptor 
potential vanilloid channels (ruthenium red, RR, 75 µM) and then exposed to 2fly (30 nM) or 
ACh (300 nM). ECs were constantly perfused with the inhibitor and agonist combinations in 
buffer solution, 2mM [Ca
2+
]o. Ca
2+
-events was then assessed as described in section 3.2, and 
compared to measurements from cells without channel inhibitors or agonist. Inhibition of IP3R 
with XeC abolished the 2fly and ACh-mediated increase of Ca
2+
-release sites in PAR2-WT 
controls and Ang II (p < 0.001, Ca
2+
-release sites/cell, Figure 7a, 7b). Inhibition of TRPV with 
RR partly reduced the 2fly and ACh mediated number of Ca
2+
-release sites in PAR2-WT 
controls and Ang II (Figure 7a, 7b). Data collected from PAR2-KO confirmed that par2 
genotype had no effect on inhibition of Ca
2+
-activities elicited by ACh in controls or Ang II. 
PAR2-KO did not show increased Ca
2+
-events to PAR2 agonist 2fly. See supplement Tables S3-
S5 for detailed statistics. 
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Figure 7. Effect of IP3R and TRPV channel inhibitors on Ca
2+
-activities in endothelial cells from saline 
and Ang II-infused PAR2-WT mice. Freshly isolated mesenteric endothelial cells from saline and angiotensin II 
(Ang II) -infused male PAR2-WT were incubated with inhibitors  xestospongin c (XeC, 2 µM) and/or ruthenium red 
(RR, 75 µM) and then exposed to agonists (a) 2-furoyl-LIGRLO-amide (2fly, 30 nM) or (b) acetylcholine (ACh, 300 
nM). Controls = saline-treated PAR2-WT. Data were analyzed by 2 way ANOVA (inhibitor x genotype/treatment group) 
followed by Bonferonni post-hoc testing. Where S.E.M. = 0, unweighted 2 way ANOVA was used. n = 10 cells, 4 
animals per group. (a) cp < 0.001, Ca2+-release site density, 2fly + XeC, + RR, + (RR + XeC) vs Controls. (b) cp < 0.001, 
Ca2+-release site density, ACh + XeC, + RR (saline)  + (RR + XeC)  vs Controls; ap < 0.05, Ca2+-release site density, 
ACh + RR (Ang II) vs Controls.  
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3.5 Specific Ca
2+
-transients in endothelial cells  
3.5.1 Identification of peripheral and central Ca
2+
-transients 
 Ca
2+
-transients induced by 2fly (3 µM) in saline PAR2-WT could be separated by 
plotting their frequency and amplitude distributions. The amplitude distribution histogram 
(Figure 8) revealed two distinct groups in the overall population of Ca
2+
-transients induced by 
2fly (3 µM). Group 1 was composed of Ca
2+
-events with amplitude F/Fo = 1.77 ± 0.01and group 
2 encompassed Ca
2+
-transients of larger amplitudes F/Fo = 3.14 ± 0.02 (p < 0.001, Amplitude, 
Figure 8 and Table 4). Interestingly, most events of group 1 were found at the periphery of the 
cell, whereas the vast majority of group 2 events were located at the cell centre. The distribution 
of Ca
2+
-events was skewed towards more peripheral events. 
  Interestingly, there was a higher proportion of peripheral events recruited by 2fly (3 µM) 
than by ACh (30 µM), 87% vs 69% of total events respectively (Table 4). The same amplitude 
difference between Ca
2+
-transient types was also found for baseline and ACh-induced Ca
2+
-
events in all other treatment and genotype groups. Choice of agonist did not affect the dynamic 
(amplitude, FWHM) or kinetic (trise, t1/2) parameters of either type of Ca
2+
-transient compared to 
baseline (Table 4). Ang II treatment had no effect on the distribution or characteristics of 
peripheral and central Ca
2+
-events.  
 Line-scans of 2fly (3 µM) induced peripheral and central Ca
2+
-transients over a 300 
frame (10 s) acquisition period are depicted in a 2D heat map (Figure 9). Surface plots of 
peripheral and central Ca
2+
-transients (Figure 10) illustrate kinetic and dynamic differences 
between the two event types. Three characteristics differentiated each type of event. First, the 
time to rise from baseline to maximum amplitude was shorter for peripheral than central events 
(p < 0.001, trise: 80 ± 1 ms vs 98 ± 1 ms). Second, the time to fall from maximum amplitude to 
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half maximum amplitude was longer for peripheral than central events (p < 0.001, t1/2: 205 ± 1 
ms vs 115 ± 1 ms). Third, a regular frequency was measured in the occurrence of large central 
events  (0.64 ± 0.12 Hz) and Ca
2+
-release clearly originated from the same locus within the cells. 
This was confirmed by consecutively analyzing central events through different vertical confocal 
planes. Ca
2+
-transient parameters were unaffected by the choice of agonist (Figure 11, Table 4). 
Endothelial dysfunction produced by Ang II, and par2 genotype did not affect the characteristics 
of events. See Table 4 for spatial and temporal characteristics of Ca
2+
-transients. 
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Figure 8. Distinct peripheral and central Ca
2+
-transients induced by 2fly in saline treated 
PAR2-WT. Ca2+-transients analyzed from 2-furoyl-LIGRLO-amide (2fly, 3 µM) induced events in saline 
treated PAR2-WT endothelial cells. Controls = saline-treated PAR2-WT.  The curves shown represent the 
best fit Gaussian distribution for the frequency distribution data (bin width F/Fo = 0.02) of peripheral Ca
2+-
events (left, solid curve) and central-repeating Ca2+-transients (right, hatched curve). 2fly amplitude 
distributions are not significantly different from Ca2+-events induced spontaneously at baseline or by 
acetylcholine (ACh, 30 µM). ***p < 0.001, Amplitude, central vs peripheral. 
56 
 
  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
 
 
 
Figure 9. Representative line scan images of peripheral and central-repeating Ca
2+
-transients 
induced by 2fly in saline treated PAR2-WT. Ca2+-transients induced by 2-furoyl-LIGRLO-amide (2fly, 
3 µM) collected over a 10 s acquisition period in saline treated PAR2-WT endothelial cells. FWHM, full width 
at half maximum amplitude. (a) Peripheral Ca2+-transients with average amplitude F/Fo ≈ 1.77, (FWHM 20 % 
cell length); (b) central-repeating Ca2+-transients with average amplitude F/Fo ≈ 3.14, (FWHM 34 % cell 
length). The characteristics of Ca2+-transients were not significantly different across agonist, genotype or 
treatment groups (see Table 4). 
Figure 10. 3D surface plot of peripheral and central Ca
2+
-transients induced by 2fly in saline 
treated PAR2-WT. Ca2+-transients induced by 2-furoyl-LIGRLO-amide (2fly, 3 µM) collected over a 10 s 
acquisition period in saline treated PAR2-WT endothelial cells. trise, time to rise to maximum amplitude; t1/2; 
half-life of Ca2+-transients. (a) Representative plot of peripheral Ca2+-transients with average trise ≈ 80 ms , t1/2 ≈ 
205 ms ; (b) Representative plot of central Ca2+-transients with average trise ≈ 98, t1/2 ≈ 115. The trise and t1/2 of 
Ca2+-transients were not significantly different across agonist, genotype or treatment groups (see Table 4). 
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Figure 11. Average spatial and temporal characteristics of peripheral and central Ca
2+
-
transients from saline treated PAR2-WT. Freshly isolated mesenteric endothelial cells from saline 
treated PAR2-WT were exposed to 2-furoyl-LIGRLO-amide (2fly, 3 µM), acetylcholine (ACh, 30 µM) or at 
baseline (without agonist). Average characteristics of peripheral (a, b) and central (c, d) Ca2+-transients’ spatial 
(a, c) and temporal (b, d) profiles are presented. Values are means ± S.E.M., n = number of Ca2+-events from 
10 cells, 5 animals per group. S.E.M. calculated from number of cells with Ca2+-transients present. Values 
were obtained by line scan analysis of Ca2+-events in freshly isolated PAR2-WT mesenteric endothelial cells. 
Data were analyzed by 2 way ANOVA (Ca2+-event type x genotype/treatment group) followed by Bonferonni 
post-hoc testing. (a) Insert: Sample raw plot of peripheral 2fly-induced Ca2+-transient amplitude measured 
across the space of an endothelial cell. (c) Insert: Sample raw plot of central 2fly-induced Ca2+-transient 
amplitude measured across the space of an endothelial cell. ***p < 0.001, Amplitude; FWHM, central vs 
peripheral. (d) ***p < 0.001, trise; t1/2, central vs peripheral. 
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Ca
2+
-Event 
Type 
Treatment Genotype Agonist n 
Amplitude 
(F/Fo)
 
FWHM (% 
max cell 
length) 
trise (ms)
 
t1/2
 
(ms)
 Frequency
ac
 
(Hz) 
Peripheral 
Saline 
PAR2-WT 
Baseline 10 1.80 ± 0.03 20 ± 1 80 ± 2 203 ± 3 N/A 
2fly 303 1.77 ± 0.01 20 ± 1 80 ± 1 205 ± 1 N/A 
ACh 137 1.78 ± 0.02 20 ± 1 80 ± 1 206 ± 1 N/A 
PAR2-KO 
Baseline 9 1.81 ± 0.03 20 ± 2 78 ± 2 203 ± 2 N/A 
2fly 9 1.75 ± 0.03 19 ± 1 78 ± 3 203 ± 3 N/A 
ACh 126 1.76 ± 0.01 20 ± 1 80 ± 1 205 ± 1 N/A 
Ang II 
PAR2-WT 
Baseline 5 1.78 ± 0.04 22 ± 2 81 ± 3 205 ± 3 N/A 
2fly 289 1.77 ± 0.01 20 ± 1 80 ± 1 204 ± 1 N/A 
ACh 92 1.80 ± 0.02 20 ± 1 80 ± 1 204 ± 1 N/A 
PAR2-KO 
Baseline 6 1.79 ± 0.05 19 ± 2 79 ± 3 203 ± 2 N/A 
2fly 7 1.76 ± 0.04 20 ± 2 81 ± 2 206 ± 2 N/A 
ACh 93 1.78 ± 0.03 20 ± 1 81 ± 1 206 ± 1 N/A 
Central*** 
Saline 
PAR2-WT 
Baseline 4 3.11 ± 0.06 33 ± 1 101 ± 4 113 ± 4 0.02 ± 0.02 
2fly 45 3.14 ± 0.02 34 ± 1 98 ± 1 115 ± 1 0.64 ± 0.12c 
ACh 63 3.12 ± 0.02 33 ± 1 99 ± 1 115 ± 1 0.82 ± 0.18c 
PAR2-KO 
Baseline 3 3.17 ± 0.05 31 ± 2 93 ± 2 116 ± 5 0.03 ± 0.02 
2fly 3 3.16 ± 0.07 32 ± 1 99 ± 4 112 ± 2 0.02 ± 0.01 
ACh 65 3.14 ± 0.02 33 ± 1 100 ± 1 116 ± 1 0.77 ± 0.06c 
Ang II 
PAR2-WT 
Baseline 3 3.19 ± 0.05 31 ± 1 102 ± 3 112 ± 1 0.02 ± 0.02 
2fly 43 3.14 ± 0.02 33 ± 1 101 ± 1 115 ± 1 0.52 ± 0.11c 
ACh 30 3.14 ± 0.02 33 ± 1 99 ± 2 115 ± 1 0.32 ± 0.06a 
PAR2-KO 
Baseline 3 3.21 ± 0.05 33 ± 2 102 ± 2 112 ± 4 0.02 ± 0.02 
2fly 4 3.11 ± 0.12 36 ± 1 99 ± 5 117 ± 2 0.04 ± 0.02 
ACh 33 3.13 ± 0.02 33 ± 1 100 ± 2 113 ± 2 0.34 ± 0.04a 
Table 4. Effect of PAR2 and M3 activation on characteristics of peripheral and central Ca
2+
-events from mice with and 
without endothelial dysfunction. Values are means ± S.E.M., n = number of Ca2+-events from 10 cells, 5 animals per group. 
S.E.M. calculated from number of cells with Ca2+-transients present.  S.E.M. = 0 indicates that all cells observed had the same 
number of Ca2+-release sites or rate.2-furoyl-LIGRLO-amide (2fly, 3 µM); acetylcholine (ACh, 30 µM); Baseline (without 
agonist); FWHM, full width at half-maximum Ca2+-event amplitude (% maximum cell length). Values were obtained by line 
scan analysis of Ca2+-events in freshly isolated PAR2-WT and PAR2-KO mesenteric endothelial cells. Data were analyzed by 
2 way ANOVA (Ca2+-event type x genotype/treatment group) followed by Bonfferoni post-hoc testing. Where S.E.M. = 0, 
unweighted 2 way ANOVA was used. cp < 0.001, Frequency, saline and Ang II PAR2-WT 2fly vs baseline. cp < 0.001, 
Frequency, saline PAR2-WT and PAR2-KO ACh  vs  baseline. ap < 0.05, Frequency, Ang II PAR2-WT and PAR2-KO ACh vs 
baseline. ***p < 0.001, all parameters, central vs peripheral. 
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3.5.2 Effect of endothelial dysfunction on PAR2 and M3-mediated peripheral and central 
Ca
2+
-transients 
 To assess whether agonists and endothelial dysfunction had different effects on 
peripheral and central Ca
2+
-events, data from Figure 6 were reanalyzed based on the location of 
Ca
2+
-events. 2fly, compared to ACh, was a more potent activator of endothelial cells for both 
types of Ca
2+
 events (Figure 12a, 12b). Activation of peripheral events occurred at lower 
concentrations of 2fly and ACh than for central events.   
 PAR2 agonist 2fly (Figures 13a, 14a), recruited the same number of sites of peripheral 
and central Ca
2+
 events per cell in PAR2-WT controls and Ang II. ACh compared to 2fly 
produced half the number of sites of peripheral and central Ca
2+
 events per cell. ACh peripheral 
and central Ca
2+
-transients (Figure 13b, 14b) were decreased by 22% and 23%, respectively in 
Ang II treated PAR2-WT (p < 0.05, peripheral, Emax; p < 0.01, central, Emax). Similarly for ACh 
(Figures 13d, 14d), the firing rate of peripheral and central Ca
2+
-release units in PAR2-WT were 
decreased by 20-50% in Ang II treated cells compared to controls. 
 Data collected from PAR2-KO confirmed the specificity of 2fly for PAR2 recruitment of 
both peripheral and central Ca
2+
-transients (Figure 13a, 13c and 14a, 14c). PAR2-KO data 
demonstrated that the par2 genotype had no effect on peripheral or central Ca
2+
-events elicited 
by ACh in controls or Ang II (Figure 13b, 13d and 14b, 14d). Curve-fit function variables for 
CRCs are located in supplement Table S6 and Table S7. 
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Figure 12. PAR2-activating peptide 2fly vs ACh activation of Ca
2+
-release units in mesenteric 
arterial endothelial cells from PAR2-WT. Concentration-response data from PAR2-WT of 2-furoyl-
LIGRLO-amide (2fly) vs acetylcholine (ACh) recruitment of cells displaying (a) peripheral and (b) central 
Ca2+-release units. 2fly activation of PAR2 is a more potent mechanism for endothelial cell Ca2+-events 
recruitment than M3 activation by ACh. n = 10 cells per group at each concentration of agonist. Horizontal 
dashed line indicates the mean response rate under baseline (no agonist) conditions in cells from wild-type 
saline-treated mice (n = 20 cells). 
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Figure 13. Effect of angiotensin II infusion on PAR2 and M3-mediated peripheral Ca
2+
-transients 
in endothelial cells. Freshly isolated mesenteric endothelial cells from saline and angiotensin II-infused male 
PAR2-WT and PAR2-KO were perfused with varying concentrations of either (a, c) 2-furoyl-LIGRLO-amide 
(2fly) or (b, d) acetylcholine (ACh). Top graphs (a, b) represent peripheral Ca2+-event site recruitment by agonists, 
bottom graphs (c, d) represent peripheral Ca2+-transient release rate by agonists. Symbols are means ± S.E.M., n = 
number of endothelial cells per point, 5 animals per curve. Lines represent 4 parameter logistic curves which 
calculate the variables: pD2, Emax and Hill slope. Variables were compared by 2 way ANOVA (treatment x 
genotype), followed by Bonferroni post-hoc testing. (b) 
ap < 0.05, Emax, Ang II PAR2-WT and PAR2-KO vs 
Controls. (d) cp < 0.001, Emax, Ang II PAR2-WT and PAR2-KO vs Controls. 
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Figure 14. Effect of angiotensin II infusion on PAR2 and M3-mediated central Ca
2+
-transients in 
endothelial cells. Freshly isolated mesenteric endothelial cells from saline and angiotensin II-infused male 
PAR2-WT and PAR2-KO were perfused with varying concentrations of either (a, c) 2-furoyl-LIGRLO-amide 
(2fly) or (b, d) acetylcholine (ACh). Top graphs (a, b) represent central Ca2+-event site recruitment by agonists, 
bottom graphs (c, d) represent central Ca2+-transient release rate by agonists. Symbols are means ± S.E.M., n = 
number of endothelial cells per point, 5 animals per curve. Controls = saline-treated PAR2-WT. Lines represent 
4 parameter logistic curves which calculate the variables: pD2, Emax and Hill slope. Variables were compared by 
2 way ANOVA (treatment x genotype), followed by Bonferroni post-hoc testing. (b) 
cp < 0.001, Emax, Ang II 
PAR2-WT and PAR2-KO vs Controls. (d) cp < 0.001, Emax, Ang II PAR2-WT and PAR2-KO vs 
Controls. 
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3.5.3 Effect of IP3R and TRPV channel inhibition on peripheral and central Ca
2+
-transient 
events in endothelial cells 
 To determine whether the molecular characteristics of the Ca
2+
-release units for 
peripheral events differed from central events, the data from Figure 10 were re-analyzed by event 
type.  Inhibition of IP3R with XeC decreased the Ca
2+
-release site density by 2fly and ACh of 
peripheral and central Ca
2+
-release units in Ang II-treated and control PAR2-WT (p < 0.001, 
Ca
2+
-release site density, Figure 15).  TRPV inhibitor RR reduced PAR2-mediated peripheral 
and central Ca
2+
-release site density (Figure 15a, c). For M3 receptor-mediated events, only 
central Ca
2+
-events in control PAR2-WT showed partial attenuation to RR (p < 0.01, Ca
2+
-
release site density, Figure 15d). The combination of XeC + RR affected Ca
2+
-release site 
recruitment similarly to XeC alone. 
 Endothelial dysfunction did not alter the inhibition by XeC, RR, and RR + XeC of 
peripheral Ca
2+
-release by 2fly or ACh in PAR2-WT (p > 0.05, Ca
2+
-release site density, Figure 
15a, 15b). Inhibition  of central Ca
2+
-release site density by XeC and RR + XeC was not 
different across treatment groups (p > 0.05, Ca
2+
-release site density, Figure 15c, 15d). In ACh 
central Ca
2+
-events, release site density was attenuated by RR in control PAR2-WT but not in 
Ang II treated animals. Data collected from PAR2-KO confirmed that par2 genotype had no 
effect on inhibition of peripheral or central Ca
2+
-events elicited by ACh in controls or Ang II. 
See supplement Tables S8-S13 for detailed statistics separated by Ca
2+
-transient type. 
 The inhibitors also attenuated the dynamic and kinetic characteristics of the Ca
2+
-events. 
IP3R inhibition with XeC reduced 2fly-induced peripheral Ca
2+
-transient amplitude by 32% and 
FWHM by 55%, and increased the rise time of events (Figure 16a, 16b). XeC had similar, but 
more profound effects on central Ca
2+
-transients (Figure 16c, 16d). RR attenuated the FWHM of 
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2fly-induced peripheral Ca
2+
-transients by 20%, but did not change the amplitude or temporal 
parameters (Figure 16a, 16b). Interestingly, TRPV channel inhibition with RR had different 
effects on central Ca
2+
-transients. RR attenuated the amplitude, but not FWHM, of PAR2-
mediated central Ca
2+
-transients by 32% (Figure 16c). There was no effect of RR on the 
temporal characteristics of central Ca
2+
-transients (Figure 16d). The combination of RR and XeC 
produced the similar effects as XeC alone. The effects of inhibitors on Ang II treated EC Ca
2+
-
transients were similar to controls. There was no combination effect of treatment (saline or Ang 
II) and inhibitors on the spatial or temporal characteristics of Ca
2+
-transients. See supplement 
Tables S14-S17 for detailed statistics of the inhibitory study Ca
2+
-event characteristics. 
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Figure 15. Effect of IP3R and TRPV channel inhibitors on peripheral Ca
2+
-activities in endothelial 
cells from saline and Ang II-infused PAR2-WT. Freshly isolated mesenteric endothelial cells from saline and 
angiotensin II (Ang II) -infused male PAR2-WT were incubated with inhibitors xestospongin c (XeC, 2 µM) and or 
ruthenium red (RR, 75 µM) and then exposed to agonists (a,c) 2-furoyl-LIGRLO-amide (2fly, 30 nM) or (b,d) 
acetylcholine (ACh, 300 nM). Ca2+-events were separated by type: peripheral (a,b) and central (c,d). Controls = saline-
treated PAR2-WT. Data were analyzed by 2 way ANOVA (inhibitor x genotype/treatment group) followed by 
Bonferonni post-hoc testing. Where S.E.M. = 0, unweighted 2 way ANOVA was used. n = 10 cells, 4 animals per 
group. (a) cp < 0.001, Ca2+-release site density, 2fly + XeC, + RR, + (RR + XeC) vs Controls. (b) cp < 0.001, Ca2+-
release site density, ACh + XeC, + (RR  + XeC) vs Controls. (c) cp < 0.001, Ca2+-release site density, 2fly + XeC, + RR, 
+ (RR + XeC) vs Controls. (d) cp < 0.001, Ca2+-release site density, ACh + XeC, + (RR + XeC) vs Controls; bp < 0.01, 
Ca2+-release site density, ACh + RR (saline) vs Controls. 
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Figure 16. Effect of inhibitors XeC and RR on characteristics of PAR2-mediated peripheral 
and central Ca
2+
-event profiles from saline-infused PAR2-WT. Freshly isolated mesenteric 
endothelial cells from saline treated PAR2-WT were exposed to combinations of xestospongin c (XeC, 2 µM) 
or ruthenium red (RR, 75 µM) and Control (no inhibitor) plus 2-furoyl-LIGRLO-amide (2fly, 3µM). 
Peripheral (a, b) and central (c, d) Ca2+-transients spatial (a, c) and temporal (b, d) characteristics were 
assessed. Values are means ± S.E.M., n = number of Ca2+-events from 10 cells, 5 animals per group. S.E.M. 
calculated from number of cells with Ca2+-transients present. Values were obtained by line scan analysis of 
Ca2+-events in freshly isolated PAR2-WT mesenteric endothelial cells. Controls = saline-treated PAR2-WT.  
Data were analyzed by 2 way ANOVA (Ca2+-event type x genotype/treatment group) followed by Bonferonni 
post-hoc testing. Where S.E.M. = 0, unweighted 2 way ANOVA was used. (a) cp < 0.001, Amplitude; FWHM, 
XeC vs Controls. bp < 0.01, FWHM, RR vs Controls. (b) cp < 0.001, trise, XeC vs Controls. (c) 
cp < 0.001, 
Amplitude; FWHM, XeC vs Controls. cp < 0.001,  Amplitude, RR vs Controls. (d) cp < 0.001, trise, XeC vs 
Controls.  
 
 
67 
 
3.6 Effects of endothelial dysfunction on the subcellular distribution of PAR2, 
IP3R, eNOS, SKca and IKca in endothelial cells 
3.6.1 Identification of endothelial cells 
 Immunocytochemistry experiments were carried out to determine the effects of Ang II 
treatment on protein expression in endothelial cells. In addition to morphology, ECs were 
identified by probing for platelet endothelial cell adhesion molecule type 1 (PECAM-1) located 
on the plasma membrane. In all ICC experiments positive PECAM-1 signal verified the identity 
of endothelial cells (Figure 17) and delineated the periphery of the plasma membrane (Figure 
18). Primary antibody for PECAM-1 was detected by staining with a Texas Red secondary 
antibody. VSMCs did not express red fluorescent signal when determined at 522 nm in the 
presence of PECAM-1 and Texas Red antibody. PECAM-1 staining did not vary across par2 
genotype or with Ang II treatment. 
 
 
 
 
(a) (b)
Endothelail Cell Vascular Smooth Muscle Cell
Figure 17. Texas Red staining of PECAM-1 identified endothelial cells. Isolated and fixed saline 
treated PAR2-WT endothelial cell (a) and vascular smooth muscle cell (b) probed with PECAM-1 primary 
antibody and Texas Red fluorescent secondary antibody. Images are Texas Red channels at 522 nm 
superimposed on white light images from the same cell plane. Positive PECAM-1 probing presents as a red 
colored signal. Red signal not on cells indicates the presence of debris which absorbed Texas Red secondary 
antibody. White line at bottom right of images is a scale bar = 10 µm. Magnification 960 x.  
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Figure 18. Identification of PAR2 on the plasma membrane in PAR2-WT endothelial cells. Plasma 
membranes of endothelial cells were demarcated by peak intensity of peripheral Texas Red signal. FITC, 
fluorescein isothiocyanate. Position zero (µm) is the origin of the line scan analysis for PECAM-1 fluorescent 
signal. (a) PECAM-1 Texas Red signal on the periphery of a representative saline treated PAR2-WT endothelial 
cell. (b) FITC signal for the same cell (below) demonstrates that PAR2 lies on the plasma membrane. (c) Saline 
treated PAR2-WT endothelial cell probed for PECAM-1 and PAR2. (i) PAR2 signal, green FITC; (ii) PECAM-1, 
Texas Red and (iii) FITC, Texas Red and white light composite image. Yellow signal indicates colocalization of 
PAR2 and PECAM-1. White line at bottom right of images is a scale bar = 10 µm. Magnification 960 x. 
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3.6.2 Effect of par2 genotype and endothelial dysfunction on protein expression in 
mesenteric endothelial cells 
PAR2 expression 
 To determine whether an increase in PAR2 expression preserved the Ca
2+
-signals by 
PAR2 agonist, PAR2 specific immunofluorescence across cells was compared between Ang II 
and saline treated PAR2-WT.  Staining of PAR2 in ECs from saline and Ang II PAR2-WT 
overlapped with PECAM-1 near the periphery, and was observed to a lesser extent 
heterogeneously throughout the cell (Figure 19a-d). PAR2 immunofluorescence specificity in 
PAR2-WT was confirmed by comparing to PAR2-KO cells (Figure 19e-h). We found that the 
distribution of PAR2 immunofluorescence in Ang II treated ECs were unchanged from that of 
saline controls (Figure 20).  
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Saline Ang II
PAR2-WT
PAR2-KO
Figure 19. PAR2 immunocytochemistry staining from mesenteric endothelial cells across par2 
genotypes and treatment groups. Isolated and fixed mesenteric endothelial cells from saline (a, c, e, g) 
and angiotensin II (b, d, f, h) treated PAR2-WT (a-d) and PAR2-KO (e-h) were probed with primary antibody 
for PAR2 and PECAM-1. Secondary antibody labeling with Texas Red (PECAM-1, red) and FITC, 
fluorescein isothiocyanate, (PAR2, green) reveal the location of PAR2 and PECAM-1 proteins in each group. 
Top panels (a, b, e, f) are FITC channel images showing the location of PAR2 signal only; bottom panels (c, d, 
g, h) are white light, FITC and Texas Red composite channel images showing the location of gross cellular 
structures, PAR2 and PECAM-1. Yellow signal indicates colocalization of PAR2 and PECAM-1. Acellular 
structures with red, green or yellow fluorescent signals are debris that have absorbed secondary antibody. 
There are no significant differences in green FITC PAR2 signal distribution between Ang II and saline PAR2-
WT (a-d). PAR2-KO did not express green FITC PAR2-signal. White line at bottom right of images is a scale 
bar = 10 µm. Magnification 960 x. 
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IP3R expression 
 Based on the live cell imaging data using XeC, IP3R were the predominant Ca
2+
-release 
unit protein in endothelial cells. We investigated whether endothelial dysfunction altered the 
expression of these channels by measuring the distribution of IP3R pan-isoform immunostaining 
in endothelial cells (Figure 21a-h). We found IP3R immunofluorescence distributed as two 
different levels of intensity throughout confocal plane of an endothelial cell.  The highest 
intensity level of IP3R staining corresponded to the periphery of the cells, inside the plasma 
membrane (i.e. PECAM-1 staining). A lower intensity level of IP3R signal was distributed 
throughout the interior of the cell. We did not find a difference between saline and Ang II treated 
PAR2-WT for the distribution of IP3R (Figure 22). PAR2-KO ICC experiments confirmed that 
the par2 gene did not affect the expression of pan-isoform IP3R antibody. 
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Figure 20. Spatial distribution of PAR2 in PAR2-WT endothelial cells with and without 
endothelial dysfunction. Isolated and fixed endothelial cells from saline or angiotensin II treated PAR2-WT 
and PAR2-KO were incubated with primary antibody specific for PAR2. FITC, fluorescein isothiocyanate 
fluorescent conjugate secondary antibody was detected at 498 nm under line scan confocal microscopy. The 
confocal plane presented is from the center of a z-stack series of images. Lines are means, n = 6 cells, 4 animals 
per group. PAR2 staining is congruent with the peripheral boundary of endothelial cells. There was no 
difference in the distribution of PAR2 fluorescent signal between PAR2-WT treatment groups. PAR2-KO 
endothelial cells did not stain with F ITC PAR2 fluorescent secondary antibody (not shown).  
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(e) (f)
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Saline Ang II
PAR2-WT
PAR2-KO
Figure 21. IP3R immunocytochemistry staining from mesenteric endothelial cells across par2 
genotypes and treatment groups. Isolated and fixed mesenteric endothelial cells from saline (a, c, e, g) 
and angiotensin II (b, d, f, h) treated PAR2-WT (a-d) and PAR2-KO (e-h) were probed with primary antibody 
for pan-IP3R subtypes and PECAM-1. Secondary antibody labeling with Texas Red (PECAM-1, red) and 
FITC, fluorescein isothiocyanate, (IP3R, green) reveal the location of IP3R and PECAM-1 proteins in each 
group. Top panels (a, b, e, f) are FITC channel images showing the location of IP3R signal only; bottom 
panels (c, d, g, h) are white light, FITC and Texas Red composite channel images showing the location of 
gross cellular structures, IP3R and PECAM-1. Yellow signal indicates colocalization of IP3R and PECAM-1. 
Acellular structures with red, green or yellow fluorescent signals are debris that have absorbed secondary 
antibody. There are no significant differences in green FITC IP3R signal distribution between Ang II and 
saline PAR2-WT (a-d). There were no differences between PAR2-WT and PAR2-KO IP3R expression (a-h). 
White line at bottom right of images is a scale bar = 10 µm. Magnification 960 x. 
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Expression of downstream Ca
2+
-signaling targets: eNOS, SKca and IKca 
 We also assessed the distribution of several known Ca
2+
-sensitive downstream targets of 
PAR2 signals within the endothelial cells from mice with and without endothelial dysfunction. 
Immunofluorescence staining for eNOS (Figure 23 and Figure 24), but not SKca (Figure 25) or 
IKca (Figure 26), was differently distributed in Ang II treated cells than in control cells. 
Specifically, we found the spread of immunofluorescence for eNOS from the peripheral edges to 
the centre of the cells was reduced in Ang II treated cells compared to controls (Figure 24). The 
expression of both SKca and IKca appeared as discrete loci of fluorescence that were 
discontinuous around the peripheral edges of endothelial cells. Immunofluorescence staining for 
SKca and IKca (Figure 27) in Ang II treated cells were unchanged compared to saline controls. 
There was no effect of the par2 genotype on the expression of the downstream Ca
2+
-signaling 
target proteins.  
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Figure 22. Spatial distribution of IP3R in PAR2-WT endothelial cells with and without 
endothelial dysfunction. Isolated and fixed endothelial cells from saline or angiotensin II treated PAR2-
WT and PAR2-KO were incubated with primary antibody specific for IP3R. FITC, fluorescein isothiocyanate 
fluorescent conjugate secondary antibody was detected at 498 nm under line scan confocal microscopy. The 
confocal plane presented is from the center of a z-stack series of images. Lines are means, n = 6 cells, 4 
animals per group. IP3R staining is congruent with the subplasmalemmal region of endothelial cells. A lower 
level of IP3R expression was noted throughout the cell. There was no difference in the distribution of IP3R 
fluorescent signal between PAR2-WT and PAR2-KO treatment groups (not shown).  
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Figure 23. eNOS immunocytochemistry staining from mesenteric endothelial cells across par2 
genotypes and treatment groups. Isolated and fixed mesenteric endothelial cells from saline (a, c, e, g) and 
angiotensin II (b, d, f, h) treated PAR2-WT (a-d) and PAR2-KO (e-h) were probed with primary antibody for 
eNOS and PECAM-1. Secondary antibody labeling with Texas Red (PECAM-1, red) and FITC, fluorescein 
isothiocyanate, (eNOS, green) reveal the location of eNOS and PECAM-1 proteins in each group. Top panels (a, 
b, e, f) are FITC channel images showing the location of eNOS signal only; bottom panels (c, d, g, h) are white 
light, FITC and Texas Red composite channel images showing the location of gross cellular structures, eNOS 
and PECAM-1. Yellow signal indicates colocalization of eNOS and PECAM-1. Acellular structures with red, 
green or yellow fluorescent signals are debris that have absorbed secondary antibody. Angiotensin II treatment 
reduced PAR2-WT eNOS penetration by 30% and PAR2-KO eNOS expression by 29%, p < 0.001. par2 
genotype had no effect on eNOS fluorescent signal distribution. White line at bottom right of images is a scale 
bar = 10 µm. Magnification 960 x. 
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Figure 24. Spatial distribution of eNOS in PAR2-WT endothelial cells with and without 
endothelial dysfunction. Isolated and fixed endothelial cells from saline or angiotensin II treated PAR2-WT 
and PAR2-KO were incubated with primary antibody specific for eNOS. FITC, fluorescein isothiocyanate 
fluorescent conjugate secondary antibody was detected at 498 nm under line scan confocal microscopy. The 
confocal plane presented is from the center of a z-stack series of images. Lines are means, n = 6 cells, 4 animals 
per group. eNOS staining was expressed continuously at the periphery and penetrated into the cell. Lower 
density fluorescence from eNOS FITC secondary antibody was observed throughout the center of cells. Solid 
line with light grey fill is the integral of area under the curve from saline treated PAR2-WT. Hatched line with 
dark grey fill is the integral of area under the curve from angiotensin II treated PAR2-WT. Integrals were 
calculated as (Maximum Fluorescence (%) x Maximum Cell Length (%)): 5072 ± 43 saline PAR2-WT; 3561 ± 
35 Ang II PAR2-WT. ***p < 0.001, Integral of eNOS expression, Ang II PAR2-WT vs saline PAR2-WT. PAR2-
KO immunocytochemistry revealed that there was no effect of the par2 genotype on the distribution of eNOS 
staining (not shown).  
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Figure 25. SKca immunocytochemistry staining from mesenteric endothelial cells across par2 
genotypes and treatment groups. Isolated and fixed mesenteric endothelial cells from saline (a, c, e, g) and 
angiotensin II (b, d, f, h) treated PAR2-WT (a-d) and PAR2-KO (e-h) were probed with primary antibody for 
SKca and PECAM-1. Secondary antibody labeling with Texas Red (PECAM-1, red) and FITC, fluorescein 
isothiocyanate, (SKca, green) reveal the location of SKca and PECAM-1 proteins in each group. Top panels (a, b, 
e, f) are FITC channel images showing the location of SKca signal only; bottom panels (c, d, g, h) are white light, 
FITC and Texas Red composite channel images showing the location of gross cellular structures, SKca and 
PECAM-1. Yellow signal indicates colocalization of SKca and PECAM-1. Acellular structures with red, green or 
yellow fluorescent signals are debris that have absorbed secondary antibody. Angiotensin II treatment and par2 
genotype had no effect on SKca distribution. White line at bottom right of images is a scale bar = 10 µm. 
Magnification 960 x. 
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Figure 26. IKca immunocytochemistry staining from mesenteric endothelial cells across par2 
genotypes and treatment groups. Isolated and fixed mesenteric endothelial cells from saline (a, c, e, g) and 
angiotensin II (b, d, f, h) treated PAR2-WT (a-d) and PAR2-KO (e-h) were probed with primary antibody for 
IKca and PECAM-1. Secondary antibody labeling with Texas Red (PECAM-1, red) and FITC, fluorescein 
isothiocyanate, (IKca, green) reveal the location of IKca and PECAM-1 proteins in each group. Top panels (a, b, e, 
f) are FITC channel images showing the location of IKca signal only; bottom panels (c, d, g, h) are white light, 
FITC and Texas Red composite channel images showing the location of gross cellular structures, IKca and 
PECAM-1. Yellow signal indicates colocalization of IKca and PECAM-1. Acellular structures with red, green or 
yellow fluorescent signals are debris that have absorbed secondary antibody. Angiotensin II treatment and par2 
genotype had no effect on IKca distribution. White line at bottom right of images is a scale bar = 10 µm. 
Magnification 960 x. 
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Figure 27. Expression of KCNN3 (SKca) and KCNN4 (IKca) in PAR2-WT endothelial cells with 
and without endothelial dysfunction. Isolated and fixed endothelial cells from saline or angiotensin II 
treated PAR2-WT and PAR2-KO were incubated with primary antibody specific for SKca or IKca. FITC, 
fluorescein isothiocyanate fluorescent conjugate secondary antibody was detected at 498 nm under line scan 
confocal microscopy. The confocal plane presented is from the center of a z-stack series of images. Bars are 
means ± S.E.M. n = 6 cells, 4 animals per group. SKca and IKca expression was observed as discrete regions of 
fluorescence congruent with the plasma membrane and did not penetrate into the cell. For comparison:  
peripheral line-scan analysis integrated the fluorescence of secondary antibody (FITC) with the circumference 
of cells. There was no effect of par2 genotype (not shown) or angiotensin II treatment on SKca or IKca staining.   
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Chapter 4: Discussion 
4.1 Main findings 
 This study is the first to investigate the Ca
2+
-signals elicited by PAR2 activation with and 
without endothelial dysfunction in single isolated endothelial cells from small caliber arteries. 
The first hypothesis tested the effects of Ang II treatment on PAR2 and muscarinic –induced 
Ca
2+
-events in murine small caliber ECs. The primary finding is that endothelial dysfunction 
attenuates muscarinic but not PAR2-mediated Ca
2+
-events. Ang II treatment did not change 
PAR2 Ca
2+
-event CRC variables compared to controls, yet CRCs from M3 Ca
2+
-event numbers 
were reduced in Ang II-treated mice. Analysis of the Ca
2+
-events uncovered two separate 
populations of Ca
2+
-transients in the isolated ECs. These events are referred to as peripheral (i.e. 
near the plasma membrane) and central (i.e. in the center of the cell) Ca
2+
-transients. 
 The second hypothesis tested if IP3R and TRPV channels contribute to the Ca
2+
-events 
observed in our ECs. I found that the Ca
2+
-events of both events was entirely abolished by IP3R 
inhibitor XeC, but less attenuated by TRPV channel inhibitor RR. These results show that both 
peripheral and central Ca
2+
-transients are primarily dependent on IP3R channel activity, and less 
on Ca
2+
-entry through TRPV channels. 
 The third hypothesis used immunocytochemistry to test if protein expression and 
distribution of PAR2 and IKca was increased in PAR2-WT with endothelial dysfunction. The 
third hypothesis also tested if eNOS expression was attenuated in response to experimental 
endothelial dysfunction. We found that the expression and distribution of PAR2, PECAM-1, 
IP3R, SKca and IKca were unchanged across treatment groups. Endothelial dysfunction attenuated 
the expression of eNOS in both par2 genotypes. Interestingly, the study revealed two separate 
pools of IP3R expression in our ECs, which may account for the differences between peripheral 
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and central Ca
2+
-transients. Collectively the data suggest that PAR2 Ca
2+
-signaling is preserved 
in our model of endothelial dysfunction. Yet an attenuation of muscarinic signaling was detected 
under the same conditions.  
4.2 Main limitations of the experimental design and techniques 
 The main limitations to the experimental design and techniques used in this thesis 
include: use of fluorescent indicator dye Fluo-4 without another reference standard, the effect of 
out-of-plane Ca
2+
-events on confocal measurements, endothelial cell sensitivity to the laser used 
for imaging and only measuring two GPCR responses (PAR2 and M3). A disadvantage to the use 
of fluorescent indicators (Fluo-4) include challenges in the standardization (Takahashi et al., 
1999). Furthermore, fluorescent molecules have incomplete affinities for [Ca
2+
]i. An inherent 
limitation to the general use of confocal imaging (both line scan and 2D) includes the possible 
acquisition of Ca
2+
-events outside the confocal plane of focus. Such events can radiate into the 
confocal plane and create artifacts or increased background noise. We expect these effects to be 
minimized in our preparation because ECs had a relatively small thickness of 4 µm, where the 
confocal plane was 25% of this thickness at 1 µm. In addition F/F0 image division for each Ca
2+
-
event analyzed removed most of the background noise during the events. Our isolated ECs were 
sensitive to the 488 nm laser excitation. After exposures of more than 10 s cells were observed to 
form vacuoles and leak fluorescent contents into the surrounding medium. Therefore all 
exposures were limited to 10 s or less. It is possible that not all forms of Ca
2+
-event phenomena 
were captured due to the short exposure times. Finally we only measured responses to two 
GPCRs, PAR2 and M3. It is possible that the Ang II-induced attenuation of M3-mediated Ca
2+
-
events would not have been observed for another GPCR, like the bradykinin B2 receptor. A more 
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comprehensive evaluation of other endothelial cell GPCR Ca
2+
-events will allow for a listing of 
pathways that are preserved or attenuated by Ang II-induced endothelial cell dysfunction. 
4.3 Identification of two distinct Ca
2+
-transient types in isolated small caliber 
arterial endothelial cells 
 In this study I resolved the Ca
2+ 
-signals elicited by PAR2 activation at the single EC 
level.  It is well established that PAR2 agonists cause transient increases in global cytosolic 
[Ca
2+
]i (Al-Ani et al., 1999a; Kanke et al., 2009), but previous studies have relied on cells in 
cultured conditions and intracellular Ca
2+
 measuring techniques with limited resolution. We 
obtained new understanding of PAR2 Ca
2+
-signals by applying 2D spinning disk confocal 
fluorescence imaging techniques on freshly isolated single ECs. In our EC preparations, Ca
2+
 
transients were a composition of two distinct types of events. PAR2 agonist 2fly increased the 
activity of both types of events in a concentration-dependent manner. The temporal and spatial 
characteristics of each event type were the same at baseline and when elicited by agonists, which 
indicates that PAR2 increases the open probability of Ca
2+
 channels. Chronic infusion with Ang 
II, par2 genotype and choice of agonist did not influence the kinetic or dynamic characteristics 
of either event.  
 The first type of event, referred to as peripheral Ca
2+
-transients, originated just below the 
level of the EC plasma membrane. We characterized these events as sporadic, with no repetitive 
firing pattern at individual sites (i.e. no measurable frequency). The peripheral Ca
2+
-transients 
we describe have similar properties to Xenopus oocyte EC ‘puffs’ described by other researchers 
(Sun et al., 1998; Thomas et al., 2000; Yao et al., 1995). These ‘puffs’ have also been described 
in situ in murine mesenteric artery EC tubes (Socha et al., 2012). It is important to note that 
variance in analytic techniques across laboratories make comparison of amplitude (F/Fo) data 
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challenging. With this variability in image analysis throughout the literature it is possible that the 
same cytosolic [Ca
2+
]i could result in two different F/Fo. Nevertheless, our isolated EC peripheral 
transients shared IP3R CRU origin with the described in situ EC ‘puffs’ (Socha et al., 2012). 
These similarities suggest that the peripheral Ca
2+
-transients observed by us in isolated ECs are 
possibly translatable to intact vessels. 
 The second type of event, central Ca
2+
-transients, were observed near the cell center at 
the edge of the nucleus. These events typically arose from single loci, generating a measureable 
frequency of large Ca
2+
-releases. Ca
2+
-events similar to our central transients have been 
described in the literature as ‘pulsars’ (Ledoux et al., 2008; Nausch et al., 2012). However, 
‘pulsars’ have been identified as originating near EC projections in the internal elastic lamina of 
small caliber arteries in situ (Dora et al., 2008; Ledoux et al., 2008). Much like our central Ca
2+
-
transients in isolated ECs, pulsars have a rapid decay that is ~ 69% of the trise, frequency and 
fixed release locus within the EC (Ledoux et al., 2008). An explanation for the different 
subcellular locations of our central Ca
2+
-transients and pulsars could be the EC isolation 
technique. Isolation of the ECs disrupts the in situ 3D structure of the internal elastic lamina 
projections and the underlying ER. I isolated the central Ca
2+
-transients as originating from the 
cell center by detecting a focal point of Fluo-4 signal during event initiation. This focal point 
(less than 5 pixels in diameter) was selected prior to image smoothing to improve localization of 
events. I expect that if central Ca
2+
-transients originated in an out-of-focus plane that they would 
have partially diffused upon entering the confocal plane and would not have a concentrated 
fluorescent origin.  
 Aside from their oscillatory nature, central transients had nearly double the amplitude and 
150% the area of their peripheral counterpart. Even though greater [Ca
2+
]i was released by the 
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central transients, the half-life was nearly 50% the duration of peripheral transients. This may 
indicate that SERCA pumps are in higher density or working with greater capacity at the 
centrally located ER. Indeed, SERCA has been uncovered as a major player in the maintenance 
of oscillatory Ca
2+
-event activity in ECs (Mumtaz et al., 2011). In rat artery ECs the initiation of 
Ca
2+
-waves via ‘puff’-like’ events was found to be more reliant on inositol triphosphate release, 
while oscillatory Ca
2+
-releases were intimately dependent on SERCA activity (Mumtaz et al., 
2011). SERCA3 is the main inwardly-rectifying ER Ca
2+
-pump in the endothelium (Khan et al., 
2000). Yet the discovery of other vascular endothelial SERCA subtypes such as SERCA2b 
(Mountian et al., 1999) and the identification of three IP3R isoforms (Grayson et al., 2004) may 
account for the observation of multiple Ca
2+
-transient types.   
 The literature describes cell wide Ca
2+
-waves that propagate within and between ECs 
(Burdyga et al., 2003; Mumtaz et al., 2011; Uhrenholt et al., 2007).  It should be noted that we 
did not observe any propagating Ca
2+
-waves. Current research describes these Ca
2+
-waves as 
typically initiating from ‘puffs’ or subplasmalemmal Ca2+-events (Isshiki et al., 2004). 
Experiments in other laboratories report EC Ca
2+
-waves captured over 1 min exposures to lasers, 
while our exposures to argon-gas laser pulses were 10 s in duration. We found that our ECs 
began to vacuolize and die after ≥ 10 s exposure to the laser on low-intensity settings. It is 
possible that our isolation technique sensitized the ECs to reactive oxygen species generation 
during Fluo-4 laser excitement. Indeed, the maximum frame rate for Ca
2+
-event acquisition was 
30 fps, it is possible that events occurring under 1/30
th
 s would go unnoticed. The scope of such 
rapid events includes reports of some subplasmalemmal events (Isshiki et al., 2004) or blips 
(Cheng et al., 2008). Still our work indicates that 2fly can elicit isolated Ca
2+
-transients that are 
similar to those described by classical M3 receptor activation of vessels in situ. The finding that 
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choice of agonist does not alter the dynamic or kinetic properties of Ca
2+
-events suggests that it 
is the number, and not the characteristics, of peripheral and central Ca
2+
-transients that shape 
vascular responses in small caliber arteries.  
 
4.4 PAR2-mediated Ca
2+
-events is protected from endothelial dysfunction 
 Ca
2+
-signals elicited by PAR2, but not by acetylcholine, are protected from endothelial 
dysfunction in our model. I found that both peripheral and central PAR2-mediated Ca
2+
-
transients’ site recruitment and firing rates were preserved in Ang II treated PAR2-WT ECs. We 
report ‘classic’ characteristics of endothelial dysfunction, described in blood vessels of the Ang 
II infusion model (Chia et al., 2011), are present in single ECs. Specifically, we show that 
acetylcholine elicits Ca
2+
-signals in ECs from PAR2-WT controls that are decreased in cells 
from Ang II treated mice. This finding aligns with previous studies with intact small caliber 
arteries (Chia et al., 2011), where PAR2 dependent responses in endothelial cells were protected 
from endothelial dysfunction caused by Ang II. In reference to its potency and efficacy in intact 
tissues, the pD2 values for the activation of both PAR2 Ca
2+
-events (peripheral, 7.8 and central, 
7.7) correlate with published pD2 values for vasodilation of small caliber arteries (Kagota et al., 
2011; McGuire et al., 2007). It appears that the single endothelial cell measurements of Ca
2+
-
events replicate pharmacological action of the intact tissues. 
 Other studies suggest numerous mechanisms, including those originating in both 
endothelial and non-endothelial cells, that contribute to endothelial dysfunction (Fernandez-
Alfonso et al., 2013; Kagota et al., 2011; Kanikarla-Marie et al., 2014). Previous studies on 
ApoE (-/-) mice demonstrate that selective inhibition of NO synthase attenuates ACh, but not 
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SLIGRL-induced relaxation of murine mesenteric arteries (Beleznai et al., 2011). This and other 
work (McGuire JJ et al., 2002; McLean et al., 2002) suggests that PAR2 can maintain 
hyperpolarization of the vasculature during endothelial dysfunction, leading to preserved 
vasodilation. Our data indicate that this level of PAR2 signal transduction maintenance may 
originate at the level of, or earlier than, endothelial Ca
2+
-events. Banquet et al., (2011) have 
suggested that attenuations to muscarinic receptor response during endothelial dysfunction may 
originate prior to eNOS phosphorylation at Ser(1177) (Banquet et al., 2011). Due to the 
protection of PAR2, but the reduction in M3 receptor-mediated Ca
2+
-signaling, our study 
provides support for the notion that an upstream target closer to receptor activation is a 
significant site of lesion for muscarinic receptor signals in ECs. 
 The effect of PAR2 agonist was to increase the open probability of Ca
2+
 channels, 
specifically IP3R which were inhibited by XeC. In the isolated EC preparations PAR2 agonist 
2fly has a greater capacity for increasing recruitment of Ca
2+
 channels than ACh. Even in cells 
from PAR2-WT, ACh recruited half as many Ca
2+
 channels as 2fly. It has been reported 
previously that the maximal endothelium-mediated hyperpolarization of vascular smooth muscle 
by PAR2 agonist was greater than by ACh in intact tissues (McGuire et al., 2004a). This again 
demonstrates the direct translation of our single cell data to in situ whole vessel studies. On one 
hand, the single cell level provides cellular specificity for investigation. On the other hand, the 
single cell level restricted the scope of our study to endothelial cells alone. Our freshly isolated 
Ang II treated EC model may reveal other targets of endothelial dysfunction resistance. Such 
targets may have potential for de novo pharmaceutical development (i.e. to reverse and/or 
attenuate dysfunction). 
4.5 PAR2-mediated endothelial Ca
2+
-transients depend on IP3R and TRPV  
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 Our investigation of the molecular nature of Ca
2+
-release in the ECs revealed that both 
peripheral and central transients were completely dependent on IP3R channels, while they only 
partially relied on Ca
2+
-entry across TRPV channels. Blocking IP3R could entirely account for 
Ca
2+
-signals elicited by ACh and 2fly. Experiments using IP3R inhibitor XeC completely 
abolished PAR2 and M3 receptor-mediated Ca
2+
-events in ECs. We found a TRPV sensitive 
inhibition of Ca
2+
-signals elicited by ACh and 2fly, which may be produced by the cooperative 
activity of TRPV4 sparklets in endothelial cells. Sparklets were observed under conditions of 
IP3R block in whole tissues (Sonkusare et al., 2012). In various cell types and cell lines under 
cultured conditions, Ca
2+
 signals of different magnitude are explained by incrementally higher 
levels of inositol triphosphate, leading to progressive recruitment of local single IP3R channels 
(blips), close-by multiple channels (puffs), and then globally propagating (waves) channel 
activation (Foskett et al., 2007).   
 PAR2 (Chen et al., 2011; Poole et al., 2013) and M3 receptor (Aure et al., 2010; 
Sonkusare et al., 2012) activation sensitizes TRPV channels leading to rises in intracellular 
[Ca
2+
]i. Specifically, sensitization of TRPV1 and TRPV4 has been correlated to PAR2 signaling 
in non-endothelial cells (Chen et al., 2011). Though our technique did not isolate individual EC 
sparklets as described in the literature, a degree of sensitivity to TRPV inhibitor RR was still 
observed. GPCR sensitization of TRPV Ca
2+
-influx channels may play a role in the filling of 
intracellular Ca
2+
-stores (Ma et al., 2010) or initiate Ca
2+
-events which underpin vascular 
hyperpolarization (Sullivan et al., 2013). RR reduced the recruitment, but not the firing rates of 
Ca
2+
 channels; this supports the notion of an indirect effect of RR on IP3R-mediated Ca
2+
-
release. RR inhibition of TRPV could potentially inhibit Ca
2+
-stores/handling which results in a 
lower capacity for Ca
2+
-release once IP3R were activated. 
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4.6 Expression of PAR2 and downstream target proteins 
 Our immunocytochemistry experiments reveal two pools of fluorescence signal for PAR2 
and IP3R. The more peripheral pool of expression is near the plasma membrane, defined by 
PECAM-1 fluorescence labelling. A second pool of both proteins, albeit lower in fluorescence 
signal, is heterogeneous throughout the cell center. Studies with vascular and cardiac cell types 
found nuclear membranes express seven transmembrane GPCRs (i.e. AT1 and ET-1), which can 
be activated by ligands to elicit Ca
2+
-signals (Bkaily et al., 2003; Gangopadhyay et al., 2010).  
Interior cell expression of PAR2 has been described in RPC lines, a model of retinal pigment 
cells (Zhu et al., 2006). In murine lung fibroblast cell culture, antibody H99 bound ectopic PAR2 
green fluorescent protein is congruent with cell nuclei (Adams et al., 2012). Others who have 
used the PAR2 polyclonal antibody B5 used in this study have not reported central staining in 
murine neurons (Kelso et al., 2006). It is possible that we are the first to present central cellular 
expression of PAR2 in freshly isolated murine mesenteric ECs, or that the central fluorescence is 
an artifact of our methods (despite a lack of PAR2 fluorescent signal in PAR2-KO). All three 
IP3R isoforms are heterogeneously expressed in ECs, with IP3R1 expression predominating 
around the plasma membrane (Grayson et al., 2004). The distinct pools of IP3R expression may 
explain the different kinetic characteristics of peripheral versus central Ca
2+
-events. Based on 
these results we propose a cooperative relationship between GPCRs and IP3R pools that may 
contribute to the differences in recruitment of CRUs.  
 Endothelial dysfunction did not change PAR2, IP3R, SKCa or IKCa expression in ECs; 
however it did reduce the distribution of eNOS. Research showed that eNOS is down regulated 
during endothelial dysfunction in mesenteric arteries (Caliman et al., 2013; Mukohda et al., 
2013). Our results show that the penetration of eNOS expression from the level of the plasma 
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membrane toward the cell center is reduced with endothelial dysfunction. The integral of eNOS 
antibody fluorescence in experimental ECs was reduced by 29%, suggesting a global reduction 
due to Ang II infusion. Our anti-eNOS antibody was not specific for the phosphorylated protein. 
Therefore we cannot be certain that our observations in Ang II treated mice strictly correlate to a 
reduction of phosphorylated (active) eNOS. Future studies should compare the ratio of active to 
total eNOS in vascular endothelial cells from Ang II treated mice. We did not compare the 
distribution of eNOS following activation of PAR2 or M3. For upcoming studies it would be 
informative to compare the data from Figure 24 to endothelial cell immunocytochemistry after 
exposure to 2fly or ACh. 
 In small caliber arteries, key studies have suggested that expression of IP3R are 
distributed near the downstream targets of their Ca
2+
-signals: SKCa and IKCa (Dora et al., 2008; 
Sandow et al., 2006). SKCa was found to be widely distributed on the cell surface whereas IKCa 
was localized to MEGJs (Dora et al., 2008). These data infer the potential for different pools of 
IP3R to associate with Ca
2+
-sensitive targets. Our immunocytochemistry signals of SKCa and 
IKCa appear similar and are found in discrete bundles of fluorescence at the EC plasma 
membrane. It is possible that these focal points of intense KCa expression correspond to the 
former locations of endothelial projections before the mesenteric cells were enzymatic dispersed. 
Further investigation with Cx37, 40 and 43 staining (Saliez et al., 2008; Sandow et al., 2006) 
may be useful to determine if  “islands” of potassium channel expression are associated with the 
location of MEGJs hemi-channels. 
4.7 Conclusion 
 Our study is the first to examine the kinetics and dynamics of PAR2-mediated Ca
2+
-
events in freshly isolated endothelial cells. We have described methods that reliably produce 
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viable endothelial cells from resistance vasculature in mice, whose Ca
2+
-signaling is comparable 
to in situ preparations. Taken together our data suggest that PAR2 Ca
2+
-signaling is preserved in 
endothelial dysfunction that results in a selective lesion to the activation of IP3R by ACh. This 
study has also demonstrated that EC GPCRs, PAR2 and M3 receptor , trigger Ca
2+
-events from 
IP3R which are dependent on TRPV activity.  
 The preserved PAR2 activation of IP3R mediated Ca
2+
-signals in small caliber arteries 
may provide an endothelial dysfunction resistant pathway of EC-VSMC communication. The 
comparable EC50 values for Ca
2+
 and isometric tension CRCs indicate that our model of single 
cell endothelial dysfunction is translatable to physiological models like diabetes. Our work on 
single cell PAR2 Ca
2+
-events provide a foundation for future studies combining 
electrophysiology (electrical potential) of small caliber arteries mounted in myographs 
(mechanical forces) on confocal microscopes (Ca
2+
-signaling). Simultaneous experiments 
following PAR2 activation may establish a more holistic understanding for the preservation of 
PAR2 signaling in endothelial dysfunction. 
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Chapter 5: Appendices 
5.1 Appendix A 
#         Primer            Sequence (5’ to 3’)     Tm (
º C
) 
1 IMR5332 (Mutant) GCCAGAGGCCACTTGTGTAG      64.5 
2 IMR7419 (Forward) TCAAAGACTGCTGGTGGTTG     60.4 
3 IMR7420 (Reverse) GGTCCAACAGTAAGGCTGCT     62.5 
Product from (1) and (2) = 198 bp fragment → MUT→ neomycin gene present 
Product from (2) and (3) = 345 bp fragment → WT→ F2rL1, par2, gene exon 2 present 
Table 5. Oligonucleotide primer sets used in the genotyping of mice. Tm represents the melting 
temperature for the primers. Modified from McGuire Laboratory, 2013.  
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5.2 Appendix B 
 
Figure 28. Protocol for 2fly and ACh calcium signaling concentration response curve experiments. 
Saline and angiotensin II treated mice were processed as per methods section 2.7.  2fly, 2-furoyl-
LIGRLO-amide; ACh, acetylcholine. Baseline, no agonist present.  
 
 
 
 
 
Saline Angiotensin II
5 PAR2-WT 5 PAR2-KO 5 PAR2-WT 5 PAR2-KO
*as per "a" *as per "a" *as per "a"
1 animal of 5
a
Baseline
 10 cells
Low [2fly]
 10 cells
Low [ACh]
 10 cells
High [2fly]
 10 cells
High [ACh]
 10 cells
Mid [2fly]
2 cells
Mid [ACh]
2 cells
* Each treatment/genotype group underwent the same protocol
  as per line "a" from saline treated PAR2-WT
** Low [2fly] indicates concentrations between 0.1 nM and 10 nM
    Low [ACh] indicates concentrations between 1 nM and 100 nM
*** Mid [2fly] indicates concentration of 30 nM
     Mid [ACh] indicates concentration of 300 nM
**** High [2fly] indicates concentrations between 100 nM and 3 M
       High [ACh] indicates concentrations between 1 M and 30 M
** ***** ******* ***
2 cells from each animal  were taken for each mid [2fly] and [ACh]
measurement. 10 cells total from each group were used to create mid
points in 2fly and ACh concentration response curves representing all
animals.
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5.3 Appendix C 
 
Figure 29. Protocol for IP3R and TRPV inhibitor experiments. Saline and angiotensin II treated mice 
were processed as per methods section 2.7. Inhibitors of IP3R: XeC, xestospongin-c; and TRPV channels: 
RR, ruthenium red were used to examine the contribution of these proteins to endothelial calcium 
signaling. The effects of these inhibitors were examined without agonist present: BL, baseline; and in the 
presence of PAR2 agonist: 2fly, 2-furoyl-LIGRLO-amide; and with M3 agonist: ACh, acetylcholine.  
 
 
 
 
 
 
 
Saline Angiotensin II
4 PAR2-WT 4 PAR2-KO 4 PAR2-WT 4 PAR2-KO
*as per "a" *as per "a" *as per "a"
1 animal of 4
a
BL
5 cells
BL +
XeC
5 cells
BL +
RR
5 cells
BL +
XeC + RR
5 cells
2fly
5 cells
 2fly +
XeC
5 cells
2fly +
RR
5 cells
2fly +
XeC + RR
5 cells
ACh
5 cells
 ACh +
XeC
5 cells
ACh +
RR
5 cells
ACh +
XeC + RR
5 cells
2fly indicates mid [2fly] concentration of 30 nM
ACh indicates mid [ACh] concentration of 300 nM
XeC indicates [XeC] concentration of 2 M
RR indicates [RR] concentration of 75 M
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5.4 Appendix D 
Supplemental Data  
Agonist Treatment Genotype n pD2
 
(M) Emax
c
(Ca
2+
-release sites/cell) Hill slope 
2fly 
Saline 
PAR2-WT 5 7.8 ± 0.1 12.3 ± 0.4 0.9 ± 0.1 
PAR2-KO 5 N/A N/A N/A 
Ang II 
PAR2-WT 5 7.2 ± 0.1 11.7 ± 0.5 0.9 ± 0.2 
PAR2-KO 5 N/A N/A N/A 
ACh 
Saline 
PAR2-WT 5 6.8 ± 0.1 6.9 ± 0.3c 1.1 ± 0.2 
PAR2-KO 5 6.9 ± 0.1 7.2 ± 0.3 1.0 ± 0.2 
Ang II 
PAR2-WT 5 6.8 ± 0.1 5.4 ± 0.3cc 0.9 ± 0.3 
PAR2-KO 5 6.7 ± 0.1 5.6 ± 0.2c 1.1 ± 0.2 
Table S1. Characteristics for 2fly and acetylcholine Ca
2+
-event concentration response curves of 
angiotensin II and saline treated mice. Values are means ± S.E.M., n = number of mice per curve, 10 
cells per point. 2fly, 2-furoyl-LIGRLO-amide; ACh, acetylcholine. Variables were determined by curve 
fitting 2fly and acetylcholine-induced Ca2+-event recruitment data from PAR2-WT and PAR2-KO to a 4 
parameter logistic curve. Data were analyzed by 2 way ANOVA (treatment x genotype) followed by 
Bonfferoni post-hoc testing. cp < 0.001, Emax, Ang II PAR2-WT and PAR2-KO vs saline PAR2-WT and 
PAR2-KO. cp < 0.001, Emax,  saline and Ang II PAR2-WT 2fly vs saline and Ang II PAR2-WT ACh. 
 
Agonist Treatment Genotype n pD2
 
(M) Emax
ab
 (Ca
2+
-event/site/s) Hill slope
b
 
2fly 
Saline 
PAR2-WT 5 8.4 ± 0.1 0.29 ± 0.01 1.8 ± 0.6 
PAR2-KO 5 N/A N/A N/A 
Ang II 
PAR2-WT 5 8.5 ± 0.1 0.28 ± 0.01 1.6 ± 0.4 
PAR2-KO 5 N/A N/A N/A 
ACh 
Saline 
PAR2-WT 5 6.9 ± 0.1 0.32 ± 0.01 0.8 ± 0.2b 
PAR2-KO 5 7.2 ± 0.1 0.29 ± 0.01 0.9 ± 0.3 
Ang II 
PAR2-WT 5 6.8 ± 0.2 0.24 ± 0.02b 0.6 ± 0.2b 
PAR2-KO 5 6.9 ± 0.2 0.22 ± 0.01a 1.0 ± 0.3 
Table S2. Characteristics for 2fly and acetylcholine Ca
2+
-event site firing rate concentration 
response curves of angiotensin II and saline treated mice. Values are means ± S.E.M., n = number of 
mice per curve, 10 cells per point. 2fly, 2-furoyl-LIGRLO-amide; ACh, acetylcholine. Variables were 
determined by curve fitting 2fly and acetylcholine-induced Ca2+-event site firing rate data from PAR2-
WT and PAR2-KO to a 4 parameter logistic curve. Data were analyzed by 2 way ANOVA (treatment x 
genotype) followed by Bonfferoni post-hoc testing. bp < 0.01, Emax, Ang II PAR2-WT vs saline PAR2-
WT; ap < 0.05, Emax, Ang II PAR2-KO vs saline PAR2-KO. 
bp < 0.01, Hill slope, saline and Ang II 
PAR2-WT 2fly vs saline and Ang II PAR2-WT ACh. 
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Agonist Inhibitor Treatment Genotype n Ca
2+
-release sites/cell 
Baseline 
Control 
Saline 
PAR2-WT 10 0.5 ± 0.3 
PAR2-KO 10 0.3 ± 0.2 
Ang II 
PAR2-WT 10 0.5 ± 0.3 
PAR2-KO 10 0.3 ± 0.2 
XeC 
Saline 
PAR2-WT 10 0.1 ± 0 
PAR2-KO 10 0.5 ± 0.2 
Ang II 
PAR2-WT 10 0.3 ± 0.2 
PAR2-KO 10 0.2 ± 0.1 
RR 
Saline 
PAR2-WT 10 0.5 ± 0.2 
PAR2-KO 10 0.3 ± 0.2 
Ang II 
PAR2-WT 10 0.5 ± 0.2 
PAR2-KO 10 0.3 ± 0.2 
RR + XeC 
Saline 
PAR2-WT 10 0.2 ± 0 
PAR2-KO 10 0.2 ± 0.1 
Ang II 
PAR2-WT 10 0.3 ± 0.2 
PAR2-KO 10 0.4 ± 0.2 
Table S3. Effect of IP3R and TRP channel inhibitors on baseline Ca
2+
-events in 
endothelial cells from saline and Ang II-infused mice. Values are means ± S.E.M., 
n = 10 cells, 4 animals per group. S.E.M. = 0 indicates only 1 cell from 10 observed 
had Ca2+-events, or that all cells observed had the same number of Ca2+-release sites. 
Baseline, baseline no agonist; Control, no inhibitor present; RR, ruthenium red (75 
µM); XeC, xestospongin c (2 µM). Values were obtained by measuring number of 
Ca2+-releases in freshly isolated PAR2-WT and PAR2-KO mesenteric endothelial 
cells. Data were analyzed by 2 way ANOVA (inhibitor x genotype/treatment group) 
followed by Bonferonni post-hoc testing. Where S.E.M. = 0, unweighted 2 way 
ANOVA was used. No differences were observed across the inhibitors and treatment 
groups, p > 0.05.   
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Agonist Inhibitor Treatment Genotype n Ca
2+
-release sites/cell
c
 
2fly 
Control 
Saline 
PAR2-WT 10 8 ± 0.4 
PAR2-KO 10 0.4 ± 0.2 
Ang II 
PAR2-WT 10 8 ± 0.6 
PAR2-KO 10 0.3 ± 0.2 
XeC 
Saline 
PAR2-WT 10 1.1 ± 0.3c 
PAR2-KO 10 0.4 ± 0.2 
Ang II 
PAR2-WT 10 0.9 ± 0.3c 
PAR2-KO 10 0.3 ± 0.2 
RR 
Saline 
PAR2-WT 10 5.1 ± 0.4c 
PAR2-KO 10 0.4 ± 0.2 
Ang II 
PAR2-WT 10 4.8 ± 0.5c 
PAR2-KO 10 0.5 ± 0.2 
RR + XeC 
Saline 
PAR2-WT 10 0.5 ± 0.3c 
PAR2-KO 10 0.5 ± 0.3 
Ang II 
PAR2-WT 10 0.3 ± 0.2c 
PAR2-KO 10 0.2 ± 0.1 
Table S4. Effect of IP3R and TRP channel inhibitors on PAR2-mediated Ca
2+
-
events in endothelial cells from saline and Ang II-infused mice. Values are means ± 
S.E.M., n = 10 cells, 4 animals per group. S.E.M. = 0 indicates only 1 cell from 10 
observed had Ca2+-events, or that all cells observed had the same number of Ca2+-release 
sites. 2fly, 2-furoyl-LIGRLO-amide (30 nM); Control, no inhibitor present; RR, 
ruthenium red (75 µM); XeC, xestospongin c (2 µM). Values were obtained by 
measuring number of Ca
2+
-releases in freshly isolated PAR2-WT and PAR2-KO 
mesenteric endothelial cells. Data were analyzed by 2 way ANOVA (inhibitor x 
genotype/treatment group) followed by Bonfferoni post-hoc testing. Where S.E.M. = 0, 
unweighted 2 way ANOVA was used. cp < 0.001, Ca2+-release sites/cell, XeC saline and 
Ang II PAR2-WT vs Controls; cp < 0.001, Ca2+-release sites/cell, RR saline and Ang II 
PAR2-WT vs Controls; cp < 0.001, Ca2+-release sites/cell, RR + XeC saline and Ang II 
PAR2-WT vs Controls. 
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Agonist Inhibitor Treatment Genotype n Ca
2+
-release sites/cell
ac
 
ACh 
Control 
Saline 
PAR2-WT 10 5.1 ± 0.3 
PAR2-KO 10 5.4 ± 0.4 
Ang II 
PAR2-WT 10 3.4 ± 0.4 
PAR2-KO 10 3.3 ± 0.4 
XeC 
Saline 
PAR2-WT 10 0.8 ± 0.2c 
PAR2-KO 10 1 ± 0.3c 
Ang II 
PAR2-WT 10 0.5 ± 0.2c 
PAR2-KO 10 0.6 ± 0.3c 
RR 
Saline 
PAR2-WT 10 3.2 ± 0.3c 
PAR2-KO 10 3.4 ± 0.5c 
Ang II 
PAR2-WT 10 2.3 ± 0.3a 
PAR2-KO 10 2.7 ± 0.3 
RR + XeC 
Saline 
PAR2-WT 10 0.4 ± 0.2c 
PAR2-KO 10 0.4 ± 0.3c 
Ang II 
PAR2-WT 10 0.2 ± 0.1c 
PAR2-KO 10 0.5 ± 0.3c 
Table S5. Effect of IP3R and TRP channel inhibitors on M3-mediated Ca
2+
-
events in endothelial cells from saline and Ang II-infused mice. Values are means 
± S.E.M., n = 10 cells, 4 animals per group. S.E.M. = 0 indicates only 1 cell from 10 
observed had Ca2+-events, or that all cells observed had the same number of Ca2+-
release sites. ACh, acetylcholine (300 nM); Control, no inhibitor present; RR, 
ruthenium red (75 µM); XeC, xestospongin c (2 µM). Values were obtained by 
measuring number of Ca2+-releases in freshly isolated PAR2-WT and PAR2-KO 
mesenteric endothelial cells. Data were analyzed by 2 way ANOVA (inhibitor x 
genotype/treatment group) followed by Bonfferoni post-hoc testing. Where S.E.M. = 
0, unweighted 2 way ANOVA was used. cp < 0.001, Ca2+-release sites/cell, XeC 
saline and Ang II PAR2-WT and PAR2-KO vs Controls. cp < 0.001, Ca2+-release 
sites/cell, RR saline PAR2-WT and PAR2-KO vs Controls; ap < 0.05, Ca2+-release 
sites/cell, RR Ang II PAR2-WT vs Controls. cp < 0.001, Ca2+-release sites/cell, RR + 
XeC saline and Ang II PAR2-WT and PAR2-KO vs Controls. 
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Ca
2+
-event Agonist Treatment Genotype n pD2 (M) 
Emax
abc
(Ca
2+
-
release 
sites/cell) 
Hill slope 
Peripheral 
2fly 
Saline 
PAR2-WT 5 7.8 ± 0.1 8.3 ± 0.5 0.9 ± 0.1 
PAR2-KO 5 N/A N/A N/A 
Ang II 
PAR2-WT 5 7.7 ± 0.1 8.2 ± 0.6 0.9 ± 0.1 
PAR2-KO 5 N/A N/A N/A 
ACh 
Saline 
PAR2-WT 5 6.7 ± 0.1 4.5 ± 0.3 1.0 ± 0.2 
PAR2-KO 5 6.9 ± 0.1 4.3 ± 0.2 0.9 ± 0.2 
Ang II 
PAR2-WT 5 6.8 ± 0.2 3.5 ± 0.3a 0.7 ± 0.1 
PAR2-KO 5 6.7 ± 0.1 3.5 ± 0.2a 1.0 ± 0.2 
Central 
2fly 
Saline 
PAR2-WT 5 7.7 ± 0.1 4.0 ± 0.4 1.1 ± 0.2 
PAR2-KO 5 N/A N/A N/A 
Ang II 
PAR2-WT 5 7.6 ± 0.1 3.9 ± 0.3 0.8 ± 0.1 
PAR2-KO 5 N/A N/A N/A 
ACh 
Saline 
PAR2-WT 5 6.8 ± 0.1 2.6 ± 0.1 1.2 ± 0.3 
PAR2-KO 5 6.8 ± 0.1 2.8 ± 0.1 1.0 ± 0.2 
Ang II 
PAR2-WT 5 6.8 ± 0.1 2.0 ± 0.1b 1.4 ± 0.5 
PAR2-KO 5 6.7 ± 0.1 2.1 ± 0.1c 1.2 ± 0.3 
Table S6. Characteristics for 2fly and acetylcholine peripheral and central Ca
2+
-event 
concentration response curves of angiotensin II and saline treated mice. Values are means ± 
S.E.M., n = number of mice per curve. 2fly, 2-furoyl-LIGRLO-amide; ACh, acetylcholine. Variables 
were determined by curve fitting 2fly and acetylcholine-induced Ca2+-event recruitment data from 
PAR2-WT and PAR2-KO to a 4 parameter logistic curve. Data were analyzed by 2 way ANOVA 
(treatment x genotype) followed by Bonfferoni post-hoc testing. cp < 0.001, central Emax, Ang II PAR2-
KO vs saline PAR2-KO. bp < 0.01, central Emax, Ang II PAR2-WT vs saline PAR2-WT. 
ap < 0.05, 
peripheral Emax, Ang II PAR2-WT and PAR2-KO vs saline PAR2-WT and PAR2-KO. 
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Ca
2+
-event Agonist Treatment Genotype n pD2 (M) 
Emax
c
(Ca
2+
-
event/site/s) 
Hill slope 
Peripheral 
2fly 
Saline 
PAR2-WT 5 8.4 ± 0.1 0.42 ± 0.02 2.8 ± 1.6 
PAR2-KO 5 N/A N/A N/A 
Ang II 
PAR2-WT 5 8.4 ± 0.1 0.39 ± 0.02 3.4 ± 2.5 
PAR2-KO 5 N/A N/A N/A 
ACh 
Saline 
PAR2-WT 5 7.2 ± 0.1 0.33 ± 0.01 1.3 ± 0.3 
PAR2-KO 5 7.3 ± 0.1 0.33 ± 0.01 1.4 ± 0.3 
Ang II 
PAR2-WT 5 7.2 ± 0.1 0.22 ± 0.01c 1.4 ± 0.6 
PAR2-KO 5 7.2 ± 0.1 0.21 ± 0.01c 2.2 ± 0.9 
Central 
2fly 
Saline 
PAR2-WT 5 8.0 ± 0.2 0.20 ± 0.02 0.9 ± 0.4 
PAR2-KO 5 N/A N/A N/A 
Ang II 
PAR2-WT 5 7.9 ± 0.1 0.21 ± 0.01 1.2 ± 0.4 
PAR2-KO 5 N/A N/A N/A 
ACh 
Saline 
PAR2-WT 5 6.0 ± 0.1 0.50 ± 0.02 1.8 ± 0.4 
PAR2-KO 5 6.0 ± 0.1 0.48 ± 0.03 1.3 ± 0.3 
Ang II 
PAR2-WT 5 5.9 ± 0.1 0.29 ± 0.02c 1.6 ± 0.4 
PAR2-KO 5 6.0 ± 0.1 0.30 ± 0.01c 1.7 ± 0.5 
Table S7. Characteristics for 2fly and acetylcholine peripheral and central Ca
2+
-event site firing 
rate concentration response curves of angiotensin II and saline treated mice. Values are means ± 
S.E.M., n = number of mice per curve. 2fly, 2-furoyl-LIGRLO-amide; ACh, acetylcholine. Variables 
were determined by curve fitting 2fly and acetylcholine-induced Ca2+-event site firing rate data from 
PAR2-WT and PAR2-KO to a 4 parameter logistic curve. Data were analyzed by 2 way ANOVA 
(treatment x genotype) followed by Bonfferoni post-hoc testing. cp < 0.001, peripheral Emax, Ang II 
PAR2-WT and PAR2-KO vs saline PAR2-WT and PAR2-KO. cp < 0.001, central Emax, Ang II PAR2-
WT and PAR2-KO vs saline PAR2-WT and PAR2-KO. 
 
 
 
 
 
 
 
 
99 
 
Ca
2+
-event Inhibitor Treatment Genotype n Ca
2+
-release sites/cell 
Baseline 
Peripheral 
Control 
Saline 
PAR2-WT 10 0.4 ± 0.2 
PAR2-KO 10 0.3 ± 0.2 
Ang II 
PAR2-WT 10 0.4 ± 0.2 
PAR2-KO 10 0.3 ± 0.2 
XeC 
Saline 
PAR2-WT 10 0 
PAR2-KO 10 0.4 ± 0.2 
Ang II 
PAR2-WT 10 0.1 ± 0 
PAR2-KO 10 0.1 ± 0 
RR 
Saline 
PAR2-WT 10 0.4 ± 0.2 
PAR2-KO 10 0.3 ± 0.2 
Ang II 
PAR2-WT 10 0.3 ± 0.2 
PAR2-KO 10 0.2 ± 0.1 
RR+ 
XeC 
Saline 
PAR2-WT 10 0.1 ± 0 
PAR2-KO 10 0.2 ± 0.1 
Ang II 
PAR2-WT 10 0.2 ± 0.1 
PAR2-KO 10 0.4 ± 0.2 
Table S8. Effect of IP3R and TRP channel inhibitors on baseline peripheral 
Ca
2+
-events in endothelial cells from saline and Ang II-infused mice. Values 
are means ± S.E.M., n =10 cells, 4 animals per group. S.E.M. = 0 indicates only 1 
cell from 10 observed had Ca2+-events, or that all cells observed had the same 
number of Ca2+-release sites. Control, no inhibitor present; Baseline (no agonist); 
RR, ruthenium red (75 µM); XeC, xestospongin c (2 µM). Values were obtained 
by measuring number of Ca2+-releases in freshly isolated PAR2-WT and PAR2-
KO mesenteric endothelial cells. Data were analyzed by 2 way ANOVA 
(inhibitor x genotype/treatment group) followed by Bonfferoni post-hoc testing. 
Where S.E.M. = 0, unweighted 2 way ANOVA was used. p > 0.05, no differences 
between groups. 
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Ca
2+
-event Inhibitor Treatment Genotype n Ca
2+
-release sites/cell 
 Baseline 
Central 
Control 
Saline 
PAR2-WT 10 0.1 ± 0 
PAR2-KO 10 0 
Ang II 
PAR2-WT 10 0.1 ± 0 
PAR2-KO 10 N/A 
XeC 
Saline 
PAR2-WT 10 0.1 ± 0 
PAR2-KO 10 0 
Ang II 
PAR2-WT 10 0.2 ± 0.1 
PAR2-KO 10 0.1 ± 0 
RR 
Saline 
PAR2-WT 10 0.1 ± 0 
PAR2-KO 10 0.1 ± 0 
Ang II 
PAR2-WT 10 0.2 ± 0.1 
PAR2-KO 10 0.1 ± 0 
RR+ XeC 
Saline 
PAR2-WT 10 0.1 ± 0 
PAR2-KO 10 0 
Ang II 
PAR2-WT 10 0 
PAR2-KO 10 0 
Table S9. Effect of IP3R and TRP channel inhibitors on baseline central Ca
2+
-
events in endothelial cells from saline and Ang II-infused mice. Values are 
means ± S.E.M., n =10 cells, 4 animals per group. S.E.M. = 0 indicates only 1 cell 
from 10 observed had Ca2+-events, or that all cells observed had the same number 
of Ca2+-release sites. Control, no inhibitor present; Baseline (no agonist); RR, 
ruthenium red (75 µM); XeC, xestospongin c (2 µM). Values were obtained by 
measuring number of Ca2+-releases in freshly isolated PAR2-WT and PAR2-KO 
mesenteric endothelial cells. Data were analyzed by 2 way ANOVA (inhibitor x 
genotype/treatment group) followed by Bonfferoni post-hoc testing. Where S.E.M. 
= 0, unweighted 2 way ANOVA was used. p > 0.05, no differences between 
groups. 
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Ca
2+
-event Inhibitor Treatment Genotype n Ca
2+
-release sites/cell
c
 
2fly 
Peripheral 
Control 
Saline 
PAR2-WT 10 6.3 ± 0.3 
PAR2-KO 10 0.3 ± 0.2 
Ang II 
PAR2-WT 10 6.2 ± 0.6 
PAR2-KO 10 0.2 ± 0.1 
XeC 
Saline 
PAR2-WT 10 0.8 ± 0.2c 
PAR2-KO 10 0.4 ± 0.2 
Ang II 
PAR2-WT 10 0.7 ± 0.3c 
PAR2-KO 10 0.2 ± 0.1 
RR 
Saline 
PAR2-WT 10 4 ± 0.3c 
PAR2-KO 10 0.4 ± 0.2 
Ang II 
PAR2-WT 10 3.7 ± 0.4c 
PAR2-KO 10 0.3 ± 0.2 
RR+ XeC 
Saline 
PAR2-WT 10 0.4 ± 0.2c 
PAR2-KO 10 0.3 ± 0.2 
Ang II 
PAR2-WT 10 0.3 ± 0.2c 
PAR2-KO 10 0.2 ± 0.1 
Table S10. Effect of IP3R and TRP channel inhibitors on PAR2-mediated 
peripheral Ca
2+
-events in endothelial cells from saline and Ang II-infused mice. 
Values are means ± S.E.M., n =10 cells, 4 animals per group. S.E.M. = 0 indicates 
only 1 cell from 10 observed had Ca2+-events, or that all cells observed had the same 
number of Ca2+-release sites. 2fly, 2-furoyl-LIGRLO-amide (30 nM); Control, no 
inhibitor present; RR, ruthenium red (75 µM); XeC, xestospongin c (2 µM). Values 
were obtained by measuring number of Ca
2+
-releases in freshly isolated PAR2-WT 
and PAR2-KO mesenteric endothelial cells. Data were analyzed by 2 way ANOVA 
(inhibitor x genotype/treatment group) followed by Bonfferoni post-hoc testing. 
Where S.E.M. = 0, unweighted 2 way ANOVA was used. cp < 0.001, Ca2+-release 
sites/cell, XeC, RR and RR + XeC saline and Ang II PAR2-WT vs Controls. 
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Ca
2+
-event Inhibitor Treatment Genotype n Ca
2+
-release sites/cell
c
 
2fly 
Central 
Control 
Saline 
PAR2-WT 10 1.7 ± 0.2 
PAR2-KO 10 0.1 ± 0 
Ang II 
PAR2-WT 10 1.8 ± 0.1 
PAR2-KO 10 0 
XeC 
Saline 
PAR2-WT 10 0.3 ± 0.2c 
PAR2-KO 10 N/A 
Ang II 
PAR2-WT 10 0.3 ± 0.2c 
PAR2-KO 10 0 
RR 
Saline 
PAR2-WT 10 1.1 ± 0.1c 
PAR2-KO 10 0.1 ± 0 
Ang II 
PAR2-WT 10 1.1 ± 0.1c 
PAR2-KO 10 0.1 ± 0 
RR+ 
XeC 
Saline 
PAR2-WT 10 0.1 ± 0c 
PAR2-KO 10 0.1 ± 0 
Ang II 
PAR2-WT 10 0c 
PAR2-KO 10 0 
Table S11. Effect of IP3R and TRP channel inhibitors on PAR2-mediated 
central Ca
2+
-events in endothelial cells from saline and Ang II-infused mice. 
Values are means ± S.E.M., n =10 cells, 4 animals per group. S.E.M. = 0 indicates 
only 1 cell from 10 observed had Ca2+-events, or that all cells observed had the same 
number of Ca2+-release sites. 2fly, 2-furoyl-LIGRLO-amide (30 nM); Control, no 
inhibitor present; RR, ruthenium red (75 µM); XeC, xestospongin c (2 µM). Values 
were obtained by measuring number of Ca2+-releases in freshly isolated PAR2-WT 
and PAR2-KO mesenteric endothelial cells. Data were analyzed by 2 way ANOVA 
(inhibitor x genotype/treatment group) followed by Bonfferoni post-hoc testing. 
Where S.E.M. = 0, unweighted 2 way ANOVA was used. cp < 0.001, Ca2+-release 
sites/cell, XeC saline and Ang II PAR2-WT vs Controls. cp < 0.001, Ca2+-release 
sites/cell, RR saline and Ang II  PAR2-WT vs Controls. cp < 0.001, Ca2+-release 
sites/cell, RR + XeC saline PAR2-WT vs Controls. 
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Ca
2+
-event Inhibitor Treatment Genotype n Ca
2+
-release sites/cell
c
 
ACh 
Peripheral 
Control 
Saline 
PAR2-WT 10 2.8 ± 0.2 
PAR2-KO 10 2.9 ± 0.2 
Ang II 
PAR2-WT 10 1.7 ± 0.2 
PAR2-KO 10 1.7 ± 0.2 
XeC 
Saline 
PAR2-WT 10 0.6 ± 0.3c 
PAR2-KO 10 0.5 ± 0.2c 
Ang II 
PAR2-WT 10 0.5 ± 0.2c 
PAR2-KO 10 0.2 ± 0.1c 
RR 
Saline 
PAR2-WT 10 1.7 ± 0.2c 
PAR2-KO 10 1.8 ± 0.2c 
Ang II 
PAR2-WT 10 1 ± 0.1 
PAR2-KO 10 1.4 ± 0.2 
RR+ 
XeC 
Saline 
PAR2-WT 10 0.3 ± 0.2c 
PAR2-KO 10 0.3 ± 0.2c 
Ang II 
PAR2-WT 10 0.1 ± 0c 
PAR2-KO 10 0.3 ± 0.2c 
Table S12. Effect of IP3R and TRP channel inhibitors on M3-mediated 
peripheral Ca
2+
-events in endothelial cells from saline and Ang II-infused mice. 
Values are means ± S.E.M., n =10 cells, 4 animals per group. S.E.M. = 0 indicates 
only 1 cell from 10 observed had Ca2+-events, or that all cells observed had the same 
number of Ca2+-release sites. ACh, acetylcholine (300 nM); Control, no inhibitor 
present; RR, ruthenium red (75 µM); XeC, xestospongin c (2 µM). Values were 
obtained by measuring number of Ca2+-releases in freshly isolated PAR2-WT and 
PAR2-KO mesenteric endothelial cells. Data were analyzed by 2 way ANOVA 
(inhibitor x genotype/treatment group) followed by Bonfferoni post-hoc testing. 
Where S.E.M. = 0, unweighted 2 way ANOVA was used. cp < 0.001, Ca2+-release 
sites/cell, XeC saline and Ang II PAR2-WT and PAR2-KO vs Controls. cp < 0.001, 
Ca2+-release sites/cell, RR saline PAR2-WT and PAR2-KO vs Controls. cp < 0.001, 
Ca2+-release sites/cell, RR + XeC saline and Ang II PAR2-WT and PAR2-KO vs 
Controls. 
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Ca
2+
-event Inhibitor Treatment Genotype n Ca
2+
-release sites/cell
abc
 
ACh 
Central 
Control 
Saline 
PAR2-WT 10 2.1 ± 0.3 
PAR2-KO 10 2.5 ± 0.3 
Ang II 
PAR2-WT 10 0.8 ± 0.2 
PAR2-KO 10 1.1 ± 0.3 
XeC 
Saline 
PAR2-WT 10 0.2 ± 0.1c 
PAR2-KO 10 0.2 ± 0.1c 
Ang II 
PAR2-WT 10 0c 
PAR2-KO 10 0.3 ± 0.2a 
RR 
Saline 
PAR2-WT 10 1.2 ± 0.2b 
PAR2-KO 10 1.1 ± 0.3c 
Ang II 
PAR2-WT 10 0.8 ± 0.2 
PAR2-KO 10 0.8 ± 0.2 
RR+ 
XeC 
Saline 
PAR2-WT 10 0.1 ± 0c 
PAR2-KO 10 0.2 ± 0.1c 
Ang II 
PAR2-WT 10 0.1 ± 0 
PAR2-KO 10 0c 
Table S13. Effect of IP3R and TRP channel inhibitors on M3-mediated central 
Ca
2+
-events in endothelial cells from saline and Ang II-infused mice. Values are 
means ± S.E.M., n =10 cells, 4 animals per group. S.E.M. = 0 indicates only 1 cell 
from 10 observed had Ca2+-events, or that all cells observed had the same number of 
Ca2+-release sites. ACh, acetylcholine (300 nM); Control, no inhibitor present; RR, 
ruthenium red (75 µM); XeC, xestospongin c (2 µM). Values were obtained by 
measuring number of Ca
2+
-releases in freshly isolated PAR2-WT and PAR2-KO 
mesenteric endothelial cells. Data were analyzed by 2 way ANOVA (inhibitor x 
genotype/treatment group) followed by Bonfferoni post-hoc testing. Where S.E.M. = 
0, unweighted 2 way ANOVA was used. cp < 0.001, Ca2+-release sites/cell, XeC 
saline PAR2-WT and PAR2-KO vs Controls; ap < 0.05, Ca2+-release sites/cell , XeC 
Ang II PAR2-KO vs Controls. cp < 0.001, Ca2+-release sites/cell, RR saline PAR2-
KO vs Controls;  bp < 0.01, Ca2+-release sites/cell, RR saline PAR2-WT vs Controls.  
cp < 0.001, Ca2+-release sites/cell, RR + XeC saline PAR2-WT and PAR2-KO vs 
Controls. 
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Treatment
/ Genotype 
Ca
2+
-
Event 
Type 
Agonist Inhibitor n 
Amplitude
ab
c
 (F/Fo) 
FWHM
b
c
 (%) 
trise
c
 (ms) t1/2 (ms) 
Frequency
c
 
(Hz) 
Saline 
PAR2-WT 
Periphera
l 
Baseline 
Control 4 1.79 ± 0.09 23 ± 2 82 ± 4 205 ± 4 N/A 
XeC 0 N/A N/A N/A N/A N/A 
RR 4 1.63 ± 0.06 18 ± 3 75 ± 2 202 ± 4 N/A 
RR + 
XeC 
1 1.49 ± 0 9 ± 0 112 ± 0 205 ± 0 N/A 
2fly 
Control 
23
0 
1.77 ± 0.01 20 ± 1 81 ± 1 205 ± 1 N/A 
XeC 10 1.52 ± 0.09c 9 ± 1c 118 ± 3c 207 ± 3 N/A 
RR 
13
2 
1.62 ± 0.02 16 ± 1b 81 ± 1 206 ± 1 N/A 
RR + 
XeC 
5 1.48 ± 0.07b 10 ± 1c 116 ± 4c 200 ± 2 N/A 
ACh 
Control 92 1.80 ± 0.02 20 ± 1 81 ± 1 205 ± 1 N/A 
XeC 7 1.50 ± 0.04b 10 ± 1c 116 ± 2c 205 ± 3 N/A 
RR 55 1.60 ± 0.04 15 ± 1b 81 ± 1 205 ± 1 N/A 
RR + 
XeC 
4 1.46 ± 0.10a 8 ± 2c 120 ± 2c 208 ± 4 N/A 
Central 
Baseline 
Control 1 3.03 ± 0 32 ± 0 96 ± 0 122 ± 0 0.01 ± 0 
XeC 1 1.93 ± 0 11 ± 0 137 ± 0 121 ± 0 0.01 ± 0 
RR 1 2.46 ± 0 34 ± 0 93 ± 0 123 ± 0 0.01 ± 0 
RR + 
XeC 
1 1.91 ± 0 10 ± 0 133 ± 0 111 ± 0 0.01 ± 0 
2fly 
Control 36 3.14 ± 0.02 32 ± 1 99 ± 2 114 ± 1 0.40 ± 0.05 
XeC 3 1.90 ± 0.10c 11 ± 1c 130 ± 5c 115 ± 3 0.03 ± 0.02c 
RR 17 2.46 ± 0.04c 33 ± 1 98 ± 2 117 ± 2 0.17 ± 0.02c 
RR + 
XeC 
1 1.89 ± 0 9 ± 0 135 ± 0 119 ± 0 0.01 ± 0 
ACh 
Control 33 3.16 ± 0.08 32 ± 1 100 ± 2 115 ± 2 0.34 ± 0.03 
XeC 2 1.96 ± 0.10 11 ± 1 132 ± 4 114 ± 5 0.02 ± 0.01 
RR 17 2.45 ± 0.03c 33 ± 1 100 ± 2 116 ± 2 0.18 ± 0.03c 
RR + 
XeC 
1 1.95 ± 0 12 ± 0 134 ± 0 112 ± 0 0.01 ± 0 
Table S14. Effect of IP3R and TRP channel inhibitors on characteristics of peripheral and central Ca
2+
-transient 
characteristics from saline-infused PAR2-WT. Values are means ± S.E.M., n = number of Ca2+-events from 10 cells, 5 
animals per group. S.E.M. = 0 indicates only 1 cell from 10 observed had Ca2+-events, or that all cells observed had the same 
number of Ca2+-release sites or rate. S.E.M. calculated from number of cells with Ca2+-transients present. 2fly, 2-furoyl-
LIGRLO-amide (30 nM); ACh, acetylcholine (30 µM); Baseline, no agonist added; FWHM, full width at half-maximum Ca2+-
event amplitude (% maximum cell length). Values were obtained by line scan analysis of Ca2+-events in freshly isolated PAR2-
WT and PAR2-KO mesenteric endothelial cells. Data were analyzed by 2 way ANOVA (Ca2+-event type x genotype/treatment 
group) followed by Bonfferoni post-hoc testing. Where S.E.M. = 0, unweighted 2 way ANOVA was used. cp < 0.001, 
Amplitude, peripheral XeC 2fly vs Controls; central XeC, RR 2fly vs Controls; central RR ACh vs Controls.. bp < 0.01, 
Amplitude, peripheral RR + XeC 2fly vs Controls; peripheral XeC ACh vs Controls. ap < 0.05, Amplitude, peripheral RR + 
XeC ACh vs Controls. cp < 0.001, FWHM, peripheral XeC and RR + XeC  2fly and ACh vs Controls; central XeC 2fly vs 
Controls. bp < 0.01, FWHM, peripheral RR 2fly and ACh vs Controls. cp < 0.001, trise, peripheral XeC and RR + XeC 2fly and 
ACh vs Controls; central XeC 2fly vs Controls.  cp < 0.001, Frequency, central XeC, RR 2fly vs Controls; central RR ACh vs 
Controls . 
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Treatment
/ Genotype 
Ca
2+
-
Event 
Type 
Agonist Inhibitor n 
Amplitude
b
c
 (F/Fo) 
FWHM
a
c
 (%) 
trise
c
 (ms) t1/2 (ms) 
Frequency
c
 
(Hz) 
Ang II 
PAR2-WT 
Periphera
l 
Baseline 
Control 5 1.79 ± 0.10 22 ± 2 83 ± 3 205 ± 3 N/A 
XeC 1 1.47 ± 0 12 ± 0 119 ± 0 210 ± 0 N/A 
RR 4 1.63 ± 0.10 16 ± 2 80 ± 3 204 ± 3 N/A 
RR + 
XeC 
4 1.5 ± 0.06b 9 ± 2c 114 ± 3c 205 ± 4 N/A 
2fly 
Control 
23
9 
1.76 ± 0.01 20 ± 1 81 ± 1 205 ± 1 N/A 
XeC 10 1.50 ± 0.04b 8 ± 1c 114 ± 2c 206 ± 2 N/A 
RR 
13
8 
1.62 ± 0.01 15 ± 1a 80 ± 1 205 ± 1 N/A 
RR + 
XeC 
3 1.49 ± 0.05b 8 ± 2c 117 ± 5c 214 ± 2 N/A 
ACh 
Control 53 1.77 ± 0.03 20 ± 1 78 ± 1 206 ± 1 N/A 
XeC 5 1.51 ± 0.08b 8 ± 1c 114 ± 3c 202 ± 3 N/A 
RR 34 1.61 ± 0.04 15 ± 1a 80 ± 1 204 ± 2 N/A 
RR + 
XeC 
1 1.5 ± 0 11 ± 0 125 ± 0 202 ± 0 N/A 
Central 
Baseline 
Control 2 3.13 ± 0.07 34 ± 1 94 ± 3 118 ± 2 0.02 ± 0.01 
XeC 2 1.93 ± 0.04 11 ± 1 126 ± 5 117 ± 5 0.02 ± 0.01 
RR 2 2.44 ± 0.06 32 ± 1 100 ± 3 123 ± 1 0.02 ± 0.01 
RR + 
XeC 
0 N/A N/A N/A N/A N/A 
2fly 
Control 37 3.17 ± 0.02 32 ± 1 101 ± 1 115 ± 1 0.38 ± 0.03 
XeC 3 1.93 ± 0.03c 9 ± 2c 127 ± 5c 122 ± 2 0.03 ± 0.02c 
RR 18 2.44 ± 0.04c 34 ± 1 100 ± 2 116 ± 2 0.18 ± 0.03c 
RR + 
XeC 
0 N/A N/A N/A N/A N/A 
ACh 
Control 15 3.21 ± 0.04 33 ± 1 99 ± 2 116 ± 2 0.15 ± 0.03 
XeC 0 N/A N/A N/A N/A N/A 
RR 13 2.44 ± 0.05c 32 ± 1 100 ± 2 114 ± 2 0.13 ± 0.03 
RR + 
XeC 
1 1.92 ± 0 12 ± 0 132 ± 0 115 ± 0 0.01 ± 0 
Table S15. Effect of IP3R and TRP channel inhibitors on characteristics of peripheral and central Ca
2+
-transient 
characteristics from Ang II-infused PAR2-WT. Values are means ± S.E.M., n = number of Ca2+-events from 10 cells, 5 
animals per group. S.E.M. = 0 indicates only 1 cell from 10 observed had Ca2+-events, or that all cells observed had the same 
number of Ca2+-release sites or rate. S.E.M. calculated from number of cells with Ca2+-transients present. 2fly, 2-furoyl-
LIGRLO-amide (30 nM); ACh, acetylcholine (30 µM); Baseline, no agonist added; FWHM, full width at half-maximum Ca2+-
event amplitude (% maximum cell length). Values were obtained by line scan analysis of Ca2+-events in freshly isolated PAR2-
WT and PAR2-KO mesenteric endothelial cells. Data were analyzed by 2 way ANOVA (Ca2+-event type x genotype/treatment 
group) followed by Bonfferoni post-hoc testing. Where S.E.M. = 0, unweighted 2 way ANOVA was used. cp < 0.001, 
Amplitude, central XeC 2fly vs Controls; central RR 2fly and ACh vs Controls. bp < 0.01, Amplitude, peripheral XeC 2fly and 
ACh vs Controls; peripheral RR + XeC Baseline and 2fly vs Controls. cp < 0.001, FWHM, peripheral XeC and RR + XeC 2fly 
vs Controls; peripheral XeC ACh vs Controls; peripheral RR + XeC Baseline vs Controls; central XeC 2fly vs Controls. ap < 
0.05, FWHM, peripheral RR 2fly and ACh vs Controls. cp < 0.001, trise, peripheral XeC and RR + XeC 2fly vs Controls; 
peripheral XeC ACh vs Controls; peripheral RR + XeC Baseline vs Controls; central XeC 2fly vs Controls. cp < 0.001, 
Frequency, central XeC and RR 2fly vs Controls. 
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Treatment
/ Genotype 
Ca
2+
-
Event 
Type 
Agonist Inhibitor n 
Amplitude
ab
c
 (F/Fo) 
FWHM
b
c
 (%) 
trise
c
 (ms) t1/2 (ms) 
Frequency
c
 
(Hz) 
Saline 
PAR2-KO 
Periphera
l 
Baseline 
Control 5 1.78 ± 0.04 20 ± 2 75 ± 2 205 ± 3 N/A 
XeC 6 1.47 ± 0.07b 12 ± 1b 115 ± 3c 204 ± 3 N/A 
RR 3 1.61 ± 0.05 16 ± 3 78 ± 5 198 ± 2 N/A 
RR + 
XeC 
2 1.48 ± 0.07 10 ± 1 124 ± 1 202 ± 2 N/A 
2fly 
Control 5 1.76 ± 0.08 19 ± 2 84 ± 3 202 ± 3 N/A 
XeC 6 1.48 ± 0.09a 7 ± 1c 116 ± 3c 203 ± 3 N/A 
RR 4 1.59 ± 0.08 17 ± 2 81 ± 4 206 ± 4 N/A 
RR + 
XeC 
4 1.49 ± 0.05a 10 ± 2b 116 ± 5c 201 ± 3 N/A 
ACh 
Control 93 1.81 ± 0.02 20 ± 1 79 ± 1 204 ± 1 N/A 
XeC 8 1.53 ± 0.06b 9 ± 1c 119 ± 2c 204 ± 3 N/A 
RR 54 1.62 ± 0.02 15 ± 1 81 ± 1 205 ± 1 N/A 
RR + 
XeC 
3 1.48 ± 0.10b 9 ± 3c 116 ± 4c 205 ± 5 N/A 
Central 
Baseline 
Control 0 N/A N/A N/A N/A N/A 
XeC 0 N/A N/A N/A N/A N/A 
RR 1 2.50 ± 0 33 ± 0 106 ± 0 124 ± 0 0.01 ± 0 
RR + 
XeC 
0 N/A N/A N/A N/A N/A 
2fly 
Control 1 3.15 ± 0 31 ± 0 101 ± 0 121 ± 0 0.01 ± 0 
XeC 0 N/A N/A N/A N/A N/A 
RR 1 2.42 ± 0 30 ± 0 107 ± 0 123 ± 0 0.01 ± 0 
RR + 
XeC 
2 1.92 ± 0.10 11 ± 2 123 ± 2 115 ± 6 0.02 ± 0.01 
ACh 
Control 33 3.16 ± 0.03 32 ± 1 100 ± 2 116 ± 1 0.33 ± 0.02 
XeC 2 1.92 ± 0.09 10 ± 1 127 ± 7 115 ± 1 0.02 ± 0.01 
RR 14 2.44 ± 0.04c 33 ± 1 98 ± 2 115 ± 2 0.14 ± 0.03c 
RR + 
XeC 
2 1.94 ± 0.08 8 ± 1 124 ± 6 111 ± 2 0.02 ± 0.01 
Table S16. Effect of IP3R and TRP channel inhibitors on characteristics of peripheral and central Ca
2+
-transient 
characteristics from saline-infused PAR2-KO. Values are means ± S.E.M., n = number of Ca2+-events from 10 cells, 5 
animals per group. S.E.M. = 0 indicates only 1 cell from 10 observed had Ca2+-events, or that all cells observed had the same 
number of Ca2+-release sites or rate. S.E.M. calculated from number of cells with Ca2+-transients present. 2fly, 2-furoyl-
LIGRLO-amide (30 nM); ACh, acetylcholine (30 µM); Baseline, no agonist added; FWHM, full width at half-maximum Ca2+-
event amplitude (% maximum cell length). Values were obtained by line scan analysis of Ca2+-events in freshly isolated PAR2-
WT and PAR2-KO mesenteric endothelial cells. Data were analyzed by 2 way ANOVA (Ca2+-event type x genotype/treatment 
group) followed by Bonfferoni post-hoc testing. Where S.E.M. = 0, unweighted 2 way ANOVA was used.  cp < 0.001, 
Amplitude, central RR ACh vs Controls. bp < 0.01, Amplitude, peripheral XeC and RR + XeC ACh vs Controls; peripheral 
XeC Baseline vs Controls. ap < 0.05, Amplitude, peripheral XeC and RR + XeC 2fly vs Controls. cp < 0.001, FWHM, 
peripheral XeC 2fly and ACh vs Controls; peripheral RR + XeC ACh vs Controls. bp < 0.01, FWHM, peripheral XeC Baseline 
vs Controls; peripheral RR + XeC 2fly vs Controls. cp < 0.001, trise, peripheral XeC and RR + XeC 2fly and ACh vs Controls; 
peripheral XeC Baseline vs Controls. cp < 0.001, Frequency, central RR ACh vs Controls. 
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Treatment/ 
Genotype 
Ca
2+
-
Event 
Type 
Agonist Inhibitor n 
Amplitude
c
 
(F/Fo) 
FWHM
bc
 
(%) 
trise
c
(ms) t1/2 (ms) 
Frequency
c
 
(Hz) 
Ang II 
PAR2-KO 
Peripheral 
Baseline 
Control 4 1.78 ± 0.05 19 ± 2 82 ± 4 203 ± 4 N/A 
XeC 1 1.48 ± 0 8 ± 0 110 ± 0 208 ± 0 N/A 
RR 4 1.61 ± 0.06 18 ± 1 81 ± 4 206 ± 4 N/A 
RR + 
XeC 
4 1.47 ± 0.09c 10 ± 2c 113 ± 5c 205 ± 3 N/A 
2fly 
Control 4 1.79 ± 0.04 18 ± 2 82 ± 2 200 ± 3 N/A 
XeC 4 1.49 ± 0.06c 10 ± 1b 116 ± 4c 202 ± 2 N/A 
RR 5 1.64 ± 0.03 17 ± 2 78 ± 2 201 ± 3 N/A 
RR + 
XeC 
2 1.49 ± 0.08 9 ± 3 117 ± 5 210 ± 5 N/A 
ACh 
Control 55 1.80 ± 0.02 21 ± 1 80 ± 1 204 ± 1 N/A 
XeC 5 1.50 ± 0.03c 11 ± 2c 116 ± 3c 205 ± 4 N/A 
RR 47 1.63 ± 0.01 16 ± 1 80 ± 1 205 ± 1 N/A 
RR + 
XeC 
6 1.51 ± 0.08c 9 ± 1c 118 ± 3c 205 ± 3 N/A 
Central 
Baseline 
Control 0 N/A N/A N/A N/A N/A 
XeC 1 1.91 ± 0 11 ± 0 120 ± 0 107 ± 0 0.01 ± 0 
RR 1 2.42 ± 0 35 ± 0 106 ± 0 124 ± 0 0.01 ± 0 
RR + 
XeC 
0 N/A N/A N/A N/A N/A 
2fly 
Control 0 N/A N/A N/A N/A N/A 
XeC 0 N/A N/A N/A N/A N/A 
RR 1 2.46 ± 0 33 ± 0 99 ± 0 116 ± 0 0.01 ± 0 
RR + 
XeC 
0 N/A N/A N/A N/A N/A 
ACh 
Control 16 3.15 ± 0.06 33 ± 1 102 ± 2 114 ± 2 0.17 ± 0.04 
XeC 3 1.91 ± 0.08c 10 ± 2c 128 ± 5c 118 ± 7 0.03 ± 0.02c 
RR 12 2.46 ± 0.04c 34 ± 1 97 ± 2 115 ± 3 0.12 ± 0.03 
RR + 
XeC 
0 N/A N/A N/A N/A N/A 
Table S17. Effect of IP3R and TRP channel inhibitors on characteristics of peripheral and central Ca
2+
-transient 
characteristics from Ang II-infused PAR2-KO. Values are means ± S.E.M., n = number of Ca2+-events from 10 cells, 5 
animals per group. S.E.M. = 0 indicates only 1 cell from 10 observed had Ca2+-events, or that all cells observed had the same 
number of Ca2+-release sites or rate. S.E.M. calculated from number of cells with Ca2+-transients present. 2fly, 2-furoyl-
LIGRLO-amide (30 nM); ACh, acetylcholine (30 µM); Baseline, no agonist added; FWHM, full width at half-maximum Ca2+-
event amplitude (% maximum cell length). Values were obtained by line scan analysis of Ca2+-events in freshly isolated 
PAR2-WT and PAR2-KO mesenteric endothelial cells. Data were analyzed by 2 way ANOVA (Ca2+-event type x 
genotype/treatment group) followed by Bonfferoni post-hoc testing. Where S.E.M. = 0, unweighted 2 way ANOVA was used. 
cp < 0.001, Amplitude, peripheral XeC and RR + XeC ACh vs Controls; peripheral XeC 2fly vs Controls; peripheral RR + 
XeC Baseline vs Controls; central XeC and RR ACh vs Controls. cp < 0.001, FWHM, peripheral XeC ACh vs Controls; 
peripheral RR + XeC Baseline and ACh vs Controls; central XeC ACh vs Controls. bp < 0.01, FWHM, peripheral XeC 2fly vs 
Controls. cp < 0.001, trise, peripheral XeC and RR + XeC ACh vs Controls; peripheral XeC 2fly vs Controls; peripheral RR + 
XeC Baseline vs Controls; central XeC ACh vs Controls. cp < 0.001, Frequency, central XeC ACh vs Controls. 
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